

# Index

## ACCESS DENIAL

To essential facility, as anticompetitive conduct under Section 2 of Sherman Act, § 6:8

## ACCOUNTABLE CARE ORGANIZATION SUMMIT

“A Common Goal: The U.S. Federal Trade Commission’s Healthcare Enforcement Program and its Implications for ACOs,” text of remarks by Julie Brill, Commissioner, FTC, before the Sixth Annual Summit Preconference (June 17, 2015), **App. E244**

“Antitrust Enforcement in Health Care: Proscription, Not Prescription,” text of remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC, before the Fifth National Summit (June 19, 2014), **App. E232**

## ACGM, INC.

Advisory opinion, **App. D45**

## ACQUISITIONS

**Mergers** (this index)

## ADMINISTRATIVE COMPLAINT

Lawsuits, **App. N17**

Matter of GTCR BC Holdings, LLC and Surmodics, Inc

FTC Matter/File Number 241 0095, Docket Number 9440, **App. N24**

## ADVANCED PRACTICE NURSING

Florida House of Representatives, FTC letter concerning regulation of advanced registered nurse practitioners, **App. D140**

FTC advocacy letter to Veterans Administration, restrictions (July 25, 2016), **App. D188**

## ADVANCED PRACTICE NURSING

### —Cont’d

FTC collaborative practice agreements between advanced practice registered nurses and physicians, **App. D152**

FTC Executive Summary, “Policy Perspectives: Competition and Regulation of Advanced Practice Nurses” (Mar. 2014), **App. E229**

Kentucky State Senate, FTC letter concerning bill relating to advanced practice registered nurses scope of practice, **App. D150**

Missouri House of Representatives, FTC Staff advocacy letter regarding advanced practice registered nurses, **App. D169**

South Carolina House of Representatives, FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D178**

Texas State Senate, FTC letter concerning regulation of advanced registered nurse practitioners, **App. D142**

West Virginia Senate, FTC Staff Advocacy letter concerning placing regulation of advanced practice registered nurse under State Board of Medicine and Osteopathy (Feb. 10, 2016), **App. D181**

## ADVERTISING

Clinic advertising, FTC staff letter to Massachusetts Department of Public Health concerning (Sept. 27, 2007), **App. D120**

Limitations on, ethical restraints, § 24:6

**ADVISORY OPINIONS**

ACGM, Inc., **App. D45**  
 Alaska House of Representatives,  
 physician joint negotiation statute (Jan. 18, 2002), **App. D92**  
 Alliance of Independent Medical Services, LLC (Dec. 22, 1997), **App. D80**  
 Alpena Public Schools (June 16, 2006), **App. D114**  
 American Dental Association (Aug. 26, 1985), **App. D15**  
 American Dental Association (Feb. 15, 1990), **App. D28**  
 American Intra-Ocular Implant Society, **App. D17**  
 American Medical Association (March 26, 1996), **App. D62**  
 American Medical Association and Chicago Medical Society, **App. D42**  
 American Podiatry Association (Aug. 18, 1983), **App. D4**  
 American Podiatry Association (March 13, 1984), **App. D7**  
 Arkansas Children's Hospital (March 13, 2003), **App. D100**  
 Associates in Neurology (Aug. 13, 1998), **App. D83**  
 Association of Quality Health Care, **App. D22**  
 Attorney General of Montana regarding "any-willing-provider" laws, **App. D36**  
 Attorney General of North Dakota regarding cooperative arrangements among hospitals, **App. D37**  
 Bay Area Preferred Physicians, **App. D104**  
 BJC Health System (Nov. 9, 1999), **App. D87**  
 Business Health Companies, Inc. (Oct. 19, 1996), **App. D66**  
 (Oct. 18, 1996), **App. D72**  
 California All Health, **App. D52**  
 California Managed Imaging Medical Group, Inc., **App. D40**

**ADVISORY OPINIONS—Cont'd**

California Senate regarding "any-willing-provider" laws, **App. D33**  
 Central Texas Medical Group (Sept. 28, 1995), **App. D58**  
 Columbine Family Health Center (Nov. 89, 1995), **App. D59**  
 Columbus Hospital (June 28, 1996), **App. D65**  
 Community Hospital, Inc. (Dec. 22, 1997), **App. D79**  
 Competition law and policy, prospective guidance FTC advisory opinions (June 26, 2002), **App. E110**  
 Connecticut Hospital Association (Dec. 20, 2001), **App. D91**  
 District of Columbia Corporation Counsel, **App. D88**  
 Dunlap Memorial Hospital, FTC staff advisory opinion to (Jan. 6, 2004), **App. D105**  
 Eastern Ohio Physicians Organization, Inc. (Sept. 28, 1995), **App. D57**  
 Elmore Community Hospital and Community Hospital, **App. D53**  
 Equitable Life Assurance Society of the United States, **App. D21**  
 Erlanger Medical Center and Memorial Hospital, **App. D51**  
 First Look, LLC (June 19, 1997), **App. D77**  
 Foundation for the Accreditation of Hematopoietic Cell Therapy (Apr. 17, 1997), **App. D74**  
 FTC  
     generally, § 10:7, **App. B5, App. D**  
     see also other entries throughout this topic  
 Generic Pharmaceutical Association (Aug. 8, 2012), **App. D154**  
 Gilbert M. Frimet, **App. D8**  
 Greater Rochester Independent Practice Association (Sept. 17, 2007), **App. D119**  
 Harvard Vanguard Medical Associates, Inc. (Dec. 18, 2001), **App. D90**

## INDEX

### ADVISORY OPINIONS—Cont'd

Health Care Management Associates,  
**App. D3**

Hematology/Oncology Care Specialists of Western Pennsylvania, P.C. (Sept. 21, 1995), **App. D56**

Henry County Memorial Hospital (Apr. 10, 1997), **App. D76**

Intracorp, **App. D26**

Kaiser Foundation Health Plan (Feb. 13, 2008), **App. D122**

Kitsap Physicians Service (March 26, 1984), **App. D9**

Kitsap Physicians Service (May 22, 1984), **App. D11**

Louisiana Health Care Association, **App. D2**

Lynch, Patrick C. (Rhode Island Attorney General), FTC staff letter to (Apr. 8, 2004), **App. D106**

Maryland Medical Eye Associates, **App. D25**

Massachusetts Department of Public Health, FTC staff letter concerning clinic advertising (Sept. 27, 2007), **App. D120**

Mayo Medical Laboratories (July 17, 1996), **App. D63**

Medical Group Management Association, staff advisory opinion to, **App. D103**

Medical Society of the County of Erie, **App. D6**

MedSouth, Inc. (Feb. 19, 2002), **App. D94**

MedSouth, Inc., FTC staff follow-up letter (June 18, 2007) to 2002 advisory opinion, **App. D118**

Mesa County Physician Independent Practice Association (Nov. 6, 1997), **App. D78A**

Michael A. Duncheon, **App. D20**

Michael D. McNeely, Assistant Director, Bureau of Competition, to Clifton E. Johnson, **App. D44**

Missouri Board of Chiropractic Examiners regarding free or discounted services, **App. D35**

### ADVISORY OPINIONS—Cont'd

Mobile Health Resources, LLC (Jan. 23, 1997), **App. D69**

Montana Deaconess Medical Center (June 28, 1996), **App. D65**

Montana House of Representatives involving denturists, **App. D34**

National Capital Society of Plastic and Reconstructive Surgeons (Apr. 23, 1991), **App. D30**

New Hampshire Senate regarding “any-willing-provider” laws, **App. D32**

New Jersey Pharmacists Association (Aug. 12, 1997), **App. D78**

North Carolina Chiropractic Association, **App. D5**

Northeast Pharmacy Service Corporation (July 27, 2000), **App. D89**

North Mississippi Health Services (Oct. 3, 1996), **App. D71**  
(Jan. 7, 1998), **App. D81**  
(Aug. 16, 2005), **App. D112**

North Ottawa Community Hospital (Oct. 22, 1996), **App. D73**

North Texas Chapter, American College of Surgeons, **App. D18**

Northwestern Nevada Orthopaedic Surgery Alliance, **App. D54**

Oakland Physician Network, **App. D50**

Ohio Ambulance Network, Inc. (Jan. 23, 1997), **App. D68**

Orange Pharmacy Equitable Network (May 19, 1999), **App. D86**

Otolaryngology Specialty Providers of Georgia, **App. D55**

Pacific International Health, **App. D23**

Palmetto Dental Alliance, **App. D48**

Pan American Management Associates, **App. D27**

Passaic County Medical Society, **App. D19**

Peer Review Organizations of Ohio Foundation, **App. D10**

Phoenix Medical Network, Inc. (May 19, 1998), **App. D82**

**ADVISORY OPINIONS—Cont'd**

Physician IPA that sponsors a PPO, **App. D31**  
 Presentation Health System, **App. D41**  
 PriMed Physicians (Feb. 6, 2003), **App. D98**  
 Private Healthcare Systems, **App. D16**  
 Rhode Island Attorney General (Patrick C. Lynch), FTC staff letter to (Apr. 8, 2004), **App. D106**  
 Rocky Mountain Cardiovascular Affiliates, **App. D49**  
 Senator Orrin G. Hatch regarding hospital mergers, **App. D38**  
 Southeast Managed Care, Inc., **App. D46**  
 Southern Arizona Therapy Network, Inc. (Dec. 7, 1995), **App. D60**  
 Southwest Florida Oral Surgery Associates (Dec. 2, 1996), **App. D67**  
 Speech entitled “Overview of Advisory Opinion Process at FTC,” **App. E74**  
 Staff letter to State of Washington House of Representatives concerning physician joint negotiation statute (Feb. 8, 2002), **App. D93**  
 Statement Regarding Physician Agreements to Control Medical Prepayment Plans, **App. D1**  
 Stevens Hospital, staff advisory opinion to (Apr. 18, 2005), **App. D110**  
 St. John’s Health System (Sept. 13, 2006), **App. D115**  
 Suburban Health Organization, Inc., FTC staff advisory opinion to (March 28, 2006), **App. D113**  
 Suffolk County Dental Society, **App. D47**  
 Tarrant County Medical Society (July 11, 1984), **App. D13**  
 Tarrant County Medical Society (May 25, 1984), **App. D12**  
 Texas House of Representatives Concerning Joint Negotiations

**ADVISORY OPINIONS—Cont'd**

by Physicians (May 13, 1999), **App. D85**  
 TriState Health Partners, FTC letter not to recommend challenge of proposed “clinical integration” of members’ provision of health care services (Apr. 13, 2009), **App. D127**  
 URONET of Louisiana, LLC (Jan. 23, 1996), **App. D61**  
 Utah Society of Oral and Maxillofacial Surgeons, **App. D14**  
 Valley Baptist Medical Center (March 13, 2003), **App. D99**  
 Valley Baptist Medical Center (Sept. 19, 1996), **App. D70**  
 Views on HMO Exclusive Contracts, **App. D24**  
 Viquet and Pitt Country Memorial Hospital (Mar. 8, 2002), **App. D96**  
 Washington House of Representatives, physician joint negotiation statute (Feb. 8, 2002), **App. D93**  
 Wesley Health Center, Inc. (Apr. 29, 1999), **App. D84**  
 Wichita, Kansas, Chamber of Commerce, **App. D29**  
 William W. Backus Hospital (June 11, 1996), **App. D64**  
 Yellowstone Physicians, LLC (May 14, 1997), **App. D75**

**AFFORDABLE CARE ACT**

Integration, Consolidation, Competition in the Wake of the Affordable Care Act, text of remarks of Bill Baer, Assistant Attorney General, before the New Health Care Industry Conference (Nov. 15, 2015), **App. E248**  
 Mergers, analyzing hospital, § 15:22  
 Respecting proposed regulations implementing, statement by FTC Commissioner, **App. E188**

**AGREEMENTS**

Amgen Inc. and Horizon Therapeutics plc, FTC File No. DO9414, **App. N8**

## INDEX

### AGREEMENTS—Cont'd

Bid-rigging agreements, under Section 1, Sherman Act, § **4:5**

Business Review Letter to CEO Roundtable on clinical trial agreements for cancer treatments (Sept. 28, 2008), **App. C101**

Employee non-compete agreements, ethical restraints, § **18:4**

**Exclusionary Dealing Agreements (Hospital/Physician)** (this index)

**Horizontal Agreements** (this index)

**Market-Allocation Agreements** (this index)

Participation agreements between providers and payers, health plan market power, § **21:3**

**Price-Fixing Agreements** (this index)

Reciprocal dealing agreements as vertical agreements under Section 1 of Sherman Act, § **5:8**

Sherman Act Section 1 violations generally, § **3:2 to 3:6**  
see also specific types of agreements

capacity to conspire, § **3:5**

conspiracy in fact, § **3:6**

**Vertical Agreements** (this index)

**“A HEALTH CARE CHECK ON COPAS; ASSESSING THE IMPACT OF CERTIFICATES OF PUBLIC ADVANTAGE IN HEALTH CARE MARKETS” (JUNE 18, 2019)**

Joseph J. Simons, remarks, FTC workshop, **App. E268**

### ALASKA HOUSE OF REPRESENTATIVES

Advisory opinions, physician joint negotiation statute (Jan. 18, 2002), **App. D92**

Certificate-of-need laws and Alaska, joint statement of FTC and Antitrust Division (Apr. 7, 2017), **App. D194**

### ALASKA HOUSE OF

#### REPRESENTATIVES—Cont'd

Federal Trade Commission prepared statement concerning certificate of need (Feb. 15, 2008), **App. E159**

Telehealth services, FTC Advocacy letter to State Legislature concerning (Mar. 25, 2016), **App. D184**

### ALASKA SENATE

Certificate-of-need laws and Bill 62. FTC Statement (Feb. 6, 2018), **App. D197**

Committee on Labor and Commerce, Certificate-of-Need Laws and SB 62, statement of FTC (Feb. 6, 2018), **App. E256**

### ALLERGY & ASTHMA CONSULTANTS, INC.

Business review letters (April 24, 1996), **App. C66**

### ALLIANCE OF INDEPENDENT MEDICAL SERVICES, LLC

Advisory opinions (Dec. 22, 1997), **App. D80**

### ALLIED COLON AND RECTAL SPECIALISTS

Business review letters (July 1, 1996), **App. C69**

### ALLIED HEALTH PRACTITIONERS

In credentialing process, § **13:19**

### ALL-PRODUCTS PROVISIONS

Health plan market power, payer monopoly power and all-products provisions, § **21:7**

### ALPENA PUBLIC SCHOOLS

FTC staff advisory opinion to (June 16, 2006), **App. D114**

### AMBULATORY SURGERY CENTERS (ASCS)

Physician-owned facilities, § **18:2 et seq.**

**AMERICAN ANTITRUST  
INSTITUTE**

“Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care,” text of remarks of Martin Gaynor, Director, Bureau of Economics, FTC, before the 2014 Annual Conference, **App. E234**

**AMERICAN ASSOCIATION OF  
OPHTHALMOLOGY**

Business review letter, **App. C8**

**AMERICAN BAR ASSOCIATION**

“Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers,” text of remarks of Joshua D. Wright, Commissioner, FTC, before the ABA Master Course VII (Oct. 10, 2014), **App. E235**

“Enforcement Strategies in the Health Care Industry,” prepared remarks of J. Thomas Rosch before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E167**

“Observations on and From the Antitrust Division’s buyer-side cases: How can ‘lower’ prices violate the antitrust laws,” remarks of Mark Botti at Antitrust Law Spring Meeting (Apr. 19, 2007), **App. E147**

“Origin of the Species: The 100 Year Evolution of the Clayton Act,” text of remarks of William J. Baer, Assistant Attorney General, Antitrust Division, before the ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014), **App. E237**

“Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,” Joshua D. Wright before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E222**

**AMERICAN BAR ASSOCIATION  
—Cont’d**

“What’s Past is Prologue: FTC’s Competition and Consumer Protection Priorities,” text of remarks by Julie Bill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E236**

**AMERICAN DENTAL  
ASSOCIATION**

Advisory opinions

August 26, 1985, **App. D15**

February 15, 1990, **App. D28**

**AMERICAN HEART  
ASSOCIATION**

Business review letter, **App. C27**

**AMERICAN HEART  
ASSOCIATION  
PHARMACEUTICAL  
ROUNDTABLE**

Business review letters (Mar. 20, 1998), **App. C85**

**AMERICAN HOSPITAL  
ASSOCIATION**

Business review letter, **App. C5**

“Clinical Integration: The Changing Climate and What It Means for Care Coordination,” remarks of Pamela Jones Harbour, Commissioner, FTC at annual membership meeting (Apr. 27, 2009), **App. E170**

**AMERICAN INTRA-OCULAR  
IMPLANT SOCIETY**

Advisory opinion, **App. D17**

**AMERICAN MEDICAL  
ASSOCIATION**

Advisory opinions (March 26, 1996), **App. D62**

Business review letters and advisory opinion

December 2, 1986, **App. C20**

February 14, 1994, **App. D42**

March 9, 1979, **App. C7**

## INDEX

### AMERICAN PODIATRY ASSOCIATION

Advisory opinions  
August 18, 1983, **App. D4**  
March 13, 1984, **App. D7**

### AMERICAN RED CROSS

Business review letter, **App. C21**

### AMGEN INC. AND HORIZON THERAPEUTICS PLC, FTC FILE NO. D09414

Consent order agreement, **App. N8**

### AMICUS BRIEF

FTC, Jazz Pharmaceuticals v. Avadel  
CNS Pharmaceuticals, **App.  
D207**

### ANCILLARY PRICE-FIXING AGREEMENTS

Provider-controlled contracting  
networks, clinical integration,  
§ 20:8

### ANNUAL ANTITRUST SEMINAR

“The Rhetoric of Gun Jumping,”  
remarks before Association of  
Corporate Counsel Annual  
Antitrust Seminar of Greater  
New York Chapter (Nov. 10,  
2005), **App. E138**

### ANNUAL REPORT

FTC and Department of Justice 44th  
Hart-Scott-Rodino, **App. D209**

### ANTHEM, INC.

Acquisition of WellPoint Health  
Networks, Inc., Antitrust Divi-  
sion statement on closing of  
investigation of (March 9,  
2004), **App. E128**

### “ANTICOMPETITIVE ASPECTS OF EXCLUSIVE DEALING AND RELATED PRACTICES”

(Speech), **App. E88**

### ANTICOMPETITIVE CONDUCT (MONOPOLIZATION)

Generally, § 6:4  
Denial of access to essential facility,  
§ 6:8

### ANTICOMPETITIVE CONDUCT (MONOPOLIZATION)

#### —Cont’d

Leveraging, § 6:9  
Mergers, § 6:11  
Monopoly pricing, § 6:5  
Other predatory or unreasonably  
exclusionary conduct, § 6:12  
Predatory pricing, § 6:6  
Refusals to deal, § 6:7  
Vertical integration, § 6:10

### ANTICOMPETITIVE EFFECT ELEMENT (SHERMAN ACT SECTION 1 VIOLATIONS)

Hybrid analyses, § 3:13  
Per se rule, § 3:12  
Rule of reason, § 3:11  
Unreasonably, generally, § 3:10

### ANTICOMPETITIVE PURPOSE OR INTENT ELEMENT

Civil antitrust cases, § 3:8  
Criminal antitrust cases, § 3:9  
Intent in criminal antitrust cases,  
§ 3:9  
Of Sherman Act Section 1 violations,  
§ 3:7  
Purpose and intent in civil antitrust  
cases, § 3:8

### ANTI-KICKBACK STATUTE

“Statement to Negotiated Rulemak-  
ing Committee on Shared Risk  
Exception to Anti-Kickback  
Statute” (speech), **App. E77**

### ANTITRUST, JUDICIARY SUBCOMMITTEE

Competition Policy and Consumer  
Rights 8220 Oversight of the  
Enforcement of the Antitrust  
Laws, 8221 United States Senate  
Committee on the Judiciary  
Subcommittee on Antitrust,  
**App. E287**

### “ANTITRUST ANALYSIS OF HOSPITAL NETWORKS AND SHARED SERVICES ARRANGEMENTS”

(Speech), **App. E65**

**“ANTITRUST AND HEALTH CARE PROVIDERS: POLICIES TO PROMOTE COMPETITION AND PROTECT PATIENTS”**

Rebecca Kelly Slaughter, prepared remarks, **App. E267**

**ANTITRUST CIVIL PROCESS ACT**  
Generally, **App. A9**

**ANTITRUST DEFENSES**

See also **Defenses** (this index)  
To defense actions in nonantitrust cases, § **11:12**

**ANTITRUST DIVISION, DEPARTMENT OF JUSTICE**  
**Justice Department (United States Department of Justice; Antitrust Division)** (this index)

**ANTITRUST GUIDELINES**

Federal trade commission (ftc)  
DOJ and FTC Antitrust Guidelines for Business Activities Affecting Workers  
(January 2025), **App. N26**

**ANTITRUST/HEALTH CARE GUIDELINES**

Generally, **App. F**  
ABA/AHLA Antitrust in Healthcare Conference, Christine A. Varney prepared remarks, **App. E181**  
“An Ounce of Antitrust Prevention is Worth a Pound of Consumer Welfare: The Importance of Competition Advocacy and Premerger Notification,” before Eleventh Annual Competition Day, Santiago, Chile (Nov. 5, 2013), **App. E225**  
“Antitrust and Health Care Providers: Policies to Promote Competition and Protect Patients,” Rebecca Kelly Slaughter, prepared remarks, **App. E267**  
Antitrust Division Evaluation of Corporate Compliance Programs in Criminal Antitrust Investiga-

**ANTITRUST/HEALTH CARE GUIDELINES—Cont’d**

tions (November 2024), **App. N20**

Antitrust in Healthcare Conference: A Prescription for Competition, Benard A. Nigro, Jr., prepared remarks, **App. E263**

FTC topic and yearly indices of advisory opinions, commission and staff, **App. L3**

“Patent Settlements, Patent Reform, and Mergers: Recent Developments in Pharmaceutical Antitrust,” **App. E190**

Telehealth services, advocacy letter to Antitrust Division (Nov. 29, 2016), **App. C105**

“The FTC’s Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets,” Joshua D. Wright before the 2013 Georgetown Global Antitrust Symposium Dinner, Washington, D.C. (Sept. 24, 2013), **App. E223**

US GAO Report, stakeholders perspectives, adequacy of guidance, **App. B15**

**“ANTITRUST IN HEALTHCARE: A KEYNOTE ADDRESS”**

(Speech), **App. E124**  
FTC chairwoman, Health Law Conference (May 12, 2016), **App. E252**

**ANTITRUST IN HEALTHCARE CONFERENCE: A PRESCRIPTION FOR COMPETITION**

Remarks, text of, prepared for, **App. E263**

**ANTITRUST IN HEALTH CARE SEMINAR**

“Clinical Integration in Antitrust: Prospects for the Future,” remarks before AHLA and ABA Antitrust and Health Law Section 2007 Antitrust in Health Care Seminar, prepared remarks

## INDEX

### **ANTITRUST IN HEALTH CARE SEMINAR—Cont'd**

of J. Thomas Rosch, Commissioner, FTC (Sept. 17, 2007),  
**App. E154**

### **“ANTITRUST ISSUES RAISED BY RURAL HEALTH CARE NETWORKS”**

(Speech), **App. E80**

### **ANTITRUST LAW 2007 FALL FORUM**

Prepared slides of Jeffrey Schmidt,  
Director, Bureau of Competition,  
before ABA Section  
concerning “Critical Loss Analysis:  
A Merger Lawyer’s View”  
(Nov. 16, 2007), **App. E157**

### **ANTITRUST LAWS**

Generally, § **1:1**

See also more specific entries  
throughout this index

Conclusion, § **1:9**

Federal government guidelines, § **1:8**

Goals of, § **1:4**

Government enforcement statements,  
§ **1:7**

Health care and, § **1:5**

History and overview of, § **1:3**

History of enforcement of, in health  
care sector, § **1:6**

Legislative changes, § **1:7**

Managed care, effect of, § **1:7**

Provider-controlled contracting  
networks, price-fixing agree-  
ments, § **20:11**

Purpose and definition of, § **1:2**

Relevant federal, in mergers, § **15:3**

Resources, § **1:10**

### **ANTITRUST SAFETY ZONE**

Provider-controlled contracting  
networks, § **20:5**, § **20:6**

### **“ANY-WILLING-PROVIDER” LAWS (FTC LETTERS)**

To the Attorney General of North  
Dakota regarding, **App. D36**

To the California Senate regarding,  
**App. D33**

### **“ANY-WILLING-PROVIDER” LAWS (FTC LETTERS)**

—Cont'd

To the New Hampshire Senate  
regarding, **App. D32**

### **ASSOCIATES IN NEUROLOGY**

Advisory opinions (Aug. 13, 1998),  
**App. D83**

### **ASSOCIATION OF CORPORATE COUNSEL**

“The Rhetoric of Gun Jumping,”  
remarks before Association  
(Nov. 10, 2005), **App. E138**

### **ASSOCIATION OF QUALITY HEALTH CARE**

Advisory opinion, **App. D22**

### **ATTEMPTED MONOPOLIZATION**

Diversification and, under Section 2,  
Sherman Act

generally, § **17:8**

essential facilities doctrine and,  
§ **17:10**

leveraging and, § **17:11**

predatory refusals to deal, § **17:9**

Under Section 2, Sherman Act

generally, § **6:13**

dangerous probability of success,  
§ **6:15**

specific intent and predatory  
conduct, § **6:14**

### **AUTHORITY**

FTC enforcement, § **10:7**

### **BAER, WILLIAM J.**

“Origin of the Species: The 100 Year  
Evolution of the Clayton Act,”  
text of remarks of William J.  
Baer, Assistant Attorney Gen-  
eral, Antitrust Division, before  
the ABA Clayton Act 100th  
Anniversary Symposium (Dec.  
4, 2014), **App. E237**

### **BARRIERS TO GENERIC ENTRY**

Special Committee on Aging, U.S.  
Senate, Prepared Statement of  
FTC Before (July 20, 2006),  
**App. E142**

**BATES WHITE ANNUAL  
ANTITRUST CONFERENCE**

“Litigating Merger Challenges: Lessons Learned,” prepared remarks by J. Thomas Rosch at Fifth Annual Antitrust Conference (June 2, 2008), **App. E165**

**BAXTER HEALTHCARE  
CORPORATION**

Business review letter, **App. C26**

**BAY AREA BUSINESS GROUP ON  
HEALTH**

Business review letter, **App. C37**

**BAY AREA PREFERRED  
PHYSICIANS**

Advisory opinion, **App. D104**

**BEDOYA, ALVARO M.**

Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E288**

**BEIJING, CHINA**

Joshua D. Wright, “Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,” before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E222**

**BIDDING**

Agreements not to engage in competitive, ethical restraints on, **§ 24:4**

**BID-RIGGING AGREEMENTS**

Horizontal, under Section 1, Sherman Act, **§ 4:5**

**“BIGGER THAN BIG TECH? THE  
NEED TO REFORM OUR  
HEALTH CARE MARKETS  
USING CHOICE AND  
COMPETITION” CHRISTINE  
S. WILSON, (SEPTEMBER 9,  
2019)**

Federal trade commission (ftc), **App. E269**

**BIOSIMILARS**

FDA/FTC workshop  
competitive marketplace for biosimilars, **App. D208**  
opening remarks of Chairman Joseph Simons, **App. E271**

**BIRMINGHAM COOPERATIVE  
CLINICAL BENCHMARKING  
DEMONSTRATION PROJECT**

Business review letter, **App. C42**

**BISHOP, MICHAEL D.**

Antitrust Division letter to Michigan Senate Majority Leader Bishop concerning proposed standards of Michigan Certificate of Need Commission (June 6, 2008), **App. C100**

**BJC HEALTH SYSTEM**

Advisory opinions (Nov. 9, 1999), **App. D87**

**BLUMENTHAL, WILLIAM**

“The Rhetoric of Gun Jumping,” remarks before Association of Corporate Counsel Annual Antitrust Seminar of Greater New York Chapter (Nov. 10, 2005), **App. E138**

**BONE & JOINT CENTER OF  
MOBILE, PA**

Business review letters (Apr. 16, 1997), **App. C79**

**BOYCOTTS**

Physician-owned facilities, **§ 18:3**  
Practitioner credentialing, analysis under Section 1 of Sherman Act, **§ 13:10 to 13:17**

**BRIBERY**

Commercial, as vertical agreement under Section 1, Sherman Act, **§ 5:9**

**BRILL, JULIE**

“A Common Goal: The U.S. Federal Trade Commission’s Healthcare Enforcement Program and its Implications for ACOs,” text of remarks by Julie Brill, Commis-

## INDEX

### BRILL, JULIE—Cont'd

sioner, FTC, before the Sixth Annual Accountable Care Organization Summit Preconference (June 17, 2015), **App. E244**

“Bending the Cost Curve: The View from the Federal Trade Commission,” speech by Julie Brill, FTC Comm., **App. E206**

“Competition in Health Care Markets,” text of remarks by Julie Brill, Commissioner, FTC, at 2014 Hal White Antitrust Conference (June 9, 2014), **App. E231**

North Carolina Bar Assoc., prepared remarks before, **App. E198**

“What’s Past is Prologue: FTC’s Competition and Consumer Protection Priorities,” text of remarks by Julie Bill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E236**

### BUREAU OF COMPETITION

Advisory opinion, guidance on requesting and obtaining, **App. D201**

“Antitrust Enforcement in Health Care: Proscription, Not Prescription,” remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC before the Fifth National Accountable Care Organization Summit (June 19, 2014), **App. E232**

FTC Staff Advisory Opinion to Mesa County Physician Independent Practice Association (Nov. 6, 1997), **App. D78A**

Prepared slides of Jeffrey Schmidt, Director, before ABA Section of Antitrust Law 2007 Fall Forum “Critical Loss Analysis: A Merger Lawyer’s View” (Nov. 16, 2007), **App. E157**

Statement of the Federal Trade Commission’s Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002), **App. B3F**

### BUREAU OF COMPETITION

#### —Cont'd

“The Forward-Looking Nature of Merger Analysis,” remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC (Feb. 6, 2014), **App. E230**

### BURNS, TIMOTHY G.

FTC letter to Hon. Timothy G. Burns, Louisiana House of Representatives, concerning in-school dentistry regulation (May 1, 2009), **App. D128**

### BUSINESS

See also **Companies; Firms** (this index)

As element of damage action, § 11:4

Partial integration of functions. **Joint Ventures** (this index)

### BUSINESS HEALTH COMPANIES, INC.

Advisory opinions

(Oct. 19, 1996), **App. D66**

(Oct. 22, 1996), **App. D72**

### BUSINESS JUSTIFICATION

Legitimate, exclusive contracts and, § 14:9

### BUSINESS OF INSURANCE

As antitrust exemption, § 9:10

### BUSINESS REVIEW LETTERS

Generally, **App. C et seq., App. C7, App. C20, App. E106**

AdviNet, Inc., **App. C53**

Allergy & Asthma Consultants, Inc. (April 24, 1996), **App. C66**

Allied Colon and Rectal Specialists (July 1, 1996), **App. C69**

American Association of Ophthalmology, **App. C8**

American Heart Association, **App. C27**

American Heart Association Pharmaceutical Roundtable (Mar. 20, 1998), **App. C85**

American Hospital Association, **App. C5**

**BUSINESS REVIEW LETTERS**

**—Cont'd**

- American Medical Association, **App. C7**
- American Red Cross, **App. C21**
- Baxalta, Emergent BioSolutions, Grifols Therapeutics, and CSL Plasma, **App. C107**
- Baxter Healthcare Corporation, **App. C26**
- Bay Area Business Group on Health, **App. C37**
- Bone & Joint Center of Mobile, PA (Apr. 16, 1997), **App. C79**
- California Chiropractic Association, **App. C36**
- California Pharmaceutical Association, **App. C2**
- Case Western University School of Medicine, **App. C30**
- Central Virginia Health Systems Agency, **App. C9**
- CEO Roundtable on cancer (Sept. 28, 2008), **App. C101**
- Certificate-of-need regulation (Dec. 8, 2006), **App. C99**
- Chicagoland Radiological Network, **App. C49**
- Children's Healthcare, P.A. (March 1, 1996), **App. C62**
- Cincinnati Regional Orthopedic and Sports Medicine Associates, Inc. (Oct. 4, 1996), **App. C74**
- CVT Surgical Center and Vascular Surgery Associates of Baton Rouge (Apr. 16, 1997), **App. C80**
- Danbury Surgical Associates, **App. C24**
- December 2, 1986, **App. C20**
- Demonstration Project, **App. C42**
- Department of Justice. See entries throughout this topic
- Dermatologists, review letter to Dr. Oswald L. Mikell regarding proposed network of, **App. C56**
- Dermnet, Inc. (Dec. 5, 1995), **App. C59**
- Des Moines Collaborative Provider Organization, Inc., **App. C44**

**BUSINESS REVIEW LETTERS**

**—Cont'd**

- Diana West (May 25, 2004), **App. C98**
- Eli Lilly, AbCellera Biologics, Amgen, AstraZeneca, Genentech, and GSK, **App. C108**
- El Paso Surgical Group (July 24, 1996), **App. C71**
- February 5, 2002, **App. E106**
- First Priority Health (Nov. 3, 1997), **App. C84**
- Gainsharing program, Greater New York Hospital Assoc., **App. C104**
- Gales Rexall Drug, **App. C1**
- Gastroenterology Associates, Ltd (July 7, 1997), **App. C82**
- Georgia Preferred Podiatric Medical Network (Nov. 3, 1995), **App. C58**
- GI Associates, P.C. (July 7, 1997), **App. C82**
- Hanger Orthopedic Group, Inc. (Sept 15, 1995), **App. C55**
- Health and Personal Care Conference, Inc., **App. C34**
- Health Care Management Associates, **App. C14**
- Heritage Alliance and Lackawanna Physicians Organization (Sept. 15, 1998), **App. C86**
- Hillhaven Corp., **App. C51**
- Home Care Alliance, Inc. (Oct. 4, 1996), **App. C73**
- Hospice Network of New Jersey, Inc. (April 24, 1996), **App. C67**
- Hospital Corporation of America, **App. C15**
- Hotel Employees and Restaurant Employees International Union Welfare Fund, **App. C41**
- Houston Health Care Coalition, **App. C39**
- Hyatt Ott & Blount, P.C., **App. C28**
- Independent Drug Wholesalers Group, **App. C23**
- International Chiropractors Association, **App. C3**

## INDEX

### BUSINESS REVIEW LETTERS

#### —Cont'd

International Chiropractors Association of California, **App. C46**  
Itasca Clinic and Grand Rapids Medical Associates (March 19, 1996), **App. C65**  
Lexecon Health Service, **App. C17**  
Linen Systems for Healthcare, LLC (Aug. 8, 2006), **App. C97**  
March 9, 1979, **App. C7**  
Marin General Hospital (Feb. 11, 1997), **App. C77**  
Maryland Health Care Coalition, **App. C11**  
Memorial Health, Inc. (Sept. 4, 2009), **App. C102**  
Michigan Hospital Group, Inc. (April 3, 2002), **App. C93**  
Mid-South Health Plan, **App. C52**  
Midwest Behavioral Health LLC (Feb. 4, 2000), **App. C90**  
Morros & Associates, **App. C6**  
National Cardiovascular Network, Inc., **App. C32**  
New Jersey Hospital Association, **App. C38**  
North Mississippi Health Services, **App. C22**  
Northwestern National Life Insurance Company, **App. C50**  
NSM Purchasing Association (Jan. 13, 1999), **App. C88**  
Ohio Hospital Purchasing Consortium, **App. C13**  
Oklahoma Physicians Network-IPA, Inc. (Jan. 17, 1996), **App. C61**  
Olympus America, Ind. (Aug. 29, 2001), **App. C92**  
Optometric care, **App. D109**  
Orange Los Angeles Medical Group, Inc. (March 8, 1996), **App. C64**  
Orthopedic Associates of Mobile, PA (Apr. 16, 1997), **App. C79**  
Pacific Business Group on Health (Apr. 26, 2010), **App. C103**  
Pennsylvania Insurance Commissioner, **App. C31**

### BUSINESS REVIEW LETTERS

#### —Cont'd

Pennsylvania Orthotics & Prosthetics Enterprise, **App. C54**  
Pharmaceutical benefit managers regulation, letter to Virginia House of Delegates (Oct. 2, 2006), **App. D116**  
Pharmaceutical Care Network, **App. C18**  
Pharmaceutical Manufacturers Association, **App. C33**  
Pharmacy benefit managers (“PBMs”) and “covered entities,” House Bill 1332 (“HB 1332” or the “Bill”) that would regulate the contractual relationships between, **App. D108**  
Physician Care, Inc., **App. C47**  
Plastic Surgery Associates of Connecticut, LLC (June 28, 1996), **App. C68**  
PPE collaboration, **App. C106**  
Preferred Laboratory Access Network (Dec. 7, 1995), **App. C60**  
Preferred Physicians Medical Group (July 23, 1999), **App. C89**  
Preferred Podiatric Network Inc., **App. C45**  
Primary and Specialist Medical Center, LLC (July 2, 1996), **App. C70**  
PROklahoma Care, Inc. (Jan. 17, 1996), **App. C61**  
Pulmonary Associates, Ltd., and Albuquerque Pulmonary Consultants, P.A., **App. C48**  
Relating to Wisconsin Rate Review Program, **App. C4**  
Rio Grande Eye Associates, P.A., **App. C91**  
Ross Hospital (Feb. 11, 1997), **App. C77**  
RWHC Network, Inc. (Nov. 12, 1996), **App. C76**  
Santa Fe, New Mexico Managed Care Organization, Inc. (Feb. 12, 1997), **App. C78**  
(Sept. 16, 1998), **App. C87**

**BUSINESS REVIEW LETTERS**

**—Cont'd**

Seeskin, Paas, Blackburn & Co.,  
**App. C43**

Service For You, **App. C19**

Sierra CommCare, Inc. (Aug. 15,  
1996), **App. C72**

South Carolina State Health Planning  
Committee, concerning certifi-  
cate-of-need regulation (Dec. 8,  
2006), **App. C99**

Southern Health Corporation (March  
5, 1996), **App. C63**

Southwestern Michigan Health  
Systems Agency, **App. C12**

Southwest Oncology Group (Nov. 2,  
1995), **App. C57**

Southwest Orthopedic Specialists  
(June 10, 1997), **App. C81**

St. Anthony Medical Center, **App.  
C35**

Stark County Health Care Coalition,  
**App. C16**

St. Joseph's/Candler Health System  
(Sept. 4, 2009), **App. C102**

St. Louis Area Business Health  
Coalition, **App. C25**

Terence L. Smith, M.D. (Oct. 17,  
1996), **App. C75**

To Senator Howard Metzenbaum,  
**App. C40**

Transplant Associates, **App. C29**

Valley Gastroenterologists (July 7,  
1997), **App. C82**

Vermont Physicians Clinic (July 30,  
1997), **App. C83**

Virginia House of Delegates concern-  
ing regulation of pharmaceutical  
benefit managers (Oct. 2, 1997),  
**App. D116**

Washington State Medical Associa-  
tion, **App. C94**

Westlake Health Campus Associa-  
tion, **App. C10**

**BUSINESS REVIEW PROCEDURE**

Of Antitrust Division enforcement,  
**§ 10:6, App. B4**

**“BUYER POWER CONCERNS  
AND THE  
AETNA/PRUDENTIAL  
MERGER”**

(Speech), **App. E91**

**CALIFORNIA CHIROPRACTIC  
ASSOCIATION**

Business review letter, **App. C36**

**CALIFORNIA MANAGED  
IMAGING MEDICAL GROUP,  
INC.**

Advisory opinion, **App. D40**

**CALIFORNIA  
PHARMACEUTICAL  
ASSOCIATION**

Business review letter, **App. C2**

**CANADA**

Dental licenses, FTC staff comment  
on New York's proposal to  
allow licensure by endorsement  
of Canadian, **App. D199**

**CANCER**

Business Review Letter to CEO  
Roundtable on clinical trials for  
cancer treatments (Sept. 28,  
2008), **App. C101**

**CAPACITY**

To conspire, practitioner credential-  
ing and, Section 1 of Sherman  
Act, **§ 13:11**

**CAREMARK RX/ADVANCEPCS  
MERGER**

FTC statement in closing investiga-  
tion of (Feb. 11, 2004), **App.  
E127**

**CASE WESTERN UNIVERSITY  
SCHOOL OF MEDICINE**

Business review letter, **App. C30**

**CAUSATION**

As element of damage action, **§ 11:5**

**CENTERS FOR MEDICARE AND  
MEDICAID SERVICES**

Medicare prescription drug benefit  
programs, FTC Staff Advocacy

## INDEX

### CENTERS FOR MEDICARE AND MEDICAID SERVICES

#### —Cont’d

Letter to CMMS concerning  
any-willing-provider changes  
(Mar. 7, 2014), **App. D164**

### CENTRAL TEXAS MEDICAL GROUP

Advisory opinions (Sept. 28, 1995),  
**App. D58**

### CENTRAL VIRGINIA HEALTH SYSTEMS AGENCY

Business review letter, **App. C9**

### CEO ROUNDTABLE

Business Review Letter to CEO  
Roundtable on cancer (Sept. 28,  
2008), **App. C101**

### CERTIFICATE-OF-NEED (CON)

Agency opposition, § 22:3

Alaska Senate Committee on Labor  
and Commerce, Certificate-of-  
Need Laws and SB 62, state-  
ment of FTC (Feb. 6, 2018),  
**App. E256**

Antitrust ramifications of certificate-  
of-need proceedings, § 22:4

“Competition in healthcare and cer-  
tificate of need” prepared  
testimony of U.S. Department of  
Justice Antitrust Division to  
Georgia General Assembly (Feb.  
23, 2007), **App. E145**

Federal Trade Commission prepared  
statement before Alaska House  
of Representatives (Feb. 15,  
2008), **App. E159**

Federal Trade Commission prepared  
statement before Florida State  
Senate (Apr. 2, 2008), **App.  
E163**

Federal Trade Commission Staff  
advocacy letter concerning bill  
to modify North Carolina law  
(July 10, 2015), **App. D174**

FTC and Antitrust Division joint  
statement to Alaska House of  
Representatives, (Apr. 7, 2017),  
**App. D194**

### CERTIFICATE-OF-NEED (CON) —Cont’d

FTC statement to Alaska Senate on  
CON laws and Bill 62 (Feb. 6,  
2018), **App. D197**

Letter from Joseph Miller, Assistant  
Chief, Antitrust Division, to Sen.  
Michael D. Bishop, Michigan  
Senate Majority Leader,  
concerning proposed standards  
(June 6, 2008), **App. C100**

Letter from U.S. Department of  
Justice Antitrust Division to  
South Carolina State Health  
Planning Committee concerning  
regulation (Dec. 8, 2006), **App.  
C99**

Physician-owned facilities, hospital’s  
opposition, § 18:3

Pros and cons, § 22:3

South Carolina, joint statement of  
FTC and Antitrust Division on  
Certificate-of-Need laws and  
proposed legislation (Jan. 16,  
2016), **App. D179**

Virginia, joint statement of FTC and  
Antitrust Division to Virginia  
Certificate of Need Work Group  
(Oct. 26, 2015), **App. D177**

### CERTIFICATE OF PUBLIC ADVANTAGE

“A Health Care Check on COPAs;  
Assessing the Impact of Certifi-  
cates of Public Advantage in  
Health Care Markets” Joseph J.  
Simons, remarks, (June 18,  
2019), **App. E268**

FTC Staff advocacy letter to Malaka  
Watson, Tennessee Department  
of Health, concerning coopera-  
tive agreements and certificates  
of public advantage (Sept. 24,  
2015), **App. D176**

### CERTIFICATES OF PUBLIC ADVANTAGE

FTC policy, **App. D205**

### CHILDREN’S HEALTHCARE, P.A.

Business review letters (March 1,  
1996), **App. C62**

**CHINA**

“Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,” Joshua D. Wright before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E222**

**CINCINNATI REGIONAL  
ORTHOPEDIC AND SPORTS  
MEDICINE ASSOCIATES,  
INC.**

Business review letters (Oct. 4, 1996), **App. C74**

**CIVIL ANTITRUST  
INVESTIGATION BASICS**  
(Speech), **App. E66**

**CIVIL ENFORCEMENT**

See also **Enforcement** (this index)  
By Antitrust Division, § 10:4

**CLAYTON ACT**

100th anniversary, “Origin of the Species: The 100 Year Evolution of the Clayton Act,” text of remarks of William J. Baer, Assistant Attorney General, Antitrust Division, before the ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014), **App. E237**

Section 7

generally, § 8:1  
Antitrust Division and Federal Trade Commission, § 8:18  
conclusion, § 8:20  
conglomerate mergers, § 8:15  
diversification and, § 17:7  
joint ventures, § 8:16  
mergers and, § 15:3  
preliminary issues, § 8:2  
premerger notification requirements, § 8:17  
relevant markets, § 8:4  
2010 merger guidelines and merger analysis, § 8:3  
vertical mergers, § 8:14  
Section 8, § 7:12

**CLAYTON ACT—Cont’d**

Section 7A, Hart Scott-Rodino premerger notification filings revised jurisdictional thresholds, **App. B26**

Section 7A, premerger notification form and instructions under amended, **App. B3**

Section 7: horizontal mergers

generally, § 8:5  
collusion, market characteristics and ease of, § 8:10

concentration, § 8:6

defenses, § 8:13

efficiencies from merger, § 8:12

financial viability, § 8:11

guidelines, Department of Justice and Federal Trade Commission, § 15:9, **App. B6**

other factors, § 8:7

Section 2. **Robinson-Patman Act**  
(this index)

Text of, excerpts, **App. A2**

**CLEARANCE PROCEDURES**

Memorandum of Agreement between FTC and Antitrust Division of the U.S. Dept. of Justice concerning clearance procedures for investigations, **App. B7**

**CLINICAL INTEGRATION**

“Clinical Integration: The Changing Climate and What It Means for Care Coordination” (Apr. 27, 2009), remarks of Pamela Jones Harbour, Commissioner, FTC, **App. E170**

Provider-controlled contracting networks, ancillary price-fixing agreements and clinical integration, § 20:8

TriState Health Partners, FTC letter not to recommend challenge of proposed “clinical integration” of members’ provision of health care services (Apr. 13, 2009), **App. D127**

**CLINICAL TRIAL AGREEMENT**

Business Review Letter to CEO Roundtable on cancer (Sept. 28,

## INDEX

### CLINICAL TRIAL AGREEMENT

—Cont'd

2008), **App. C101**

### COLLABORATION GUIDELINES

Generally, **App. G, App. G1**

Antitrust guidelines for collaborations among competitors, § **3:14**

Medical school collaboration agreements, FTC Staff Advocacy letter to Alabama State Senate concerning antitrust exemption (May. 2, 2016), **App. D186**

Overview of, § **16:6**

State-action protection to certain collaborative activity, FTC Staff Advocacy letter to West Virginia House of Delegates concerning (Mar. 9, 2016), **App. D183**

### COLLECTIVE BARGAINING

FTC staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D123**

Legislative exemption, letter from FTC to Insurance Committee, Ohio House of Representatives, **App. D95**

### COLLECTIVE NEGOTIATION OF FEES

FTC Staff letter to Puerto Rico Treasury and Financial Affairs Committee objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D121**

### COLUMBINE FAMILY HEALTH CENTER

Advisory opinions (Nov. 89, 1995), **App. D59**

### COLUMBUS HOSPITAL

Advisory opinions (June 28, 1996), **App. D65**

### “COMBINATION AND COLLABORATION IN HEALTH CARE MARKETS: ANTITRUST AS A CONSTRAINT IN A TIME OF CHANGE”

Speech, **App. E41**

### COMMERCIAL BRIBERY

As vertical agreement under Section 1, Sherman Act, § **5:9**

### COMMUNITY AND PAYER MORAL SUASION

Physician-owned facilities, § **18:3**

### COMMUNITY CAREPARTNERS

Federal Trade Commission (FTC), staff advisory opinion to Community CarePartners concerning the Non-Profit Institutions Act, **App. D132**

### COMMUNITY HOSPITAL, INC.

Advisory opinions (Dec. 22, 1997), **App. D79**

### COMMUNITY PHARMACY FAIRNESS ACT

Prepared Statement of FTC Before U.S. House of Representatives Judicial Committee concerning HR 971, “Community Pharmacy Fairness Act of 2007” (Oct. 18, 2007)—David Wales, Bureau of Competition, **App. E156**

### COMPANIES

See also **Business** (this index)

### COMPETITION

See more specific entries throughout this index

### COMPETITIVE BIDDING

Agreements not to engage in, ethical restraints on, § **24:4**

### COMPETITIVE EFFECTS

Under Section 2(a), Robinson-Patman Act, § **7:5**

**COMPETITIVELY SENSITIVE  
HEALTH CARE  
INFORMATION**

Federal Trade Commission advocacy letter to Minnesota House of Representatives regarding a bill to permit disclosure (June 29, 2015), **App. D173**

**COMPETITIVE MARKETPLACE**

Summary report, FDA/FTC workshop for biosimilars, **App. D208**

**COMPETITOR IDENTIFICATION**

Mergers and, § 15:12

**CONCENTRATION**

Mergers and  
as factor in horizontal merger under Section 7 of Clayton Act, § 8:6

**CONFLICTS OF INTEREST**

Physician-owned facilities, § 18:2, § 18:3

**CONGLOMERATE MERGERS**

Under Section 7 of Clayton Act, § 8:15

**CONNECTICUT BAR  
ASSOCIATION**

“Health Care Technology: Promoting Competition and Protecting Innovation,” Maureen K. Ohlhausen, Commissioner of FTC, before Connecticut Bar Association Antitrust and Trade Regulation and Consumer Law Sections (Feb. 26, 2014), **App. E228**

**CONNECTICUT HOSPITAL  
ASSOCIATION**

Advisory opinions (Dec. 20, 2001), **App. D91**

**CONSENT ORDER**

Amgen Inc. and Horizon Therapeutics plc, FTC File No. DO9414, **App. N8**

**CONSPIRACY**

See also **Agreements** (this index)

Capacity to conspire, practitioner credentialing and, under Section 1, Sherman Act, § 13:11

In fact, practitioner credentialing and, under Section 1 of Sherman Act, § 13:12

To monopolize, § 6:16

**CONSUMER**

Competition Policy and Consumer Rights 8220 Oversight of the Enforcement of the Antitrust Laws, 8221 **App. E287**

“Interface of Competition and Consumer Protection” (October 31, 2002), **App. E113**

**CONTRACTS**

Exclusive. **Exclusive Contracts** (this index)

Networks. **Provider-Controlled Contracting Networks** (this index)

**COOPERATIVE AGREEMENTS**

FTC Staff advisory letter to Susan Puglisi, Virginia Department of Health, concerning cooperative agreements (Sept. 17, 2015), **App. D175**

FTC Staff advocacy letter to Malaka Watson, Tennessee Department of Health, concerning cooperative agreements and certificates of public advantage (Sept. 24, 2015), **App. D176**

**CORONAVIRUS**

DOJ and FTC joint antitrust statement regarding COVID-19 (March 2020), **App. K1**

**“COST-SHIFTING”**

Physician-owned facilities, § 18:2

**COVENANTS**

Horizontal, not to compete, under Section 1 of Sherman Act, § 4:6

**COVID-19**

DOJ and FTC joint antitrust statement regarding COVID-19

## INDEX

### COVID-19—Cont'd

(March 2020), **App. K1**

### CREDENTIALING

**Practitioner Credentialing** (this index)

### CREDIT SUISSE 2018

#### WASHINGTON PERSPECTIVES CONFERENCE

Remarks at, (Jan. 10, 2018), **App. E262**

### CRIMINAL ENFORCEMENT

See also **Enforcement** (this index)  
By Antitrust Division, § **10:3**

### CROSS-MARKET

Mergers, § **15:29**

### “CROSS-SUBSIDIZATION”

Physician-owned facilities, § **18:2**

### “CURRENT ISSUES IN HEALTH CARE ANTITRUST ENFORCEMENT AT FTC”

(Speech), **App. E67**

### CVT SURGICAL CENTER AND VASCULAR SURGERY ASSOCIATES OF BATON ROUGE

Business review letters (Apr. 16, 1997), **App. C80**

### DAMAGES

Private actions, § **11:1**

### DANBURY SURGICAL ASSOCIATES

Business review letter, **App. C24**

### DEAL

**Refusals to Deal** (this index)

### DEALING AGREEMENTS

Under Section 1, Sherman Act  
exclusive dealing, § **5:7**  
reciprocal dealing, § **5:8**

### DEFENSES

Damage action  
generally, § **11:9**

### DEFENSES—Cont'd

Damage action—Cont'd  
antitrust defenses in nonantitrust  
cases, § **11:12**  
in pari delicto and related defenses,  
§ **11:11**  
statute of limitations, § **11:10**  
Mergers, failing company, § **15:20**  
To horizontal mergers under Section  
7 of Clayton Act, § **8:13**  
Under Section 2(a), Robinson-Pat-  
man Act, § **7:6**

### DELAWARE

Board of Dietetics/Nutrition,  
Telehealth Dietetic and Nutrition  
Services), FTC staff advocacy  
letter (Aug. 16, 2016), **App. D190**

Board of Occupational Therapy  
Practice, occupational therapist  
telehealth supervision, FTC staff  
advocacy letter (Aug. 3, 2016),  
**App. D189**

Board of Speech/Language Patholo-  
gists, Audiologists, and Hearing  
Aid Dispensers, amendment to  
telecommunication and  
telehealth regulations, FTC  
advocacy letter (Nov. 29, 2016),  
**App. D191**

### DENIAL OF ACCESS

To essential facility, as anticompeti-  
tive conduct under Section 2 of  
Sherman Act, § **6:8**

### DENTISTS AND ORAL SURGEONS

Canadian dental licenses, FTC staff  
comment on New York's pro-  
posal to allow licensure by  
endorsement of, **App. D199**

Dental Accreditation Commission,  
**App. D161, App. D163, App. D167**

Education accreditation standards  
modifications to Louisiana Rules  
regarding the practice of por-  
table and mobile dentistry,  
FTC Staff comments to Loui-  
siana State Board of Dentistry  
(Dec. 9, 2009), **App. D130**

## DENTISTS AND ORAL SURGEONS

### —Cont’d

Education accreditation standards

### —Cont’d

Staff advocacy letter to Sherin

Tooks, Commission on Dental Accreditation (Dec. 12, 2014), **App. D167**

Staff letter to Commission on Dental Accreditation (Dec. 2, 2013), **App. D161, App. D163**

In-school dentistry regulation, FTC letter to Hon. Timothy G. Burns, Louisiana House of Representatives (May 1, 2009), **App. D128**

Practices, business organizations supporting, **App. D153**

Southwest Florida Oral Surgery Associates (Dec. 2, 1996), advisory opinions, **App. D67**

Supervision of dental hygienists, Advocacy letter to Georgia State Senate (Jan. 29, 2016), **App. D180**

Therapist licensing, staff advocacy letter (Mar. 3, 2017), **App. D192**

Utah Society of Oral and Maxillofacial Surgeons, advisory opinions, **App. D14**

## DENTURISTS

FTC Advocacy letter to Kentucky House of Representatives concerning regulation (Mar. 25, 2016), **App. D185**

## DEPARTMENTAL CLOSINGS

Exclusive contracts and, § 14:14

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

FTC Staff advocacy letter to Department of Health and Human Services concerning interoperability of health information technology (Apr. 3, 2015), **App. D168**

## DEPARTMENT OF JUSTICE

Additional information, documentary material request, **App. B9**

## DEPARTMENT OF JUSTICE

### —Cont’d

Antitrust division. **Justice Department (United States Department of Justice; Antitrust Division)** (this index)

DOJ and FTC 2023 Merger Guidelines, **App. B20**

DOJ Complaint in matter of U.S., et al. v. Unitedhealth Group Incorporated, et al., **App. N21**

44th Hart-Scott-Rodino annual report, **App. D209**

Keynote remarks of Commissioner Rebecca Kelly Slaughter, Pharmaceutical Task Force Workshop, **App. E286**

Orange book, brand drug manufacturers improper listing of patents, statement, **App. B22**

Press release, FTC, DOJ and HHS work

lower health care and drug costs, **App. B21**

Strengthen enforcement against illegal mergers, **App. B19**

## DERMATOLOGISTS

Business review letters to Dr. Oswald L. Mikell regarding proposed network of, **App. C56**

## DERMNET, INC.

Business review letters (Dec. 5, 1995), **App. C59**

## DES MOINES COLLABORATIVE PROVIDER ORGANIZATION, INC.

Business review letter, **App. C44**

## “DIAGNOSING PHYSICIAN-HOSPITAL ORGANIZATIONS”

(Speech), **App. E125**

## DIRTY TRICKS

Under Section 1 of Sherman Act, as horizontal agreements, § 4:9

## DISMISSAL

**Summary Judgments** (this index)

## INDEX

### **DISTRIBUTORSHIP TERMINATIONS**

Under Section 1 of Sherman Act, as  
vertical agreements, § 5:4

### **DIVERSIFICATION**

Provider. **Provider Diversification**  
(this index)

### **DOJ ANTITRUST DIVISION**

Economic analysis group discussion  
paper  
Online Reviews and Hospital  
Choices, EAG 22-1  
December 2022, **App. N5**

### **DUAL DISTRIBUTION**

Under Section 1 of Sherman Act, as  
vertical agreements, § 5:5

### **DUNCHEON, MICHAEL A.**

Advisory opinion, **App. D20**

### **DUNLAP MEMORIAL HOSPITAL**

FTC staff advisory opinion to (Jan. 6,  
2004), **App. D105**

### **EASTERN OHIO PHYSICIANS ORGANIZATION, INC.**

Advisory opinions (Sept. 28, 1995),  
**App. D57**

### **ECONOMIC CREDENTIALING**

Physician-owned facilities, § 18:3

### **ECONOMIC EFFECTS**

Of mergers, § 15:2

### **ECONOMIC INTEREST**

In sale of tied product, exclusive  
contracts and, § 14:8  
**Physician-Owned Facilities** (this  
index)

### **ECONOMIC TOOLS**

“FTC v. Sysco: Old School Antitrust  
With Modern Economic Tools”  
text of remarks of Deborah L.  
Feinstein before GCR Live  
(Sept. 18, 2015), **App. E246**

### **EFFICIENCIES**

“Efficiencies and antitrust: an Ongo-  
ing Evolution” (November 8,  
2002), **App. E114**

### **EFFICIENCIES—Cont’d**

“Efficiency Justifications for  
Hospital Mergers” (speech),  
**App. E45**

### **EL PASO SURGICAL GROUP**

Business review letters (July 24,  
1996), **App. C71**

### **EMMER, TOM**

FTC letter to Hon. Tom Emmer, Min-  
nesota House of Representa-  
tives, concerning rural health  
care cooperatives joint negotia-  
tions (Mar 18, 2009), **App.  
D125**

### **ENFORCEMENT (ANTITRUST DIVISION AND FTC)**

Generally, § 10:1

Adoption of the Statement of  
Enforcement Policy, Unfair  
Methods of Competition Under  
Section 5 of the FTC Act, **App.  
E288**

Antitrust Division

generally, § 10:2

business review procedure

generally, § 10:6

see also **Business Review Let-  
ters** (this index)

civil enforcement, § 10:4

criminal enforcement, § 10:3

organization, § 10:2

relief in civil cases, § 10:5

Edith Ramirez, “Oversight of  
Enforcement of Antitrust  
Laws,” before U.S. House of  
Representatives, Washington  
D.C. (Nov 15, 2003), **App.  
E226**

Federal Trade Commission

generally, § 10:7

advisory opinions

generally, § 10:9, **App. B5**

see also **Advisory Opinions**  
(this index)

Government enforcement statements,  
§ 1:7

History of, in health care sector, § 1:6

**ENFORCEMENT (ANTITRUST  
DIVISION AND FTC)—Cont'd**

Joshua D. Wright, “Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,” before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E222**

J. Thomas Rosch, “Enforcement Strategies in the Health Care Industry,” prepared remarks before the ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E167**

Maureen K. Ohlhausen, “When Regulation Protects Privilege Instead of People: Government Restraints of Trade-A Competition Enforcer’s Perspective,” text of remarks before The Antitrust Enforcement Symposium 2015 of Journal of Antitrust Enforcement (June 27, 2015), **App. E245**

“Oversight of the Enforcement of Antitrust Law,” FTC prepared statement before U.S. Senate Committee on the Judiciary (Mar 9, 2016), **App. E251**

“Oversight of the Enforcement of Antitrust Laws,” Edith Ramirez before U.S. House of Representatives, Washington D.C. (Nov 15, 2003), **App. E226**

“Oversight of the Enforcement of the Antitrust Laws” FTC prepared statement before US House of Representatives (May 15, 2015), **App. E242**

Statements of enforcement policy and analytical principles relating to health care and antitrust, withdrawn, **App. F1**

Terrell McSweeney, “Reflections on an Active Year in Merger Enforcement,” keynote remarks at Antitrust Law Leaders Forum (Feb. 5, 2016), **App. E250**

**EQUIPMENT**

Joint ventures among competitors to provide new, § **16:9**

**EQUITABLE LIFE ASSURANCE  
SOCIETY OF THE UNITED  
STATES**

Advisory opinion, **App. D21**

**EQUITABLE RELIEF**

In Federal Trade Commission, plaintiff, v. Surescripts, LLC stipulated order, **App. N7**

**ESSENTIAL FACILITY**

Denial of access to, as anticompetitive conduct under Section 2 of Sherman Act, § **6:8**

Diversification and essential facilities doctrine, § **17:10**

**ETHICAL RESTRAINTS**

Generally, § **24:1**

Agreements not to engage in competitive bidding, § **24:4**

Conclusion, § **24:10**

Employee non-compete agreements, § **18:4**

Generally applicable antitrust principles, § **24:2**

Limitations on advertising and solicitation, § **24:6**

Membership restrictions, § **24:8**

“Poaching,” limitations on, § **24:5**

Price-fixing agreements, § **24:3**

Restraints on practice form, § **24:7**

Standards of practice relating to quality, § **24:9**

**“EXAMINING COMPETITION IN  
GROUP HEALTH CARE”**

Prepared Statement of FTC Before U.S. Senate Committee on Judiciary, (Sept. 6, 2006), **App. E142A**

**EXCLUSIONARY CONDUCT**

See also **Anticompetitive Conduct** (this index)

Unreasonably, as anticompetitive conduct under Section 2 of Sherman Act, § **6:12**

## INDEX

### “EXCLUSIONARY VERTICAL AGREEMENTS”

(Speech), **App. E85**

### EXCLUSION FROM FACILITY

**Practitioner Credentialing** (this index)

### EXCLUSION PAYMENT SETTLEMENTS

“Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,” prepared statement of FTC before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E169**

“Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-c-k!,” prepared remarks before second annual in-house counsel’s forum on pharmaceutical antitrust (Apr. 24, 2006), **App. E141**

“FTC v. Actavis and the Future of Reverse Payment Cases,” remarks of Joshua D. Wright, Commissioner, FTC, before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E224**

“How Pay-for-Delay Settlements Make Consumers and Federal Government Pay More for Much Needed Drugs,” prepared statement of J. Thomas Rosch, Commissioner, FTC, before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009), **App. E168**

Pay-for-Delay Settlements generally, **25:1, 25:2**

Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law

### EXCLUSION PAYMENT

#### SETTLEMENTS—Cont’d

Pay-for-Delay Settlements—Cont’d  
Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E174**  
recent cases, **25:2**

### EXCLUSIVE CONTRACTS

Health plan market power, **§ 21:9**  
Hospital/physician. **Exclusive Contracts (Hospital/Physician)** (this index)  
Physician-owned facilities, **§ 18:3**

### EXCLUSIVE CONTRACTS (HOSPITAL/PHYSICIAN)

Generally, **§ 14:1**  
And vertical price-fixing agreements, **§ 14:15**  
Antitrust theories, **§ 14:2**  
As tying arrangements generally, **§ 14:3**  
conditional sale of one service on purchase of another, **§ 14:5**  
economic interest in sale of tied product, **§ 14:8**  
effect on substantial amount of interstate commerce, **§ 14:7**  
legitimate business justification, **§ 14:9**  
market power in market for tying product, **§ 14:6**  
separate and distinct products, **§ 14:4**  
As violations of Section 2 of Sherman Act, **§ 14:13**  
Departmental closings, **§ 14:14**  
Exclusive dealing agreements generally, **§ 14:10**  
effect on competition, **§ 14:12**  
relevant market, **§ 14:11**  
Minimizing antitrust risk, **§ 14:16**

### EXCLUSIVE DEALING AGREEMENTS (HOSPITAL/PHYSICIAN)

Generally, **§ 14:10**

**EXCLUSIVE DEALING**

**AGREEMENTS**

**(HOSPITAL/PHYSICIAN)**

**—Cont’d**

“Anticompetitive Aspects of Exclusive Dealing and Related Practices” (speech), **App. E88**  
 As vertical agreements under Section 1 of Sherman Act, § **5:7**  
 Diversification resulting from, § **17:4**  
 Effect on competition, § **14:12**  
 Relevant market, § **14:11**

**EXCLUSIVE JURISDICTION**

Generally, § **9:6**

**EXEMPTIONS AND IMMUNITIES**

Generally, § **9:1**  
 Business of insurance, § **9:10**  
 Federal government and federally regulated industries generally, § **9:3**  
 express immunity, § **9:4**  
 federal government immunity, § **9:3**  
 implied repeal, § **9:5**  
 primary and exclusive jurisdiction, § **9:6**  
 Health Care Quality Improvement Act, § **9:12**  
 Hospital medical staff credentialing, § **9:12**  
 Labor, § **9:11**  
 Local Government Antitrust Act, § **9:9**  
 Nonprofit entities and noncommercial conduct, § **9:2**  
 Physician peer-review activities, § **9:12**  
 Robinson-Patman Act, § **7:10**  
 Solicitation of government action, § **9:8**  
 State action, § **9:7**  
 from antitrust, § **9:7**  
 mergers, economic effects, § **15:6**  
 “Reflections on Supreme Court’s North Carolina Dental Decision and the FTC’s Campaign to Rein in State Action Immunity,” Maureen K.

**EXEMPTIONS AND IMMUNITIES**

**—Cont’d**

State action, § **9:7**—Cont’d  
 Ohlhausen, Commissioner, (Mar 31, 2015), **App. E240**

**EXPRESS IMMUNITY**

From antitrust, § **9:4**

**FACILITY**

Denial of access to essential, as anticompetitive conduct under Section 2 of Sherman Act, § **6:8**

**FEDERAL COMPLAINT FOR INJUNCTION**

FTC v. U.S. Anesthesia Partners, Inc., **App. N9**

**FEDERAL GOVERNMENT**

And federally regulated industries.  
**Exemptions and Immunities**  
 (this index)

**FEDERAL TRADE COMMISSION (FTC)**

For detailed matters, see more specific entries throughout this index  
 Generally, **App. B3C, App. B3E**  
 Accountable Care Organizations, § **20:15, App. H1**  
 Accountable Care Organizations participating in Medicare Shared Savings Program, **App. E215**  
 Administrative Complaint  
 Matter of GTCR BC Holdings, LLC and Surmodics, Inc  
 FTC Matter/File Number 241 0095, Docket Number 9440, **App. N24**  
 Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E288**  
 Advanced practice nurses, “Policy Perspectives: Competition and Regulation of Advanced Practice Nurses” FTC Executive Summary (Mar. 2014), **App. E229**

## INDEX

### FEDERAL TRADE COMMISSION (FTC)—Cont'd

Advanced practice registered nurses,  
advocacy letter regarding, **App. D158, App. D169, App. D181**  
“Advancing Economic Liberty,”  
**App. E257**

Advisory opinions of  
for detailed matters, see **Advisory  
Opinions** (this index)  
generally, § **10:9**

Affiliation agreement, close of  
investigation of, **App. E205**

“A Health Care Check on COPAs;  
Assessing the Impact of Certifi-  
cates of Public Advantage in  
Health Care Markets” Joseph J.  
Simons, (June 18, 2019), **App. E268**

Alabama State Board of Medical  
Examiners, FTC staff comments  
concerning proposed regulation  
of interventional pain manage-  
ment services, **App. D135**

Alaska House of Representatives,  
prepared statement of FTC  
concerning certificate of need  
(Feb. 15, 2008), **App. E159**

Alaska Senate Committee on Labor  
and Commerce, Certificate-of-  
Need Laws and SB 62, state-  
ment of FTC (Feb. 6, 2018),  
**App. E256**

Amicus brief, Jazz Pharmaceuticals  
v. Avadel CNS Pharmaceuticals,  
**App. D207**

Annual report, 44th Hart-Scott-  
Rodino, **App. D209**

“Antitrust Analysis of Reverse Pay-  
ments After Actavis: Three  
Questions and Proposed  
Answers,” text of remarks of  
Joshua D. Wright, Commis-  
sioner, FTC, before the ABA  
Master Course VII (Oct. 10,  
2014), **App. E235**

Appeal procedure for requests for  
additional information, **App. B8**

Assistant attorney general Jonathan  
Kanter announces task force on

### FEDERAL TRADE COMMISSION (FTC)—Cont'd

health care monopolies and col-  
lusion (May 9, 2024), **App. N15**

Attempted merger of Rhode Island’s  
largest healthcare providers,  
**App. E282**

“Bigger than Big Tech? The Need to  
Reform Our Health Care  
Markets Using Choice and  
Competition” Christine S.  
Wilson, (September 9, 2019),  
**App. E269**

Bureau of Competition. **Bureau of  
Competition** (this index)

Caremark Rx/AdvancePCS merger,  
FTC statement in closing  
investigation of (Feb. 11, 2004),  
**App. E127**

Certificate-of-need

Alaska Senate Bill 62 (Feb. 6,  
2018), **App. D197**

Alaska Senate Committee on  
Labor and Commerce, Certifi-  
cate-of-Need Laws and SB  
62, statement of FTC (Feb. 6,  
2018), **App. E256**

application, advocacy letter, **App. D195**

laws and Alaska, joint statement of  
FTC and Antitrust Division  
(Apr. 7, 2017), **App. D194**

laws and Alaska Senate Bill 62  
(Feb. 6, 2018), **App. D197**

Certificates of Public Advantage,  
advocacy letter regarding, **App. D170**

Certified nurse practitioners,  
advocacy letter, **App. D196**

Chronic pain treatment by certified  
registered nurse anesthetists,  
**App. D159**

“Clinical Integration: The Changing  
Climate and What It Means for  
Care Coordination” (Apr. 27,  
2009), remarks of Pamela Jones  
Harbour, Commissioner, FTC,  
**App. E170**

Collaborative activity, FTC Staff  
Advocacy letter to West Virginia

**FEDERAL TRADE COMMISSION  
(FTC)—Cont'd**

- concerning state-action protection (Mar. 9, 2016), **App. D183**
- Collaborative practice agreements between advanced practice registered nurses and physicians, **App. D152**
- Competition in health care markets, text of remarks regarding, **App. E218**
- Competition Policy and Consumer Rights 8220Oversight of the Enforcement of the Antitrust Laws,8221 United States Senate Committee on the Judiciary Subcommittee on Antitrust, **App. E287**
- Competitively sensitive health care information, advocacy letter regarding a bill to permit disclosure, **App. D173**
- Competitive marketplace for biosimilars, FDA/FTC workshop, **App. D208**
- Concurring statement of commissioner Andrew N. Ferguson regarding the pharmacy benefit managers interim staff report (July 9, 2024), **App. N14**
- Connecticut General Assembly, letter concerning bill to establish provider cooperative care arrangements, **App. D145**
- “Death by a Thousand Haircuts: Economic Liberty and Occupational Licensure Reform,” **App. E258**
- Delaware** (this index)
- Dentists and Oral Surgeons** (this index)
- Denturists regulation, FTC Advocacy letter to Kentucky House of Representatives (Mar. 25, 2016), **App. D185**
- Divestiture of locations to address concerns regarding proposed acquisition, **App. E212**
- DOJ and FTC Antitrust Guidelines for Business Activities Affecting Workers (January 2025), **App. N26**

**FEDERAL TRADE COMMISSION  
(FTC)—Cont'd**

- DOJ and FTC 2023 Merger Guidelines, **App. B20**
- DOJ Antitrust Division, Economic analysis group discussion paper Online Reviews and Hospital Choices, EAG 22-1 December 2022, **App. N5**
- “Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care,” text of remarks of Martin Gaynor, Director, Bureau of Economics, FTC, before the 2014 American Antitrust Institute Annual Conference, **App. E234**
- Eliminating certain occupational licensing requirements, staff advocacy letter (Mar. 15, 2017), **App. D193**
- Enforcement against illegal mergers, **App. B19**
- Enforcement by generally, § 10:7  
see also **Enforcement** (this index)
- FDA draft guidance biosimilar drugs comment letter (August 20, 2024), **App. N16**
- FDA/FTC workshop on a competitive marketplace for biosimilars, **App. D208**
- Florida House of Representatives, letter concerning regulation of advanced registered nurse practitioners, **App. D140**
- 44th Hart-Scott-Rodino annual report, **App. D209**
- FTC amicus brief  
re Bystolic Antitrust Litigation, **App. D211**
- Georgia Board of Dentistry, FTC comments concerning proposed amendments to rules governing supervision of hygienists, **App. D136**
- Hart-Scott-Rodino annual report, 44th, **App. D209**
- Health care hospitals collaboration, advocacy letter regarding autho-

**FEDERAL TRADE COMMISSION  
(FTC)—Cont’d**

- rization, **App. D172**
- Health care information exchanges, advocacy letter regarding proposed antitrust immunity, **App. D171**
- “Health Care Technology: Promoting Competition and Protecting Innovation,” Maureen K. Ohlhausen, Commissioner, before Connecticut Bar Association Antitrust amp: Trade Regulation and Consumer Law Sections (Feb. 26, 2014), **App. E228**
- Health information technology, advocacy letter regarding interoperability, **App. D168**
- “Hospital Consolidation: The Good, The Bad, and The Ugly,” **App. E214**
- HSR, FAQ, **App. B12**
- HSR premerger, withdrawal and refiling, **App. B13**
- Human resource professionals, DOJ and FTC antitrust guidance (Oct. 2016), **App. J1**
- Illinois State Senate, letter concerning limiting chronic pain treatment by certified registered nurse anesthetists, **App. D159**
- “Importance of Competition and Antitrust Enforcement to Lower-Cost, Higher-Quality Health Care” Prepared Statement of FTC before Senate Subcommittee on Consumer Protection, Product Safety, and Insurance (July 16, 2009), **App. E172**
- In re Davita, proposed order, re-instituted use of prior approval provisions in merger orders, **App. 18**
- Interim staff report on pharmacy benefit managers the powerful middlemen inflating drug costs and squeezing main street pharmacies (July 2024), **App. N11**

**FEDERAL TRADE COMMISSION  
(FTC)—Cont’d**

- J. Thomas Roche, Antitrust/Intellectual Property Interface, **App. E184**
- J. Thomas Roche, letter concerning antitrust ramifications of accountable care organizations, **App. D138**
- Kentucky Cabinet for Health and Family Services, FTC staff comments concerning proposed rule to regulate limited service clinics, **App. D133**
- Kentucky State Senate, letter concerning bill relating to advanced practice registered nurses scope of practice, **App. D150**
- Keynote remarks of Commissioner Rebecca Kelly Slaughter, Pharmaceutical Task Force Workshop, **App. E286**
- Lifespan Corporation and Care New England Health System, statement, **App. E281**
- “Looking Back to Move Forward: Preserving the Progressive Tradition at the FTC,” **App. E213**
- Louisiana State Representatives, letter concerning Registered Nurse Collaborative Agreements (Apr. 20, 2012), **App. D152**
- Maine Board of Dental Examiners, letter concerning proposed rule to limit x-ray procedures by dental hygienists, **App. D149**
- Massachusetts House of Representatives, letter concerning removal of supervision requirement from nurse practitioners and nurse anesthesiologists (Jan. 17, 2014), **App. D162**
- Medical school collaboration agreements, letter to Alabama State Senate concerning antitrust exemption for public university medical school agreements (May. 2, 2016), **App. D186**
- Medicare Prescription Drug Benefit Programs, Staff Advocacy Letter

**FEDERAL TRADE COMMISSION  
(FTC)—Cont'd**

- to Centers for Medicare and Medicaid Services concerning any-willing-provider changes (Mar. 7, 2014), **App. D164**
- Memorandum of Agreement between FTC and Antitrust Division of the U.S. Dept. of Justice concerning clearance procedures for investigations, **App. B7**
- Mergers and generally, § **15:3**
- Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E127**
- consent orders, FAQ, § **15:36**
- guidelines on horizontal mergers, § **15:9, App. B6**
- “Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks of Edith Ramirez before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**
- staff letter to Louisiana attorney general concerning Tenet Healthcare Corporation’s proposed acquisition of Slidell Memorial Hospital (Apr. 1, 2003), **App. D101**
- statement on horizontal mergers (1982), **App. B2**
- Minnesota House of Representatives, FTC Staff advocacy letter regarding bill to permit disclosure of competitively sensitive health care information, **App. D173**
- Mississippi House of Representatives, letter concerning regulation of pharmacy benefit managers, **App. D141**
- Missouri House of Representatives, letter concerning bill relating to CRNA scope of practice, **App. D151**

**FEDERAL TRADE COMMISSION  
(FTC)—Cont'd**

- Multilateral pharmaceutical merger task force, Commissioner statement, **App. E276**
- Multilateral pharmaceutical merger task force, public input, press release, **App. D202**
- New Jersey Hospital Networks merger, **App. E283**
- New York, staff comment on proposal to allow licensure by endorsement of Canadian dental licenses, **App. D199**
- New York Senate, comment concerning regulation of mail-order pharmacies, **App. D146**
- New York Senate, letter concerning bill to permit collective negotiations among providers, **App. D148**
- New York State Assembly, FTC Staff advocacy letter regarding authorization of health care hospitals collaboration, **App. D172**
- Non-Profit Institutions Act
- Community CarePartners, staff advisory opinion to, **App. D132**
- Quest Analytics Group, staff advisory opinion to, **App. D165**
- University of Michigan, staff advisory opinion to the, **App. D131**
- Non-Profit Institutions Act, opinion concerning, **App. D155, App. D156**
- Norman Physician Hospital Organization, Staff Advisory Opinion to, **App. D157**
- North Carolina House of Representatives, FTC Staff advocacy letter concerning a bill to modify Certificate-of-Need law (July 10, 2015), **App. D174**
- North Carolina Senate Bill 743 state action defense to UNC healths collaborative activities, **App. D210**
- North Carolina State Board of Opticians, FTC staff comments

## INDEX

### FEDERAL TRADE COMMISSION (FTC)—Cont'd

- concerning proposed regulations for optical goods and optical goods business, **App. D137**
- Nurse practitioners and nurse anesthesiologists, Staff letter to Hon. Kay Khan, Massachusetts House of Representatives, concerning bill to remove supervision requirement (Jan. 17, 2014), **App. D162**
- Office of Public Affairs Director, preliminary injunction halting New Jersey hospital merger, **App. E278**
- Orange book, brand drug manufacturers improper listing of patents, statement, **App. B22**
- Order to file a special report, **App. D203**
- Oregon Legislature, FTC Staff advocacy letter concerning antitrust immunity for health care information exchanges (May 18, 2015), **App. D171**
- “Oversight of Enforcement of Antitrust Law,” prepared statement of FTC before U.S. Senate Committee on the Judiciary (Mar 9, 2016), **App. E251**
- “Oversight of Enforcement of Antitrust Laws,” Edith Ramirez before U.S. House of Representatives, Washington D.C. (Nov 15, 2003), **App. E226**
- Overview of FTC actions in health care services and products (October 2024), **App. L1**
- Overview of FTC actions in pharmaceutical products and distribution (October 2024), **App. L2**
- Pay-for-delay deals, limiting competition and costing consumers, **App. E219**
- “Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best

### FEDERAL TRADE COMMISSION (FTC)—Cont'd

- Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E174**
- PBM related advocacy and current market realities reports, **App. D212**
- Perspectives on Certificates of Public Advantage, **App. D205**
- Petition
  - FTC v. Louisiana Childrens Medical Center, **App. N6**
- Pharmaceutical merger enforcement program, Commissioner statement, **App. E275**
- Pharmaceutical mergers, analysis examination, **App. N4**
- Pharmaceutical Task Force
  - Workshop, keynote remarks of Commissioner Rebecca Kelly Slaughter, **App. E286**
- Physician collaboration, letter concerning proposed legislation, **App. D160**
- Post-patent pharmaceutical markets, issues in, **App. E260**
- Preliminary injunction
  - pursuant to Section 13(b) of the Federal Trade Commission Act, **App. N2**
- Prepared Remarks Before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E167**
- Prepared Statement Before Committee of Small Business, U.S. House of Representatives on “Competition and Potential Costs and Benefits of Professional Licensure” (Jul. 16, 2014), **App. E238**
- Prepared Statement Before Florida State Senate on health care competition and Florida’s certificate of need (CON) laws (Apr. 2, 2008), **App. E163**
- Prepared Statement before Subcommittee on Commerce, Trade, and

**FEDERAL TRADE COMMISSION  
(FTC)—Cont'd**

- Consumer Protection, Committee on Energy and Commerce, US House of Representatives on Pay-for-Delay Settlements (Mar. 31, 2009)—J. Thomas Rosch, Commissioner, FTC, **App. E168**
- Prepared Statement before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate on Anticompetitive Pay-for-Delay Settlements (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E169**
- Prepared Statement Before U.S. Senate Committee on Judiciary, “Examining Competition in Group Health Care” (Sept. 6, 2006), **App. E142A**
- Prepared Statement Before U.S. Senate Committee on the Judiciary, “License to Compete: Occupational Licensing and the State Action Doctrine” (Feb. 2, 2016), **App. E249**
- Prepared Statement Before U.S. Senate Special Committee on Aging Concerning Barriers to Generic Entry (July 20, 2006), **App. E142**
- Prepared Statement of FTC and Pharmaceutical Industry before Committee of Judiciary, US Senate (June 17, 2003)—Timothy J. Muris, Chairman, FTC, **App. E121**
- Press release, FTC, DOJ and HHS work  
lower health care and drug costs, **App. B21**
- Primary service area shares under ACO policy statement, calculating, **App. E216**
- Protecting competition in healthcare markets, **App. E261**
- Provider-controlled contracting networks, Federal Trade Commission and Department of

**FEDERAL TRADE COMMISSION  
(FTC)—Cont'd**

- Justice Statement of Antitrust Enforcement Policy, § **20:15**
- Quest Analytics Group, FTC Staff advisory opinion concerning Non-Profit Institutions Act (Mar. 7, 2014), **App. D165**
- Requests for additional information, appeal procedure for, **App. B8**
- “Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks of Edith Ramirez, Chairwoman, before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**
- Richard A. Feinstein statement to House committee on antitrust enforcement in the health care industry, **App. E185**
- Second-request form letter, **App. B3H**
- “Section 5: Principles of Navigation,” Maureen K. Ohlhausen, Commissioner, before U.S. Chamber of Commerce, Washington, DC (July 25, 2013), **App. E220**
- Sharon a. Pozen statement before Judiciary Committee on antitrust, competition policy, and consumer rights, **App. E186**
- South Carolina House of Representatives, FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D178**
- South Carolina House of Representatives, joint statement of FTC and Antitrust Division on Certificate-of-Need laws and proposed legislation (Jan. 16, 2016), **App. D179**
- Staff Comment  
North Carolina Senate Bill 743, **App. D210**
- Staff comment on New York’s proposal to allow licensure by endorsement of Canadian dental

## INDEX

### FEDERAL TRADE COMMISSION (FTC)—Cont'd

- licenses, **App. D199**
- Staff comment to Washing State Rep. Paul Graves, S.S.B. 5411/H.B. 1473 (Feb. 9 2018), **App. D198**
- Staff letter to Hon. Elaine Nekritz, Illinois State Representative, concerning proposed regulation of retail health care facilities (May 29, 2008), **App. D124**
- Staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D123**
- Staff letter to Louisiana attorney general concerning Tenet Healthcare Corporation's proposed acquisition of Sliddell Memorial Hospital (Apr. 1, 2003), **App. D101**
- Staff letter to Louisiana State Representative Timothy G. Burns concerning in-house school dentistry (May 1, 2009), **App. D128**
- Staff letter to Minnesota State Representative Tom Emmer concerning rural health care cooperatives joint negotiation (Mar. 18, 2009), **App. D125**
- Staff letter to North Carolina representative concerning dental practice managers (May 25, 2012), **App. D153**
- Staff letter to Ohio House of Representatives (Oct. 16, 2002), **App. D97**
- Staff letter to Puerto Rico Treasury and Financial Affairs Committee objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D121**
- Staff letter to Rep. Patrick McHenry Concerning Proposed Bill Regulating Pharmacy Benefit Manager Contractual Relationships (Jul. 15, 2005), **App. D111**
- Staff letter to Senator James L. Seward, New York Senate,

### FEDERAL TRADE COMMISSION (FTC)—Cont'd

- concerning pharmacy-benefit-manager regulation (Mar. 31, 2009), **App. D126**
- Staff letter to Tennessee senate concerning bill regulating optometry (Apr. 29, 2003), **App. D102**
- Staff opinion letter to TriState Health Partners (Apr. 13, 2009), **App. D127**
- State Action Doctrine, **App. E210**
- Statement before Joint Committee on Health, West Virginia Legislature, **App. E207**
- Statement of, second circuit order 8220Pharma Bro8221 Martin Shkreli's lifetime ban, upholding, **App. B25**
- Statement of chair Lina M. Khan joined by commissioners alvaro m. bedoya & rebecca kelly slaughter regarding the pharmacy benefit managers interim staff report (July 9, 2024), **App. N12**
- Statement of commissioner Rebecca Kelly slaughter regarding ftc staff interim report pharmacy benefit managers (August 1, 2024), **App. N13**
- Statement of FTC Bureau of Competition Deputy Director Rahul Rao on Lawsuit Against PBMs and the Role of Drug Manufacturers in Distorting Competition in the U.S Drug Distribution System (September 20, 2024), **App. N18**
- Statement of Richard A. Feinstein, FTC Bureau of Competition, on the FTC's Closure of its Investigation of Consummated Hospital Merger in Temple, Texas (Dec. 23, 2009), **App. E175**
- Statement of the Federal Trade Commission's Bureau of Competition on Guidelines for Merger

**FEDERAL TRADE COMMISSION  
(FTC)—Cont'd**

- Investigations (Dec. 11, 2002), **App. B3F**
- State of Rhode Island v. Lifespan Corporation and Care New England Health System, statement, **App. E279**
- Study on pharmacy benefit managers, chair remarks, **App. E280**
- Supplemental Staff Submission to Indiana Health Staff Submission to Indiana Health Department Regarding 2025, Certificate of Public Advantage Application of Union Health and Terre Haute Regional Hospital (March 17, 2025), **App. N25**
- Telehealth services, FTC Advocacy letter to Alaska State Legislature concerning (Mar. 25, 2016), **App. D184**
- Temporary restraining order pursuant to Section 13(b) of the Federal Trade Commission Act, **App. N2**
- Tennessee House of Representatives, letter concerning bill to regulate pain management services, **App. D147**
- Tennessee Legislature, letter concerning repeal of state-action exemption legislation for Tennessee public hospitals, **App. D144**
- Texas House of Representatives, letter concerning bill to permit health care collaboratives, **App. D143**
- Texas State Board Examiners, Staff advocacy letter to Simone Salloom, concerning proposed rules (Oct. 14, 2014), **App. D166**
- Texas State Senate, letter concerning regulation of advanced registered nurse practitioners, **App. D142**
- Treatment of debt as consideration, **App. B16**
- Under Section 7 of Clayton Act, § 8:18

**FEDERAL TRADE COMMISSION  
(FTC)—Cont'd**

- “Unfair Methods of Competition” under Section 5 of FTC Act, statement of enforcement principles regarding (Aug. 13, 2015), **App. I1**
- Unfair Methods of Competition Under Section 5 of the FTC Act, Adoption of the Statement of Enforcement Policy, **App. E288**
- Unfair trade practices, “Section 5: Principles of Navigation” (July 25, 2013), **App. E220**
- United States Senate Committee on the Judiciary Subcommittee on Antitrust, **App. E287**
- Use of prior approval provisions in merger orders, **App. B17**
- U.S. Senators, letter concerning antitrust and accountable care organizations, **App. D139**
- Vertically Integrated Pharmacy Specialty Generic Drugs Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers (January 14, 2025), **App. N22**
- Veterans Administration, advocacy letter, advanced practice registered nurses restrictions (July 25, 2016), **App. D188**
- Virginia Certificate of Need Work Group, joint statement of FTC and Antitrust Division (Oct. 26, 2015), **App. D177**
- “What’s Past is Prologue: FTC’s Competition and Consumer Protection Priorities,” text of remarks by Julie Brill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E236**
- Workshop summary Pharmaceutical mergers, analysis examination, **App. N4**

## INDEX

### **FEDERAL TRADE COMMISSION, PLAINTIFF, V. SURESCRIPTS, LLC**

Stipulated order for, equitable relief  
and permanent injunction, **App.  
N7**

### **FEDERAL TRADE COMMISSION ACT**

Generally, § 7:13

Adoption of the Statement of  
Enforcement Policy, Unfair  
Methods of Competition Under  
Section 5 of the FTC Act, **App.  
E288**

Text of, excerpts, **App. A5**

### **FEES**

FTC Staff letter to Puerto Rico Treas-  
ury and Financial Affairs Com-  
mittee objecting to bill permit-  
ting health-care providers to  
collectively negotiate fees (Jan.  
30, 2008), **App. D121**

### **FEINSTEIN, DEBORAH L.**

“Antitrust Enforcement in Health  
Care: Proscription, Not Prescrip-  
tion,” remarks by Deborah L.  
Feinstein, Director, Bureau of  
Competition, FTC, before the  
Fifth National Accountable Care  
Organization Summit (June 19,  
2014), **App. E232**

“The Forward-Looking Nature of  
Merger Analysis,” remarks by  
Deborah L. Feinstein, Director,  
Bureau of Competition, FTC  
(Feb. 6, 2014), **App. E230**

### **FINANCIAL RISK SHARING**

Provider-controlled contracting  
networks, antitrust safety zones,  
§ 20:5

### **FIRMS**

See also **Business** (this index)

### **FIRST LOOK, LLC**

Advisory opinions (June 19, 1997),  
**App. D77**

### **FIRST PRIORITY HEALTH**

Business review letters (Nov. 3,  
1997), **App. C84**

### **FLORIDA STATE SENATE**

Federal Trade Commission prepared  
statement concerning certificate  
of need laws (Apr. 2, 2008),  
**App. E163**

### **FOLLOW-ON BIOLOGICS**

Pay-for-Delay Settlements, Autho-  
rized Generics, and Follow-on  
Biologics: Thoughts on How  
Competition Law Can Best  
Protect Consumer Welfare in the  
Pharmaceutical Context, J.  
Thomas Rosch, Commissioner,  
FTC (Nov. 19, 2009), **App.  
E174**

### **FOOD AND DRUG**

#### **ADMINISTRATION (FDA)**

Antitrust implications, listing a drug  
in 8220Orange Book,8221 **26:1**

FDA/FTC workshop

competitive marketplace for  
biosimilars, **App. D208**

opening remarks of Chairman  
Joseph Simons, **App. E271**

Statement, collaboration to advance  
competition in biologic  
marketplace, **App. F6**

### **FORMAN, ANDREW**

Keynote speech, **App. E284**

### **FOUNDATION FOR THE ACCREDITATION OF HEMATOPOIETIC CELL THERAPY**

Advisory opinions (Apr. 17, 1997),  
**App. D74**

### **FRIMET, GILBERT M.**

Advisory opinion, **App. D8**

### **FTC**

Generally. **Federal Trade Commis-  
sion (FTC)** (this index)

### **FTC AMICUS BRIEF**

Re Bystolic Antitrust Litigation,  
**App. D211**

**FTC V. LOUISIANA CHILDRENS  
MEDICAL CENTER,**

Petition, **App. N6**

**FTC V. U.S. ANESTHESIA  
PARTNERS, INC.**

Federal complaint for injunction,  
**App. N9**

**FUNDAMENTAL CONCEPTS**

Of Section 1, Sherman Act. **Sherman  
Act** (this index)

**GALES REXALL DRUG**

Business review letter, **App. C1**

**GASTROENTEROLOGY  
ASSOCIATES, LTD**

Business review letters (July 7,  
1997), **App. C82**

**GAYNOR, MARTIN**

“Efficiencies Analysis: False  
Dichotomies, Modeling, and  
Applications to Health Care,”  
text of remarks before the 2014  
American Antitrust Institute  
Annual Conference, **App. E234**

**GENERIC DRUGS**

“How Pay-for-Delay Settlements  
Make Consumers and the  
Federal Government Pay More  
for Much Needed Drugs,” pre-  
pared statement before Subcom-  
mittee on Commerce, Trade, and  
Consumer Protection, Commit-  
tee on Energy and Commerce,  
US House of Representatives  
(Mar. 31, 2009), **App. E168**

Pay-for-Delay Settlements, Autho-  
rized Generics, and Follow-on  
Biologics: Thoughts on How  
Competition Law Can Best  
Protect Consumer Welfare in the  
Pharmaceutical Context, J.  
Thomas Rosch, Commissioner,  
FTC (Nov. 19, 2009), **App.  
E174**

**GEORGE MASON SCHOOL OF  
LAW**

“Brother, May I? The Challenge of  
Competitor Control over Market

**GEORGE MASON SCHOOL OF  
LAW—Cont’d**

Entry” remarks of Maureen K.  
Ohlhausen, Commissioner,  
before George Mason School of  
Law Global Antitrust Economics  
Conference (May 29, 2015),  
**App. E243**

**GEORGETOWN GLOBAL  
ANTITRUST SYMPOSIUM**

“The FTC’s Role in Shaping  
Antitrust Doctrine: Recent Suc-  
cesses and Future Targets,”  
Joshua D. Wright, Washington,  
D.C. (Sept. 24, 2013), **App.  
E223**

**GEORGE WASHINGTON  
UNIVERSITY LAW SCHOOL**

“Retrospectives at the FTC: Promot-  
ing an Antitrust Agenda,” text of  
remarks of Edith Ramirez,  
Chairwoman, FTC, at the  
Merger Transactions  
Symposium (June 28, 2013),  
**App. E233**

**GEORGIA GENERAL ASSEMBLY**

U.S. Department of Justice Antitrust  
Division, “Competition in  
healthcare and certificate of  
need” (Feb. 23, 2007), **App.  
E145**

**GEORGIA PREFERRED  
PODIATRIC MEDICAL  
NETWORK**

Business review letters (Nov. 3,  
1995), **App. C58**

**GEORGIA STATE SENATE**

FTC Advocacy letter to Hon.  
Valencia Seay concerning  
supervision of dental hygienists  
(Jan. 29, 2016), **App. D180**

**GERMANY**

“Protecting Consumer Welfare in the  
U.S. Health Care Sector,” before  
the Mentor Group Forum for  
EU-US Legal-Economic Affairs,  
Berlin, Germany (Sept 13,

## INDEX

**GERMANY—Cont’d**  
2013), **App. E221**

**GI ASSOCIATES, P.C.**  
Business review letters (July 7, 1997), **App. C82**

**GLOBAL ANTITRUST ECONOMICS CONFERENCE AND SYMPOSIUM**

“Brother, May I? The Challenge of Competitor Control over Market Entry” remarks of Maureen K. Ohlhausen, Commissioner, before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E243**

“The Horizontal Merger Guidelines Five Years Later” text of remarks of Edith Ramirez before Georgetown University Law Center Ninth Symposium (Sept. 29, 2015), **App. E247**

**GOVERNMENT ENFORCEMENT STATEMENTS**  
Antitrust laws, § 1:7

**GOVERNMENT JUDGMENTS**  
Effect of, in damage actions, § 11:14

**GREATER ROCHESTER INDEPENDENT PRACTICE ASSOCIATION**  
Advisory opinions (Sept. 17, 2007), **App. D119**

**GROUP PURCHASING PROGRAMS**  
Analyzing, § 16:8  
“U.S. v. AzHAA: When Does a Group Purchasing Organization Become an Illegal Monopsonist?,” prepared remarks before AHLA annual meeting (June 26, 2007), **App. E151**

**GUIDELINES**  
Federal government antitrust guidelines, § 1:8

**“GUIDEPOSTS IN THE ANALYSIS: THE FEDERAL TRADE COMMISSION AND U.S. DEPARTMENT OF JUSTICE, ANTITRUST DIVISION COMPETITOR COLLABORATION GUIDELINES”**  
(Speech), **App. E92**

**HAL WHITE ANTITRUST CONFERENCE**  
“Competition in Health Care Markets,” text of remarks by Julie Brill, Commissioner, FTC, at 2014 Conference (June 9, 2014), **App. E231**

**HANGER ORTHOPEDIC GROUP, INC.**  
Business review letters (Sept 15, 1995), **App. C55**

**HARBOUR, PAMELA JONES**  
“A ‘Check-Up’ of Selected Health Care Activity at FTC,” remarks before ABA antitrust law spring meeting (Mar. 30, 2005), **App. E132**

**HART-SCOTT-RODINO ACT**  
Generally, **App. B3D**

**HART-SCOTT-RODINO ANNUAL REPORT**  
44th, FTC and Department of Justice, **App. D209**

**HARVARD VANGUARD MEDICAL ASSOCIATES, INC.**  
Advisory opinions (Dec. 18, 2001), **App. D90**

**HEALTH AND PERSONAL CARE CONFERENCE, INC.**  
Business review letter, **App. C34**

**“HEALTH CARE GUIDELINES AND ASSOCIATIONS, HOW ASSOCIATIONS CAN WORK WITH THE DEPARTMENT OF JUSTICE”**  
(Speech), **App. E36**

**HEALTH CARE INFORMATION  
EXCHANGES**

Federal Trade Commission staff  
advocacy letter to Sen. Chip  
Shields, Oregon State  
Legislature concerning antitrust  
immunity (May 18, 2015), **App.  
D171**

**HEALTH CARE MANAGEMENT  
ASSOCIATES**

Advisory opinion, **App. D3**  
Business review letter, **App. C14**

**HEALTH CARE MARKETS**

“Thoughts on ‘Leveling the Playing  
Field’ in Health Care Markets”  
(speech), **App. E73**

**HEALTH CARE QUALITY  
IMPROVEMENT ACT**

Antitrust exemptions, § 9:12  
Practitioner credentialing and, § 9:12,  
§ 13:8  
Text of, **App. A8**

**HEALTHCARE SUMMIT**

“Enforcement Strategies in the  
Health Care Industry,” prepared  
remarks of J. Thomas Rosch  
before ABA Health Law Section  
Sixth Annual Healthcare Sum-  
mit (Nov. 17, 2008), **App. E167**

**HEALTH CARE TECHNOLOGY**

“Health Care Technology: Promoting  
Competition and Protecting  
Innovation,” Maureen K.  
Ohlhausen, Commissioner of  
FTC, before Connecticut Bar  
Association Antitrust and  
Trade Regulation and Consumer  
Law Sections (Feb. 26, 2014),  
**App. E228**

**HEALTH COVERAGE,  
INSURANCE, AND  
FINANCIAL SERVICES**

LD 97 supporting testimony  
Division Director, Licensing &  
Certification at State of  
Maine, **App. N3**

**HEALTH DEPARTMENT**

Staff Submission to Indiana Health  
Department Regarding the Cer-  
tificate of Public Advantage  
Application of Union Health and  
Terre Haute Regional Hospital  
(September 5, 2024), **App. N19**

**HEALTH INFORMATION  
TECHNOLOGY**

FTC Staff advocacy letter to Depart-  
ment of Health and Human Ser-  
vices concerning interoperability  
(Apr. 3, 2015), **App. D168**

**HEALTH PLAN MARKET POWER**

Generally, § 21:1  
All-products provisions and payer  
monopoly power, § 21:7  
Exclusions from providers from  
health plans or contracting  
networks, generally, § 21:8,  
§ 21:9  
Exclusive contracting, § 21:9  
Low reimbursement and payer  
monopoly power, § 21:5  
McCarran-Ferguson Act’s effects,  
generally, § 21:2  
Monopsony power. See Payer  
monopsony power, below  
Most-favored-nations provisions and  
payer monopoly power, § 21:6  
Networks, provider exclusions from.  
See entries throughout this topic  
Participation agreements between  
providers and payers, § 21:3  
Payer monopsony power  
generally, § 21:4 to 21:7  
all-products provisions and, § 21:7  
low reimbursement and, § 21:5  
most-favored-nations provisions  
and, § 21:6  
Provider exclusions from networks.  
See entries throughout this topic  
Reimbursement and payer monopoly  
power, low reimbursement,  
§ 21:5  
Selective and exclusive contracting,  
§ 21:9

## INDEX

### HEALTH-PLAN MERGERS

Mergers, § 15:33

### HEALTH PLANNING

Market-allocation agreements and.  
**Market-Allocation Agreements** (this index)

### HEALTH PLANNING ACT

Antitrust laws and, § 22:2

### HEMATOLOGY/ONCOLOGY CARE SPECIALISTS OF WESTERN PENNSYLVANIA, P.C.

Advisory opinions (Sept. 21, 1995),  
**App. D56**

### HENRY COUNTY MEMORIAL HOSPITAL

Advisory opinions (Apr. 10, 1997),  
**App. D76**

### HERITAGE ALLIANCE AND LACKAWANNA PHYSICIANS ORGANIZATION

Business review letters (Sept. 15,  
1998), **App. C86**

### HIGHLY INNOVATED INDUSTRIES

“Mergers that Increase Bargaining  
Leverage,” Aviv Nevo, Deputy  
Assistant Attorney General for  
Economics, Antitrust Division,  
before Stanford Institute for  
Economic Policy Research and  
Cornerstone Research Confer-  
ence on Highly Innovated  
Industries (Jan. 22, 2014), **App.  
E227**

### HISTORY

Of antitrust laws, § 1:3

Of enforcement in health care sector,  
§ 1:6

### HMO EXCLUSIVE CONTRACTS

Advisory opinion, **App. D24**

### HOME CARE ALLIANCE, INC.

Business review letters (Oct. 4,  
1996), **App. C73**

### HOME CARE PROVIDERS

FTC staff letter to Hon. William J.  
Seitz, Ohio State Senator,  
concerning collective bargaining  
by home care providers (Feb.  
14, 2008), **App. D123**

### HOME HEALTH INVESTIGATION

Vermont, U.S. Dept. of Justice state-  
ment on closing of Vermont  
home health investigation, **App.  
E139**

### HOME HEALTH SERVICES ACT OF 2005

U.S. Dept. of Justice statement on  
closing of Vermont home health  
investigation, **App. E139**

### HORIZONTAL AGREEMENTS

“A Stepwise Approach to Antitrust  
Review of Horizontal Agree-  
ments” (speech), **App. E69**

Under Section 1 of Sherman Act  
generally, § 4:1, § 4:4  
agreements to exchange or dissem-  
inate information, § 4:3  
bid-rigging agreements, § 4:5  
concerted refusals to deal, § 4:7  
covenants not to compete, § 4:6  
health planning activities and,  
§ 22:5  
horizontal market-allocation agree-  
ments, § 4:4  
horizontal price-fixing agreements,  
§ 4:2  
mergers and joint ventures, § 4:8  
standard-setting programs, § 4:10  
unfair competition and dirty tricks,  
§ 4:9

### HORIZONTAL MERGERS

Department of Justice and Federal  
Trade Commission guidelines,  
§ 15:9, **App. B1**

Department of Justice business  
review procedure, **App. B4**

FTC advisory opinions procedure,  
**App. B5**

FTC statement on (1982), **App. B2**

**HORIZONTAL MERGERS—Cont'd**

Guidelines, Department of Justice and FTC, § 15:9, **App. B1**

1984 Department of Justice guidelines, **App. B6**

“The Horizontal Merger Guidelines Five Years Later” text of remarks of Edith Ramirez before Georgetown University Law Center Ninth Annual Global Antitrust Enforcement Symposium (Sept. 29, 2015), **App. E247**

Under Section 7 of Clayton Act generally, § 8:5  
collusion, market characteristics and ease of, § 8:10

concentration, § 8:6

defenses, § 8:13

efficiencies from merger, § 8:12

entry into market, § 8:9

financial viability, § 8:11

other factors, § 8:7

rebuttal evidence, generally, § 8:8 to 8:12

**HOSPICE NETWORK OF NEW JERSEY, INC.**

Business review letters (April 24, 1996), **App. C67**

**HOSPITAL CONSOLIDATION**

Statement before Committee on the Judiciary Subcommittee on Competition Policy, Antitrust, and Consumer Rights, **App. E277**

**HOSPITAL CORPORATION OF AMERICA**

Business review letter, **App. C15**

**HOSPITAL ORGANIZATION**

Credentialing process and generally, § 13:2  
see also **Practitioner Credentialing** (this index)

**HOSPITALS**

See more specific entries throughout this index

**HOTEL EMPLOYEES AND RESTAURANT EMPLOYEES INTERNATIONAL UNION WELFARE FUND**

Business review letter, **App. C41**

**HOUSTON HEALTH CARE COALITION**

Business review letter, **App. C39**

**HUMAN RESOURCES**

DOJ and FTC antitrust guidance (Oct. 2016), **App. J1**

**HYATT OTT & BLOUNT, P.C.**

Business review letter, **App. C28**

**IDENTIFICATION**

Competitor, mergers and, § 15:12

**ILLINOIS STATE REPRESENTATIVE**

Letter from FTC concerning proposed regulation of retail health care facilities (May 29, 2008), **App. D124**

**IMMUNITIES**

**Exemptions and Immunities** (this index)

**IMPLIED REPEAL**

Of antitrust laws, § 9:5

**INDEPENDENT DRUG WHOLESALERS GROUP**

Business review letter, **App. C23**

**INDIANA HEALTH DEPARTMENT**

Supplemental Staff Submission to Indiana Health Staff Submission to  
2025, Certificate of Public Advantage  
Application of Union Health and Terre Haute Regional Hospital (March 17, 2025), **App. N25**

**INFORMATION**

Under Section 1 of Sherman Act, § 4:3

## INDEX

### INJUNCTION

FTC v. U.S. Anesthesia Partners, Inc.,  
federal complaint, **App. N9**

### INJUNCTIVE RELIEF

In damage actions, § **11:15**

### INJURY

Antitrust, as element of damage  
action, § **11:6**

In damage actions, § **11:3**

In private treble-damage litigation  
under Robinson-Patman Act,  
§ **7:11**

### IN PARI DELICTO DEFENSE

In damage actions, § **11:11**

### IN-SCHOOL DENTISTRY

FTC staff letter to Hon. Timothy G.  
Burns, Louisiana House of  
Representatives, concerning  
in-school dentistry (May 1,  
2009), **App. D128**

### INSURANCE

Business of, antitrust exemption,  
§ **9:10**

### “INTEGRATED JOINT VENTURES”

(Speech), **App. E57**

### INTENT

Purpose or. **Purpose or Intent** (this  
index)

Specific, to monopolize, under Sec-  
tion 2 of Sherman Act, § **6:14**

### INTERLOCKING DIRECTORIES

Generally, § **7:1**

### INTERNATIONAL

#### CHIROPRACTORS ASSOCIATION

Business review letter, **App. C3**

### INTERSTATE COMMERCE

Effect on substantial amount of,  
exclusive contracts and, § **14:7**

Mergers and, § **15:7**

Practitioner credentialing and, § **13:5**

Subject matter jurisdiction, § **2:2**

### INTRACORP

Advisory opinion, **App. D26**

### INVESTIGATIONS

Caremark Rx/AdvancePCS merger,  
FTC statement in closing  
investigation of (Feb. 11, 2004),  
**App. E127**

Consummated hospital merger in  
Temple, Texas, statement of  
Richard A. Feinstein, Competi-  
tion Director, FTC Bureau of  
Competition, on FTC’s closure  
of investigation of (Dec. 23,  
2009), **App. E175**

FTC enforcement, § **10:8**

Memorandum of Agreement between  
FTC and Antitrust Division of  
the U.S. Dept. of Justice  
concerning clearance procedures  
for investigations, **App. B7**

Premerger, § **15:8**

Protocol for coordination in merger  
investigations between federal  
enforcement agencies and state  
attorneys general, **App. B3G**

Vermont, U.S. Dept. of Justice state-  
ment on closing of Vermont  
home health investigation, **App.  
E139**

### INVESTMENT INTERESTS

**Physician-Owned Facilities** (this  
index)

### ITASCA CLINIC AND GRAND RAPIDS MEDICAL ASSOCIATES

Business review letters (March 19,  
1996), **App. C65**

### JAZZ PHARMACEUTICALS V. AUADEL CNS PHARMACEUTICALS

FTC amicus brief, **App. D207**

### JOINT VENTURES

Generally, § **16:1**

Analyzing agreements relating to  
operation of, § **16:5**

Analyzing formation of, § **16:4**

**JOINT VENTURES—Cont’d**

- Analyzing particular generally, § 16:7
- group purchasing programs, § 16:8
- joint venture among competitors to provide new services, expensive equipment, and specialized services, § 16:9
- joint ventures between hospitals and physicians, § 16:10
- Classifications of, § 16:3
- Collaboration Guidelines, overview of, § 16:6
- Definition of, § 16:2
- “Integrated Joint Ventures” (speech), **App. E57**
- Physician-owned facilities, § 18:3
- Practical factors and danger signals in, § 16:11
- Provider-Controlled Contracting Networks** (this index)
- Under Section 7 of Clayton Act, § 8:16
- Under Section 1 of Sherman Act, as horizontal agreements, § 4:8

**“JOINT VENTURES IN EVOLVING HEALTH CARE MARKETS”**

(Speech), **App. E34**

**JUDICIARY SUBCOMMITTEE ON ANTITRUST**

United States Senate Committee, Competition Policy and Consumer Rights Oversight of the Enforcement of the Antitrust Laws, **App. E287**

**JURISDICTION**

Primary and exclusive, § 9:6

**JUSTICE DEPARTMENT (UNITED STATES DEPARTMENT OF JUSTICE; ANTITRUST DIVISION)**

Generally, **App. B3A, App. B3B**  
 See also more specific entries throughout this index  
 Accountable Care Organizations, statement of antitrust enforce-

**JUSTICE DEPARTMENT (UNITED STATES DEPARTMENT OF JUSTICE; ANTITRUST DIVISION)—Cont’d**

ment policy regarding, **App. H1**  
 Additional information, documentary material request, **App. B9**  
 Antitrust healthcare matters resolved without a case filed, **App. N1**  
 Arbitration and case selection, guidance, **App. B11**  
 Business review procedure of generally, § 10:6, **App. B4**  
 see also **Business Review Letters** (this index)  
 Certificate-of-need laws and Alaska, joint statement of FTC and Antitrust Division (Apr. 7, 2017), **App. D194**  
 DOJ and FTC joint antitrust statement regarding COVID-19 (March 2020), **App. K1**  
 Enforcement by. **Enforcement** (this index)  
 FTC and DOJ FAQ, voluntary expedited review, statement of Antitrust Enforcement Policy Regarding ACOs, Medicare Shared Savings Program, **App. F5**  
 Guidelines on mergers generally, **App. B1**  
 horizontal mergers, § 15:9, **App. B6**  
 Health care business review letters. **Business Review Letters** (this index)  
 Human resource professionals, DOJ and FTC antitrust guidance (Oct. 2016), **App. J1**  
 Joint DOJ/FTC letter to Alaska on CON laws (March 11, 2019), **App. F4**  
 Joint DOJ/FTC letter to Tennessee on CON laws (March 7, 2019), **App. F3**  
 Joint FDA-FTC statement, collaboration to advance competition in the biologic marketplace (February 3, 2020), **App. F6**

## INDEX

### JUSTICE DEPARTMENT (UNITED STATES DEPARTMENT OF JUSTICE; ANTITRUST DIVISION)—Cont'd

Letter, Maryland, board certification of medical physicians (September 10, 2018), **App. F2**

Matters resolved without a case filed, **App. M2**

Mergers and, § 15:9, **App. B1, App. B6**

“Mergers that Increase Bargaining Leverage,” Aviv Nevo, Deputy Assistant Attorney General for Economics, Antitrust Division, before Stanford Institute for Economic Policy Research and Cornerstone Research Conference on Highly Innovated Industries (Jan. 22, 2014), **App. E227**

“Origin of the Species: The 100 Year Evolution of the Clayton Act,” text of remarks of William J. Baer, Assistant Attorney General, Antitrust Division, before the ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014), **App. E237**

Summary of business reviews, **App. C109**

Summary of health care cases (Since August 25, 1983) (2020), **App. M1**

Under Section 7 of Clayton Act, § 8:18

Vermont, U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E139**

### KAISER FOUNDATION HEALTH PLAN

FTC staff advisory opinion to Kaiser Foundation Health Plan (Feb. 13, 2008), **App. D122**

### KENTUCKY HOUSE OF REPRESENTATIVES

Denturists, FTC Advocacy letter concerning regulation (Mar. 25,

### KENTUCKY HOUSE OF REPRESENTATIVES—Cont'd

2016), **App. D185**

### KHAN, LINA M.

Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E288**

Study on Pharmacy Benefit Managers, **App. E280**

### KITSAP PHYSICIANS SERVICE

Advisory opinions

March 26, 1984, **App. D9**

May 22, 1984, **App. D11**

### LABOR

Antitrust exemption, § 9:11

### LD 97

Supporting testimony  
Division Director, Licensing & Certification at State of Maine, **App. N3**

### LEGISLATIVE CHANGES

Antitrust laws, § 1:7

### LEGISLATIVE EXEMPTION

Physician collective bargaining, letter from FTC to Insurance Committee, Ohio House of Representatives, **App. D95**

### LEVERAGING

Under Section 2 of Sherman Act as anticompetitive conduct, § 6:9  
diversification and, § 17:11

### LEXECON HEALTH SERVICE

Business review letter, **App. C17**

### LICENSURE

“Competition and Potential Costs and Benefits of Professional Licensure,” prepared Statement of Andrew Gavil, Director, Office of Policy Planning, before Committee of Small Business, U.S. House of Representatives (Jul. 16, 2014), **App. E238**

**LICENSURE—Cont'd**

“Death by a Thousand Haircuts: Economic Liberty and Occupational Licensure Reform,” **App. E258**

Eliminating certain occupational licensing requirements, FTC staff advocacy letter (Mar. 15, 2017), **App. D193**

“License to Compete: Occupational Licensing and the State Action Doctrine,” prepared Statement of FTC before the United States Senate Committee on the Judiciary (Feb. 2, 2016), **App. E249**

Occupational Licensing in Health Care: Sorting the Wheat from the Chaff (June 19, 2020), **App. E273**

**LINEN SYSTEMS FOR HEALTHCARE, LLC**

Business review letters (Aug. 8, 2006), **App. C97**

**LITIGATION**

Discovery in staff-privilege antitrust, practitioner credentialing and, § **13:20**

FTC enforcement generally, § **10:9**  
see also **Enforcement** (this index)

**LOBBYING**

Physician-owned facilities, lobbying by hospitals against, § **18:3**

**LOCAL GOVERNMENT ANTITRUST ACT**

Antitrust exemptions, § **9:9**  
Practitioner credentialing and, § **13:7**  
Text of, **App. A6**

**LOUISIANA HEALTH CARE ASSOCIATION**

Advisory opinion, **App. D2**

**LOUISIANA HOUSE OF REPRESENTATIVES**

Letter from FTC to Hon. Timothy G. Burns concerning in-school dentistry (May 1, 2009), **App. D128**

**LOUISIANA STATE BOARD OF DENTISTRY**

FTC Staff comments to Louisiana State Board of Dentistry regarding proposed modifications to Louisiana Rules regarding the practice of portable and mobile dentistry (Dec. 9, 2009), **App. D130**

**LOW REIMBURSEMENT**

Health plan market power, payer monopoly power and low reimbursement, § **21:5**

**MANAGED CARE**

Antitrust laws, § **1:7**

**MARIN GENERAL HOSPITAL**

Business review letters (Feb. 11, 1997), **App. C77**

**MARKET-ALLOCATION AGREEMENTS**

Generally, § **22:1**

Agency opposition to CON, § **22:3**

Antitrust ramifications of certificate-of-need proceedings, § **22:4**

Certificate-of-need agency opposition, § **22:3**  
antitrust ramifications of proceedings, § **22:4**

pros and cons, § **22:3**

Conclusion, § **22:6**

Health Planning Act and antitrust laws, § **22:2**

Health-planning activities and horizontal, § **22:5**

Under Section 1 of Sherman Act horizontal agreements, § **4:4**  
vertical agreements, § **5:3**

**MARKET POWER**

Health plans, generally. **Health Plan Market Power** (this index)

In market for tying product, exclusive contracts and, § **14:6**

**Provider-Controlled Contracting Networks** (this index)

## INDEX

### MARKET REALITIES REPORTS

Current, FTC statement for, **App. D212**

### MARKET REVIEW PROCESS

Massachusetts Chapter 343, An Act Enhancing  
Key Provisions in effect 4-8-25, **App. N28**

### MARKETS

Competitive effects in other, mergers and  
see also **Relevant Market** (this index)  
Summary report, FDA/FTC workshop on a competitive marketplace for biosimilars, **App. D208**

### MARKET SHARE

Calculation, mergers and, § **15:12**

### MARYLAND HEALTH CARE COALITION

Business review letter, **App. C11**

### MARYLAND MEDICAL EYE ASSOCIATES

Advisory opinion, **App. D25**

### MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH

Clinic advertising, FTC staff letter concerning (Sept. 27, 2007), **App. D120**

### MASSACHUSETTS HOUSE OF REPRESENTATIVES

Nurse practitioners and nurse anesthetists, FTC letter concerning removal of supervision requirement (Jan. 17, 2014), **App. D162**

Optometrists treating glaucoma patients, FTC and DOJ Advocacy letter concerning (Feb. 18, 2016), **App. D182**

### MAYO MEDICAL LABORATORIES

Advisory opinions (July 17, 1996), **App. D63**

### MCCARRAN-FERGUSON ACT

Health plan market power. **Health Plan Market Power** (this index)

Text of, **App. A7**

### MCSWEENEY, TERRELL

“Reflections on an Active Year in Merger Enforcement,” keynote remarks of Commissioner McSweeney (Feb. 5, 2016), **App. E250**

### MEDICAL GROUP MANAGEMENT ASSOCIATION

Advisory opinion, **App. D103**

### MEDICAL SCHOOL COLLABORATION AGREEMENTS

FTC Staff Advocacy letter to Alabama State Senate concerning antitrust exemption for public university medical school agreements (May. 2, 2016), **App. D186**

### MEDICAL SOCIETY OF THE COUNTY OF ERIE

Advisory opinion, **App. D6**

### MEDICARE PRESCRIPTION DRUG, IMPROVEMENT, AND MODERNIZATION ACT

Physician-owned facilities, § **18:2**

### MEDICARE PRESCRIPTION DRUG BENEFIT PROGRAM

FTC Staff Advocacy Letter to Centers for Medicare and Medicaid Services concerning any-willing-provider changes (Mar. 7, 2014), **App. D164**

### MEDICARE SHARED SAVINGS PROGRAM

Provider-controlled contracting networks, § **20:15**

### MEDSOUTH, INC.

Advisory opinion (Feb. 19, 2002), **App. D94**

**MEDSOUTH, INC.—Cont’d**

FTC staff follow-up letter (June 18, 2007) to 2002 staff advisory opinion, **App. D118**

**MEMBERSHIP RESTRICTIONS**

Ethical issue in, § **24:8**

**MEMORANDUM OF AGREEMENT**

FTC and Antitrust Division of the U.S. Dept. of Justice, Memorandum of Agreement concerning clearance procedures for investigations, **App. B7**

**MENTOR GROUP FORUM FOR EU-US LEGAL-ECONOMIC AFFAIRS**

“Protecting Consumer Welfare in the U.S. Health Care Sector,” Berlin, Germany (Sept 13, 2013), **App. E221**

**MERGER GUIDELINES**

DOJ and FTC 2023, **App. B20**

**MERGERS**

Generally, § **15:1**, **App. B et seq.**

Affordable Care Act, § **15:22**

Analyzing hospital generally, § **15:9**

Affordable Care Act, § **15:22**

competitor identification and market share calculation, § **15:12**

coordinating effects, § **15:15**

failing company defense, § **15:20**

nonprofit status, § **15:28**

order, special report, physician group and healthcare facility mergers, **App. B10**

party and consultant statements and documents about purpose and effect, § **15:26**

public and private commitments restraining exercise market power, § **15:27**

purchasers, below rebutting the prima facie case, below

relevant geographic market, § **15:11**

**MERGERS—Cont’d**

Analyzing hospital—Cont’d relevant product market, § **15:10**

Anthem, Inc.’s acquisition of WellPoint Health Networks, Inc., Antitrust Division statement on closing of investigation of (March 9, 2004), **App. E128**

As anticompetitive conduct under Section 2 of Sherman Act, § **6:11**

Aviv Nevo, Deputy Assistant Attorney General for Economics, Antitrust Division, “Mergers that Increase Bargaining Leverage,” Conference on Highly Innovated Industries (Jan. 22, 2014), **App. E227**

Blue Cross of Michigan and Physicians Health Plan of Mid-Michigan (Mar. 8, 2010), **App. E180**

Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E127**

Clayton Act Section 7A, premerger notification form and instructions under amended, **App. B3**

Competitors, complaints and opinions, § **15:25**

Consent order provisions, FTC frequently asked questions, § **15:36**

Cross-market, § **15:29**

Deborah L. Feinstein, Director, Bureau of Competition, FTC, “The Forward-Looking Nature of Merger Analysis,” text of remarks (Feb. 6, 2014), **App. E230**

Defenses, failing company, § **15:20**

Department of Justice business review procedure, **App. B4**

“Efficiencies in Defense of Mergers: Eighteen Months After” (speech), **App. E87**

Exemption of state-action, preliminary issues, § **15:6**

## INDEX

### MERGERS—Cont'd

#### FTC

advisory opinions procedure, **App. B5**

Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E127**

deborah L. Feinstein, Director, Bureau of Competition, FTC, “The Forward-Looking Nature of Merger Analysis,” text of remarks (Feb. 6, 2014), **App. E230**

frequently asked questions, merger consent order provisions, **§ 15:36**

guidelines on, Department of Justice and FTC, **§ 15:9**

“Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks of Edith Ramirez before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**

staff letter to Louisiana attorney general concerning Tenet Healthcare Corporation’s proposed acquisition of Slidell Memorial Hospital (Apr. 1, 2003), **App. D101**

statement in closing investigation of Caremark Rx/AdvancePCS merger (Feb. 11, 2004), **App. E127**

Statement of Richard A. Feinstein, FTC Bureau of Competition Director on the FTC’s Closure of its Investigation of Consummated hospital merger in Temple, Texas (Dec. 23, 2009), **App. E175**

statement of the Federal Trade Commission’s Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002), **App. B3F**

### MERGERS—Cont'd

Guidelines on, Department of Justice and FTC, **§ 15:9, App. B1**

“Health Care Mergers: Will We Get Efficiencies Claims Right?” (speech), **App. E79**

Health-plan mergers, **§ 15:33**

**Horizontal Mergers** (this index)

Hospital acquisition of physician practices, **§ 15:32**

#### Investigations

FTC statement in closing investigation of Caremark Rx/AdvancePCS merger (Feb. 11, 2004), **App. E127**

Statement of Richard A. Feinstein, FTC Bureau of Competition Director on the FTC’s Closure of its Investigation of Consummated hospital merger in Temple, Texas (Dec. 23, 2009), **App. E175**

Jeffrey Schmidt, Director, Bureau of Competition, prepared slides before ABA Section of Antitrust Law 2007 Fall Forum concerning “Critical Loss Analysis: A Merger Lawyer’s View” (Nov. 16, 2007), **App. E157**

“Litigating Merger Challenges: Lessons Learned,” prepared remarks by J. Thomas Rosch before Bates White Fifth Annual Antitrust Conference (June 2, 2008), **App. E165**

1984 Justice Department guidelines on, **App. B6**

Other hospital health-care sector generally, **§ 15:31**

health-plan mergers, **§ 15:33**

hospital acquisition of physician practices, **§ 15:32**

other industries, **§ 15:34**

physician practices, **§ 15:32**

Physician practices, **§ 15:32**

Planning for a hospital, **§ 15:30**

#### Preliminary issues

generally, **§ 15:2**

economic effects of mergers, **§ 15:2**

## MERGERS—Cont'd

- Preliminary issues—Cont'd
  - interstate commerce, § 15:7
  - premerger notification, investigation, and preliminary relief, § 15:8
  - relevant federal antitrust statutes, § 15:3
  - Section 7 and acquisitions by nonprofit entities, § 15:5
  - state-action exemption, § 15:6
  - virtual mergers and single entity status, § 15:4
- Protocol for coordination in merger investigations between federal enforcement agencies and state attorneys general, **App. B3G**
- Purchasers
  - complaints, § 15:24
  - opinions of, § 15:24
  - size and sophistication of, § 15:23
- Rebutting the prima facie case
  - generally, § 15:16
  - efficiencies, § 15:18
  - “flailing firm,” § 15:19
  - low entry barriers, § 15:17
  - weakened competitor, § 15:19
- “Reflections on an Active Year in Merger Enforcement,” keynote remarks of Commissioner Terrell McSweeney at Antitrust Law Leaders Forum (Feb. 5, 2016), **App. E250**
- Requests for additional information, FTC appeal procedure, **App. B8**
- “Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks of Edith Ramirez before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**
- Section 7. **Clayton Act** (this index)
- Statement of the Federal Trade Commission’s Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002), **App. B3F**
- State notification laws, § 15:35

## MERGERS—Cont'd

- Under Section 7 of Clayton Act and acquisitions by nonprofit entities, § 15:5
- conglomerate mergers and, § 8:15
- premerger notification requirements, § 8:17
- vertical mergers, § 8:14
- Under Section 1 of Sherman Act:
  - horizontal agreements, § 4:8
- Unilateral effects
  - generally, § 15:14
  - potential harms, coordinated effects, § 15:13
- United Health Group’s acquisition of Oxford Health Plans, Antitrust Division background of closing investigation of (Jul. 20, 2004), **App. E129**
- Vertical, § 15:29
- Virtual mergers and single entity status, § 15:4
- Voluntary self-disclosures
  - New Safe Harbor Policy, Deputy Attorney General Lisa O. Monaco, **App. B23**

## MESA COUNTY PHYSICIAN INDEPENDENT PRACTICE ASSOCIATION

- Federal Trade Commission Bureau of Competition staff advisory opinion regarding collective agreement, **App. D78A**

## MESSENGER ARRANGEMENTS

- Provider-controlled contracting networks, § 20:14

## MICHIGAN

- Merger proposed, Blue Cross of Michigan and Physicians Health Plan of Mid-Michigan (Mar. 8, 2010), **App. E180**

## MICHIGAN CERTIFICATE OF NEED COMMISSION

- Letter from Joseph Miller, Assistant Chief, Antitrust Division, to Sen. Michael D. Bishop, Michigan Senate Majority Leader, concerning proposed standards

## INDEX

**MICHIGAN CERTIFICATE OF  
NEED COMMISSION—Cont'd**  
(June 6, 2008), **App. C100**

**MIDWEST BEHAVIORAL  
HEALTH LLC**  
Business review letter (Feb. 4, 2000),  
**App. C90**

**MINNESOTA HOUSE OF  
REPRESENTATIVES**  
Letter from FTC concerning rural  
health care cooperative joint  
negotiations (Mar 18, 2009),  
**App. D125**

**MOBILE AND PORTABLE  
DENTISTRY**  
FTC Staff comments to Louisiana  
State Board of Dentistry regard-  
ing proposed modifications to  
Louisiana Rules regarding the  
practice of portable and mobile  
dentistry (Dec. 9, 2009), **App.  
D130**

**MOBILE HEALTH RESOURCES,  
LLC**  
Advisory opinions (Jan. 23, 1997),  
**App. D69**

**MONOPOLIZATION**  
Generally, § 6:1  
Anticompetitive conduct  
generally, § 6:4  
denial of access to essential facil-  
ity, § 6:8  
leveraging, § 6:9  
mergers, § 6:11  
monopoly pricing, § 6:5  
other predatory or unreasonably  
exclusionary conduct, § 6:12  
predatory pricing, § 6:12  
refusals to deal, § 6:7  
vertical integration, § 6:10  
**Attempted Monopolization** (this  
index)  
Conspiracy to monopolize, § 6:16  
**Health Plan Market Power** (this  
index)  
Monopoly power, § 6:3

**MONOPOLIZATION—Cont'd**  
Practitioner credentialing, analysis  
under Section 2 of Sherman Act,  
§ 13:18  
Shared monopoly, § 6:17  
“U.S. v. AzHAA: When Does a  
Group Purchasing Organization  
Become an Illegal  
Monopsonist?,” prepared  
remarks before AHLA annual  
meeting (June 26, 2007), **App.  
E151**

**MONOPSONY AND THE  
MEANING OF CONSUMER  
WELFARE**  
2006 Milton Handler Annual  
Antitrust Review, closer look at  
Weyerhaeuser (Dec. 7, 2006),  
**App. E144**

**MONTANA DEACONESS  
MEDICAL CENTER**  
Advisory opinions (June 28, 1996),  
**App. D65**

**MORROS & ASSOCIATES**  
Business review letter, **App. C6**

**MOST-FAVORED-NATIONS  
PROVISIONS**  
Health plan market power, payer  
monopoly power and most-  
favored-nations provisions,  
§ 21:6

**“NAKED” PRICE-FIXING  
AGREEMENTS**  
Generally, § 19:3

**NATIONAL CAPITAL SOCIETY  
OF PLASTIC AND  
RECONSTRUCTIVE  
SURGEONS**  
Advisory opinions (Apr. 23, 1991),  
**App. D30**

**NATIONAL CARDIOVASCULAR  
NETWORK, INC.**  
Business review letter, **App. C32**

**NEKRITZ, ELAINE**  
FTC letter to Illinois State Represen-  
tative Nekritz concerning

**NEKRITZ, ELAINE—Cont'd**

proposed regulation of retail health care facilities (May. 29, 2008), **App. D124**

**NETWORKS**

Anthem, Inc.'s acquisition of WellPoint Health Networks, Inc., Antitrust Division statement on closing of investigation of (March 9, 2004), **App. E128**

"Antitrust Analysis of Hospital Networks and Shared Services Arrangements" (speech), **App. E65**

"Antitrust Issues Raised by Rural Health Care Networks" (speech), **App. E80**

"Current Issues in Health Care Antitrust: Boycotts, Mergers, and Provider Networks" (speech), **App. E54**

Dermatologists, business review letters to Dr. Oswald L. Mikell regarding proposed network of, **App. C56**

Georgia Preferred Podiatric Medical Network, business review letters (Nov. 3, 1995), **App. C58**

Health plan market power and exclusions from networks. **Provider-Controlled Contracting Networks** (this index)

Hospice Network of New Jersey, Inc., business review letters (April 24, 1996), **App. C67**

National Cardiovascular Network, Inc., business review letter, **App. C32**

Oakland Physician Network, advisory opinions, **App. D50**

Ohio Ambulance Network, Inc., advisory opinions (Jan. 23, 1997), **App. D68**

Oklahoma Physicians Network-IPA, Inc., business review letters (Jan. 17, 1996), **App. C61**

Orange Pharmacy Equitable Network, advisory opinions (May 19, 1999), **App. D86**

**NETWORKS—Cont'd**

Pharmaceutical Care Network, business review letter, **App. C18**

Phoenix Medical Network, Inc., advisory opinions (May 19, 1998), **App. D82**

Preferred Laboratory Access Network, business review letters (Dec. 7, 1995), **App. C60**

Preferred Podiatric Network Inc., business review letter, **App. C45**

**Price-Fixing Agreements** (this index)

**Provider-Controlled Contracting Networks** (this index)

RWHC Network, Inc., business review letters (Nov. 12, 1996), **App. C76**

Southern Arizona Therapy Network, Inc., advisory opinions (Dec. 7, 1995), **App. D60**

**NEVO, AVIV**

"Mergers that Increase Bargaining Leverage," before Stanford Institute for Economic Policy Research and Cornerstone Research Conference on Highly Innovated Industries (Jan. 22, 2014), **App. E227**

**NEW HEALTH CARE INDUSTRY CONFERENCE**

Integration, Consolidation, Competition in the Wake of the Affordable Care Act, text of remarks of Bill Baer, Assistant Attorney General, before the New Health Care Industry Conference (Nov. 15, 2015), **App. E248**

**NEW JERSEY GENERAL ASSEMBLY**

Pharmacy benefit managers, letter from Federal Trade Commission Bureau of Competition and Bureau of Economics concerning regulation (Apr. 17, 2007), **App. D117**

**NEW JERSEY HOSPITAL ASSOCIATION**

Business review letter, **App. C32**

## INDEX

### NEW JERSEY PHARMACISTS ASSOCIATION

Advisory opinions (Aug. 12, 1997), **App. D78**

### NEW SAFE HARBOR POLICY

Voluntary self-disclosures, Deputy Attorney General Lisa O. Monaco, **App. B23**

### NEW YORK DEPARTMENT OF PUBLIC HEALTH

Certificates of Public Advantage, FTC staff advocacy letter concerning (Apr. 22, 2015), **App. D170**

### NEW YORK SENATE

Letter from FTC concerning pharmacy-benefit-manager regulation (Mar 31, 2009), **App. D126**

### NOERR-PENNINGTON DOCTRINE

Physician-owned facilities, § **18:3**

### NON-COMPETE AGREEMENTS

Employee, ethical restraints, **18:4**

### NONPROFIT ENTITIES

Section 7 of Clayton Act and acquisitions by, § **15:5**

### NONPROFIT HEALTH CARE PROVIDERS

Ramifications of preferential pricing of generally, § **23:4**  
see also **Resales of Preferentially Priced Commodities** (this index)  
Federal Trade Commission advisory opinions, § **23:5**

### NON-PROFIT INSTITUTIONS ACT

Federal Trade Commission (FTC), opinion concerning, **App. D155**, **App. D156**  
FTC Staff Advisory Opinions  
resales of preferentially priced commodities, § **23:5**

### NON-PROFIT INSTITUTIONS ACT —Cont'd

FTC Staff Advisory Opinions —Cont'd  
to Kaiser Foundation Health Plan, advisory opinion on purchase of discounted pharmaceuticals under Nonprofit Institutions Act exemption (Feb. 13, 2008), **App. D122**  
to Quest Analytics Group concerning Non-Profit Institutions Act (Mar. 7, 2014), **App. D165**  
Overview of, § **23:3**  
**Resales of Preferentially Priced Commodities** (this index)  
Text of, **App. A4**

### NONPROFIT STATUS

Mergers and, § **15:28**

### NORTH CAROLINA CHIROPRACTIC ASSOCIATION

Advisory opinion, **App. D5**

### NORTH CAROLINA DENTAL DECISION

“Reflections on Supreme Court’s North Carolina Dental Decision and the FTC’s Campaign to Rein in State Action Immunity,” Maureen K. Ohlhausen, Commissioner (Mar 31, 2015), **App. E240**

### NORTH CAROLINA SENATE BILL 743

Give state action defense to UNC healths collaborative activities, FTC staff comment, **App. D210**

### NORTH MISSISSIPPI HEALTH SERVICES

Advisory opinions  
(Oct. 3, 1996), **App. D71**  
(Jan. 7, 1998), **App. D81**  
Business review letter, **App. C22**  
FTC staff advisory opinion to (Aug. 16, 2005), **App. D112**

**NORTH OTTAWA COMMUNITY  
HOSPITAL**

Advisory opinions (Oct. 22, 1996),  
**App. D73**

**NORTH TEXAS CHAPTER,  
AMERICAN COLLEGE OF  
SURGEONS**

Advisory opinion, **App. D18**

**NOTIFICATION**

Premerger

merger and, § **15:8**

requirements under Section 7 of  
Clayton Act, § **8:17**

Section 7A of Clayton Act,  
premerger notification form  
and instructions under  
amended, **App. B3**

statement of Commissioner  
Christine S. Wilson in the  
matter of HSR Premerger  
Notification, **App. E285**

State merger notification laws,  
§ **15:35**

Washington AG guidance on  
healthcare transactions notifica-  
tion requirement, **App. B14**

**NSM PURCHASING  
ASSOCIATION**

Business review letters (Jan. 13,  
1999), **App. C88**

**NURSES AND NURSING**

**Advanced Practice Nursing** (this  
index)

**OHIO AMBULANCE NETWORK,  
INC.**

Advisory opinions (Jan. 23, 1997),  
**App. D68**

**OHIO EXECUTIVE ORDER  
2007-23S**

FTC staff letter to Hon. William J.  
Seitz, Ohio State Senator,  
concerning collective bargaining  
by home care providers (Feb.  
14, 2008), **App. D123**

**OHIO HOSPITAL PURCHASING  
CONSORTIUM**

Business review letter, **App. C13**

**OHLHAUSEN, MAUREEN K.**

“An Ounce of Antitrust Prevention is  
Worth a Pound of Consumer  
Welfare: The Importance of  
Competition Advocacy and  
Premerger Notification,” before  
Eleventh Annual Competition  
Day, Santiago, Chile (Nov. 5,  
2013), **App. E225**

“Brother, May I? The Challenge of  
Competitor Control over Market  
Entry” remarks before George  
Mason School of Law Global  
Antitrust Economics Conference  
(May 29, 2015), **App. E243**

“Protecting Consumer Welfare in the  
U.S. Health Care Sector,” before  
the Mentor Group Forum for  
EU-US Legal-Economic Affairs,  
Berlin, Germany (Sept 13,  
2013), **App. E221**

“Reflections on Supreme Court’s  
North Carolina Dental Decision  
and the FTC’s Campaign to  
Rein in State Action Immunity”  
(Mar 31, 2015), **App. E240**

“Section 5: Principles of Naviga-  
tion,” before U.S. Chamber of  
Commerce, Washington, DC  
(July 25, 2013), **App. E220**

“When Regulation Protects Privilege  
Instead of People: Government  
Restraints of Trade-A Competi-  
tion Enforcer’s Perspective,”  
text of remarks before The  
Antitrust Enforcement  
Symposium 2015 of Journal of  
Antitrust Enforcement (June 27,  
2015), **App. E245**

**OKLAHOMA PHYSICIANS  
NETWORK-IPA, INC.**

Business review letters (Jan. 17,  
1996), **App. C61**

**OLYMPUS AMERICA, IND.**

Business review letters (Aug. 29,  
2001), **App. C92**

**OPTOMETRY AND OPTOMETRIC  
CARE**

Business review letter, **App. D109**

## INDEX

### **OPTOMETRY AND OPTOMETRIC CARE—Cont'd**

- FTC and DOJ Advocacy letter to Massachusetts House of Representatives concerning permitting optometrists to treat glaucoma patients (Feb. 18, 2016), **App. D182**
- FTC and DOJ joint comments to Puerto Rico House of Representatives (May 18, 2016), **App. D187**
- FTC staff letter to Tennessee senate concerning bill regulating optometry (Apr. 29, 2003), **App. D102**

### **ORAL SURGEONS**

- Dentists and Oral Surgeons** (this index)

### **ORANGE BOOK**

- FDA listing, **26:1**

### **ORANGE LOS ANGELES MEDICAL GROUP, INC.**

- Business review letters (March 8, 1996), **App. C64**

### **ORANGE PHARMACY EQUITABLE NETWORK**

- Advisory opinions (May 19, 1999), **App. D86**

### **ORGANIZATION**

- And authority, FTC, enforcement, **§ 10:7**
- Antitrust Division, enforcement, **§ 10:2**

### **ORTHOPEDIC ASSOCIATES OF MOBILE, PA**

- Business review letters (Apr. 16, 1997), **App. C79**

### **8220OVERSIGHT OF THE ENFORCEMENT OF THE ANTITRUST LAWS8221**

- Prepared statement of FTC, United States Senate Committee on the Judiciary Subcommittee on Antitrust, **App. E287**

### **OXFORD HEALTH PLANS**

- Antitrust Division background of closing investigation of acquisition of Oxford Health Plans (Jul. 20, 2004), **App. E129**

### **PACIFIC INTERNATIONAL HEALTH**

- Advisory opinion, **App. D23**

### **PAN AMERICAN MANAGEMENT ASSOCIATES**

- Advisory opinion, **App. D27**

### **PARTIAL INTEGRATION OF BUSINESS FUNCTIONS**

- Joint Ventures** (this index)

### **PARTICIPATION AGREEMENTS**

- Health plan market power, participation agreements between providers and payers, **§ 21:3**

### **PARTICIPATION PERCENTAGES**

- Provider-controlled contracting networks, physician network joint ventures (Statement 8), **§ 20:6**

### **PARTIES LIABLE**

- In damage actions, **§ 11:13**

### **PASSAIC COUNTY MEDICAL SOCIETY**

- Advisory opinion, **App. D19**

### **PATENTS**

- “Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,” prepared statement of FTC before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E169**
- “Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-c-k!,” prepared remarks before second annual in-house counsel’s forum on

**PATENTS—Cont'd**

pharmaceutical antitrust (Apr. 24, 2006), **App. E141**

“FTC v. Actavis and the Future of Reverse Payment Cases,” remarks of Joshua D. Wright, Commissioner, FTC, before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E224**

“How Pay-for-Delay Settlements Make Consumers and the Federal Government Pay More for Much Needed Drugs,” prepared statement before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009), **App. E168**

**PAYER MONOPOLY POWER**

**Health Plan Market Power** (this index)

**PAYER-PROVIDER RELATIONSHIP**

**Provider-Payer Relationship** (this index)

**PAY-FOR-DELAY SETTLEMENTS**

**Exclusion Payment Settlements** (this index)

**PBM RELATED ADVOCACY**

FTC statement for, **App. D212**

**PEER REVIEW**

Practitioner credentialing based on. **Practitioner Credentialing** (this index)

**PEER REVIEW ORGANIZATIONS OF OHIO FOUNDATION**

Advisory opinion, **App. D10**

**PERMANENT INJUNCTION**

In Federal Trade Commission, plaintiff, v. Surescripts, LLC stipulated order, **App. N7**

**PER SE RULE**

“Virtual Mergers of Hospitals: When Does the Per Se Rule Apply?”

**PER SE RULE—Cont'd**

(speech), **App. E83**

**PETITION**

FTC v. Louisiana Childrens Medical Center, **App. N6**

**PHARMACEUTICAL CARE NETWORK**

Business review letter, **App. C18**

**PHARMACEUTICAL INDUSTRY**

“Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,” prepared statement of FTC before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E169**

“Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers,” text of remarks of Joshua D. Wright, Commissioner, FTC, before the ABA Master Course VII (Oct. 10, 2014), **App. E235**

“Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-c-k!,” prepared remarks before second annual in-house counsel’s forum on pharmaceutical antitrust (Apr. 24, 2006), **App. E141**

Federal Trade Commission Bureau of Competition and Bureau of Economics letter to New Jersey General Assembly concerning regulation of pharmacy benefit managers (Apr. 17, 2007), **App. D117**

Federal Trade Commission Office of Policy Planning, letter to Virginia House of Delegates concerning pharmacy-benefit managers (PBM) regulation (Oct. 2, 2006), **App. D116**

## PHARMACEUTICAL INDUSTRY

### —Cont’d

- Follow-on biologics, Pay-for-Delay Settlements, and Authorized Generics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E174**
- FTC amicus brief, Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals, **App. D207**
- FTC staff advisory opinion to Kaiser Foundation Health Plan on purchase of discounted pharmaceuticals under Nonprofit Institutions Act exemption (Feb. 13, 2008), **App. D122**
- “FTC v. Actavis and the Future of Reverse Payment Cases,” remarks of Joshua D. Wright, Commissioner, FTC, before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E224**
- House Bill 971 (Community Pharmacy Fairness Act of 2007), Prepared Statement of FTC Before U.S. House of Representatives Judicial Committee (Oct. 18, 2007)—David Wales, Bureau of Competition, **App. E156**
- House Bill 1332 (“HB 1332” or the “Bill”) that would regulate the contractual relationships between pharmacy-benefit managers (“PBMs”) and “covered entities,” **App. D108**
- Keynote remarks of Commissioner Rebecca Kelly Slaughter, FTC/DOJ Pharmaceutical task force workshop, **App. E286**
- Letter from FTC to New York Senator concerning pharmacy-benefit manager regulation (Mar. 31, 2009), **App. D126**
- Letter from Markus H. Meier, Crouse Health Hospital, sale of discount

## PHARMACEUTICAL INDUSTRY

### —Cont’d

- pharmaceuticals to employees and retirees, **App. D200**
- Overview of FTC actions in pharmaceutical products and distribution (October 2024), **App. L2**
- Patent settlements and Supreme Court, FTC prepared remarks, **App. E209**
- Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E174**
- “Pay-for-Delay Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers’ Wallets, and Help Pay for Health Care Reform (The \$ 35 Billion Solution)” prepared remarks of Jon Leibowitz (June 23, 2009), **App. E171**
- Post-patent pharmaceutical markets, issues in, **App. E260**
- Prepared Statement of FTC and Pharmaceutical Industry before Committee of Judiciary, US Senate (June 17, 2003)—Timothy J. Muris, Chairman, FTC, **App. E121**
- Prepared Statement of FTC before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009)—J. Thomas Rosch, Commissioner, FTC, **App. E168**
- Staff advisory opinion letter, Markus Meier to Doylestown Health, discounted pharmaceuticals and devices, Non-Profit Institutions Act, **App. D204**

**PHARMACEUTICAL INDUSTRY**

**—Cont'd**

- Staff letter to Rep. Patrick McHenry concerning proposed bill regulating pharmacy benefit manager contractual relationships (Jul. 15, 2005), **App. D111**
- Statement of Timothy J. Muris, Chairman, FTC before the Committee on Energy and Commerce, **App. E112**
- Study on pharmacy benefit managers, **App. E280**

**PHARMACEUTICAL MANUFACTURERS ASSOCIATION**

- Business review letter, **App. C33**

**PHARMACEUTICAL MERGERS**

- FTC-DOJ workshop summary, **App. N4**

**PHARMACEUTICAL PATENT DISPUTES**

- Settlement of disputes, antitrust issues (speech by Thomas B. Leary)  
(Part I), **App. E102**  
(Part II), **App. E103**

**PHARMACEUTICAL TASK FORCE WORKSHOP, FTC/DOJ**

- Keynote remarks of Commissioner Rebecca Kelly Slaughter, **App. E286**

**PHOENIX MEDICAL NETWORK, INC.**

- Advisory opinions (May 19, 1998), **App. D82**

**PHYSICIAN-OWNED FACILITIES**

- Generally, § 18:1 et seq.
- Actions to combat competition from medical staff members, § 18:3
- Adverse selection, § 18:2
- Ambulatory surgery centers (ASCs), § 18:2 et seq.
- Anticompetitive actions taken by hospitals, generally, § 18:2

**PHYSICIAN-OWNED FACILITIES**

**—Cont'd**

- Antitrust principles, application of, § 18:5
- Application of antitrust principles, § 18:5
- Boycotting by hospital, § 18:3
- Case summaries, § 18:5
- Certificate of need (CON), hospital's opposition, § 18:3
- Community and payer moral suasion, § 18:3
- Competition between hospitals and.  
See entries throughout this topic
- Conflicts of interest, § 18:2, § 18:3
- "Cost-shifting," § 18:2
- "Cross-subsidization," § 18:2
- Economic credentialing, § 18:3
- Economic interest. See entries throughout this topic
- Employee non-compete agreements, ethical restraints, § 18:4
- Establishment of competing facility by hospital, § 18:3
- Ethical restraints, employee non-compete agreements, § 18:4
- Exclusive contracting policies, § 18:3
- "Free-riding," § 18:2
- Hospitals and, competition between.  
See entries throughout this topic
- Investment interest. See entries throughout this topic
- Issue background, § 18:2
- Joint ventures, § 18:3
- Lobbying by hospitals against, § 18:3
- Medical staff members, actions to combat competition from, § 18:3
- Medicare Prescription Drug, Improvement, and Modernization Act, § 18:2
- Noerr-Pennington doctrine, § 18:3
- Non-compete agreements of employee, ethical restraints, § 18:4
- Referrals, § 18:2
- Selective contracting policies, § 18:3
- Single-specialty hospitals (SSHs), § 18:2 et seq.

## INDEX

### PHYSICIAN-OWNED FACILITIES —Cont'd

Stark anti-referral laws, § 18:2  
Unfair competition, § 18:2

### PHYSICIANS

See also **Practitioner Credentialing**  
(this index)

Alaska House of Representatives,  
physician joint negotiation statute (Jan. 18, 2002), **App. D92**

Collective bargaining legislative exemption, letter from FTC to Insurance Committee, Ohio House of Representatives (October 16, 2002), **App. D95**

Exclusive contracts between hospitals and. **Exclusive Contracts** (this index)

Hospital acquisition of physician practices, § 15:32

Joint negotiation statute

Alaska House of Representatives,  
physician joint negotiation statute, **App. D92**

Washington State House of Representatives, physician joint negotiation statute, **App. D93**

Joint ventures

between hospitals and physicians, analysis, § 16:10

**Provider-Controlled Contracting Networks** (this index)

Mergers of practices of, § 15:32

Network joint ventures. **Provider-Controlled Contracting Networks** (this index)

Washington State House of Representatives, physician joint negotiation statute (Feb. 8, 2002), **App. D93**

### PLANNING

See also **Health Planning; Health Planning Act; Health Plans**  
(this index)

For mergers

See also **Health Planning; Health Planning Act; Health Plans**  
(this index)

### PLANNING—Cont'd

For mergers—Cont'd  
hospitals, § 15:30

### PLASTIC SURGERY ASSOCIATES OF CONNECTICUT, LLC

Business review letters (June 28, 1996), **App. C68**

### “POACHING”

Limitations on, ethical restraints, § 24:5

### PORTABLE AND MOBILE DENTISTRY

FTC Staff comments to Louisiana State Board of Dentistry regarding proposed modifications to Louisiana Rules regarding the practice of portable and mobile dentistry (Dec. 9, 2009), **App. D130**

### PRACTICE FORM

Restraints on, ethical issue, § 24:7

### PRACTICE STANDARDS

Relating to quality, ethical issue, § 24:9

### PRACTITIONER CREDENTIALING

Generally, § 13:1

Allied health practitioners, § 13:19

Analysis under Section 1 of Sherman Act  
generally, § 13:10

capacity to conspire, § 13:11

conspiracy in fact, § 13:12

standard of analysis, § 13:13

Analysis under Section 2 of Sherman Act, § 13:18

Analysis under Section 1 of Sherman Act: analysis under rule of reason

generally, § 13:14

effect on competition, § 13:16

intent and purpose, § 13:17

relevant market, § 13:15

Antitrust standing to challenge adverse decision, § 13:9

**PRACTITIONER**

**CREDENTIALING—Cont'd**

Discovery in staff-privilege antitrust litigation, § 13:20  
 Health Care Quality Improvement Act, § 9:12, § 13:8  
 Hospital organization and the process of, § 13:2  
 Legal theories and parties, § 13:3  
 Minimizing antitrust risks, § 13:21  
 Preliminary issues  
     generally, § 13:4  
     Health Care Quality Improvement Act, § 13:8  
     interstate commerce, § 13:5  
     Local Government Antitrust Act, § 13:7  
     state-action exemption, § 13:6

**PREDATORY CONDUCT**

Section 2 of Sherman Act, diversification and  
 see also **Anticompetitive Conduct** (this index)  
 refusals to deal, § 17:9  
 steering as predatory conduct, § 17:12

**PREDATORY PRICING**

Under Section 2 of Sherman Act, § 6:6

**PREFERRED LABORATORY ACCESS NETWORK**

Business review letters (Dec. 7, 1995), **App. C60**

**PREFERRED PHYSICIANS MEDICAL GROUP**

Business review letters (July 23, 1999), **App. C89**

**PREFERRED PODIATRIC NETWORK INC.**

Business review letter, **App. C45**

**PRELIMINARY INJUNCTION**

Pursuant to Section 13(b) of the Federal Trade Commission Act, **App. N2**

**PREMERGER NOTIFICATION**

“An Ounce of Antitrust Prevention is Worth a Pound of Consumer Welfare: The Importance of Competition Advocacy and Premerger Notification,” before Eleventh Annual Competition Day, Santiago, Chile (Nov. 5, 2013), **App. E225**  
 Mergers and, § 15:8  
 Requirements under Section 7 of Clayton Act, § 8:17  
 Section 7A of Clayton Act, premerger notification form and instructions under amended, **App. B3**  
 Statement of Commissioner Christine S. Wilson in the matter of HSR Premerger Notification, **App. E285**

**PRESCRIPTION DRUGS**

FTC Staff Advocacy Letter to Centers for Medicare and Medicaid Services concerning any-willing-provider changes to Medicare prescription drug benefit program (Mar. 7, 2014), **App. D164**

**PRESENTATION HEALTH SYSTEM**

Advisory opinion, **App. D41**

**PRICE DISCRIMINATION**

Generally, § 7:1  
 As vertical agreement under Section 1 of Sherman Act, § 5:9

**PRICE EXCHANGES**

**Price-Fixing Agreements** (this index)

**PRICE-FIXING AGREEMENTS AND PRICE AND WAGE EXCHANGES**

Generally, § 19:1 et seq.  
 Ancillary price-fixing agreements, § 20:8  
 Contracting networks. **Provider-Controlled Contracting Networks** (this index)  
 Ethical restraints on, § 24:3

## INDEX

### PRICE-FIXING AGREEMENTS AND PRICE AND WAGE EXCHANGES—Cont'd

- Exchanging or disseminating pricing information, competitor agreements to, § 19:6
- Exclusive contracts and vertical, § 14:15
- Forms of provider price-fixing agreements, § 19:4
- Horizontal, under Section 1 of Sherman Act, § 4:2
- Joint ventures. **Provider-Controlled Contracting Networks** (this index)
- “Naked” price-fixing agreements, § 19:3
- Negotiations among providers with payers, concerted, § 19:5
- Networks. **Provider-Controlled Contracting Networks** (this index)
- Physician network joint ventures (Statement 8). **Provider-Controlled Contracting Networks** (this index)
- Price exchanges. See entries throughout this topic
- Provider-Controlled Networks** (this index)
- Statement 8. **Provider-Controlled Contracting Networks** (this index)
- Statement 9. **Provider-Controlled Contracting Networks** (this index)
- Vertical Price-Fixing Agreements** (this index)

### PRICING

- Monopoly, under Section 2 of Sherman Act, § 6:5
- Predatory, under Section 2 of Sherman Act, § 6:6

### PRIMARY AND EXCLUSIVE JURISDICTION

- Generally, § 9:6

### PRIMARY AND SPECIALIST MEDICAL CENTER, LLC

- Business review letters (July 2, 1996), **App. C70**

### PRIVATE ACTIONS

- Generally, § 11:1
- Damages as element of damage action, § 11:8
- Defenses
  - generally, § 11:9
  - antitrust defenses in nonantitrust cases, § 11:12
  - in pari delicto and related defenses, § 11:11
  - statute of limitations, § 11:10
- Effect of government judgments and prior violations, § 11:14
- Elements of
  - generally, § 11:2
  - antitrust injury, § 11:6
  - business or property, § 11:4
  - causation, § 10:4, § 11:5
  - damages, § 11:8
  - injury, § 11:3
  - standing, § 11:7
- Injunctive relief, § 11:15
- Parties liable, § 11:13
- Practitioner credentialing, antitrust standing to challenge, § 13:9

### PRIVATE HEALTHCARE SYSTEM

- Advisory opinion, **App. D16**

### PRIVATE TREBLE-DAMAGE LITIGATION

- Injury in, under Robinson-Patman Act, § 7:11

### PRODUCTS

- Separate and distinct, exclusive contracts and, § 14:4
- Tying Arrangements** (this index)

### PROKLAHOMA CARE, INC.

- Business review letters (Jan. 17, 1996), **App. C61**

### PROPERTY

- As element of damage action, § 11:4

### PROVIDER-CONTROLLED CONTRACTING NETWORKS

- Generally, § 20:1 et seq.
- Accountable care organizations, Federal Trade Commission and

**PROVIDER-CONTROLLED  
CONTRACTING NETWORKS**

**—Cont'd**

- Department of Justice Statement of Antitrust Enforcement Policy, § 20:15
- Ancillary price-fixing agreements and clinical integration, § 20:8
- Clinical integration, ancillary price-fixing agreements and, § 20:8
- Exclusivity in physician network joint ventures and safety zones, Statement 8, § 20:6
- Federal Trade Commission and Department of Justice Statement of Antitrust Enforcement Policy, § 20:15
- Joint ventures. Physician network joint ventures (Statement 8), below
- Market power
  - multi-provider networks, § 20:12
  - physician network joint ventures (Statement 8), § 20:9
- Medicare Shared Savings Program, Accountable care organizations, § 20:15
- Messenger arrangements, § 20:14
- Multi-provider networks (Statement 9)
  - generally, § 20:10 to 20:13
  - market power, § 20:12
  - price-fixing agreements, generally, § 20:11
  - vertical agreements, § 20:13
- Participation percentages, exclusivity, and safety zones, Statement 8, § 20:6
- Physician network joint ventures (Statement 8)
  - generally, § 20:4 to 20:9
  - ancillary price-fixing agreements and clinical integration, § 20:8
  - antitrust safety zones, § 20:5, § 20:6
  - exclusivity in physician network joint ventures and safety zones, § 20:6

**PROVIDER-CONTROLLED  
CONTRACTING NETWORKS**

**—Cont'd**

- Physician network joint ventures (Statement 8)—Cont'd
  - financial risk sharing and antitrust safety zones, § 20:5
  - market power, § 20:9
  - outside antitrust safety zones, § 20:7, § 20:8
  - participation percentages, exclusivity, and safety zones, § 20:6
- Price-fixing agreements, generally, § 20:3 et seq.
- Vertical agreements, multi-provider networks, § 20:13

**PROVIDER DIVERSIFICATION**

- Generally, § 17:1
- And Section 7 of Clayton Act, § 17:7
- And Section 1 of Sherman Act, § 17:3
- And Section 2 of Sherman Act
  - generally, § 17:8
  - steering as predatory conduct, § 17:12
- And Section 2 of Sherman Act:
  - monopolization and attempted monopolization
    - generally, § 17:8
    - diversification and leveraging, § 17:11
    - diversification and predatory refusals to deal, § 17:9
    - diversification and the essential facilities doctrine, § 17:10
- And steering by other providers, § 17:14
- Diversification and reciprocal dealing, § 17:6
- Diversification resulting from an exclusive dealing agreement, § 17:4
- Diversification resulting in a tying arrangement, § 17:5
- Relevant legal theories, § 17:2
- Risk minimization in hospital diversification, § 17:13

## INDEX

### PUERTO RICO

Optometry, FTC and DOJ joint comments to Puerto Rico House of Representatives (May 18, 2016), **App. D187**

Treasury and Financial Affairs Committee, FTC Staff letter objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D121**

### PURCHASERS

Group purchasing programs, joint ventures and, § 16:8

**Mergers** (this index)

### PURPOSE OR INTENT

Practitioner credentialing and, under Section 1 of Sherman Act generally, § 13:17

see also **Anticompetitive Purpose or Intent Element** (this index)

### QUALITY

Standards of practice relating to, as ethical issue, § 24:9

### QUALITY HEALTH-CARE COALITION ACT

Speeches, **App. E82, App. E89, App. E90**

### QUEST ANALYTICS GROUP

FTC Staff Advisory Opinion concerning Non-Profit Institutions Act (Mar. 7, 2014), **App. D165**

### “QUICK LOOK” RULE

Sherman Act Section 1 violations, anticompetitive effect elements, § 3:13

### RAMIREZ, EDITH

“Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**

### RE BYSTOLIC ANTITRUST LITIGATION

FTC amicus brief, **App. D211**

### RECIPROCAL DEALING

Diversification and, § 17:6

### RECIPROCAL DEALING AGREEMENTS

As vertical agreements under Section 1 of Sherman Act, § 5:8

### REFERRALS

Physician-owned facilities, § 18:2

### REFUSAL TO DEAL

As anticompetitive conduct under Section 2 of Sherman Act, § 6:7

Concerted, under Section 1 of Sherman Act, § 4:7

Diversification and predatory, § 17:9

### REGULATED INDUSTRIES

**Federal Government** (this index)

### REIMBURSEMENT

Health plan market power, payer monopoly power and low reimbursement, § 21:5

### RELATING TO WISCONSIN RATE REVIEW PROGRAM

Business review letter, **App. C4**

### RELEVANT MARKETS

Generally, § 2:1 to 2:6

Conclusion, § 2:6

Exclusive contracts and, § 14:11

Interstate commerce requirement, § 2:2

Mergers and

geographic markets, § 15:11

product market, § 15:10

Under Section 7 of Clayton Act, § 8:4

Under Section 1 of Sherman Act geographic market, § 2:5  
practitioner credentialing and, § 13:15

product market, § 2:4

**RELIEF**

In civil cases of Antitrust Division,  
§ 10:5

Injunctive, in damage actions,  
§ 11:15

Preliminary, mergers and, § 15:8

Under Section 7 of Clayton Act  
generally, § 8:18

Antitrust Division and Federal  
Trade Commission, § 8:18  
private parties, § 8:19

**REMARKS OF BILL BAER**

Integration, Consolidation, Competi-  
tion in the Wake of the Afford-  
able Care Act, text of remarks  
before the New Health Care  
Industry Conference (Nov. 15,  
2015), **App. E248**

**REMARKS OF DEBORAH L.  
FEINSTEIN**

“Antitrust Enforcement in Health  
Care: Proscription, Not Prescrip-  
tion,” text of remarks before the  
Fifth National Accountable Care  
Organization Summit (June 19,  
2014), **App. E232**

“FTC v. Sysco: Old School Antitrust  
With Modern Economic Tools”  
text of remarks before GCR  
Live (Sept. 18, 2015), **App.  
E246**

“The Forward-Looking Nature of  
Merger Analysis,” text of  
remarks (Feb. 6, 2014), **App.  
E230**

**REMARKS OF EDITH RAMIREZ**

“Retrospectives at the FTC: Promot-  
ing an Antitrust Agenda,” text of  
remarks before the George  
Washington University Law  
School Merger Transactions  
Symposium (June 28, 2013),  
**App. E233**

“The Horizontal Merger Guidelines  
Five Years Later” text of  
remarks before Georgetown  
University Law Center Ninth  
Annual Global Antitrust  
Enforcement Symposium (Sept.

**REMARKS OF EDITH RAMIREZ**  
—Cont’d

29, 2015), **App. E247**

**REMARKS OF JON LEIBOWITZ**

“Exclusion Payments to Settle  
Pharmaceutical Patent Cases:  
They’re B-a-c-k!,” prepared  
remarks before second annual  
in-house counsel’s forum on  
pharmaceutical antitrust (Apr.  
24, 2006), **App. E141**

“Pay-for-Delay Settlements in the  
Pharmaceutical Industry: How  
Congress Can Stop Anticompeti-  
tive Conduct, Protect Consum-  
ers’ Wallets, and Help Pay for  
Health Care Reform (The \$ 35  
Billion Solution)” (June 23,  
2009), **App. E171**

**REMARKS OF JOSHUA D.  
WRIGHT**

“Antitrust Analysis of Reverse Pay-  
ments After Actavis: Three  
Questions and Proposed  
Answers,” text of remarks  
before the ABA Master Course  
VII (Oct. 10, 2014), **App. E235**

“FTC v. Actavis and the Future of  
Reverse Payment Cases,” before  
the Concurrences Journal  
Annual Dinner, New York, New  
York (Sept. 26, 2013), **App.  
E224**

“Recent Antitrust Enforcement  
Initiatives at the U.S. Federal  
Trade Commission,” before the  
ABA Section of International  
Law Conference, Beijing, China  
(Sept. 16, 2013), **App. E222**

“The FTC’s Role in Shaping  
Antitrust Doctrine: Recent Suc-  
cesses and Future Targets,”  
before the 2013 Georgetown  
Global Antitrust Symposium  
Dinner, Washington, D.C. (Sept.  
24, 2013), **App. E223**

**REMARKS OF J. THOMAS ROSCH**

“Clinical Integration in Antitrust:  
Prospects for the Future,” pre-

## INDEX

### REMARKS OF J. THOMAS ROSCH —Cont'd

pared remarks before AHLA and ABA Antitrust and Health Law Section 2007 Antitrust in Health Care Seminar (Sept. 17, 2007), **App. E154**

“Enforcement Strategies in the Health Care Industry,” prepared remarks before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E167**

“Litigating Merger Challenges: Lessons Learned,” prepared remarks before Bates White Fifth Annual Antitrust Conference (June 2, 2008), **App. E165**

Monopsony and the meaning of consumer welfare, a closer look at Weyerhaeuser (Dec. 7, 2006), **App. E144**

Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context (Nov. 19, 2009), **App. E174**

### REMARKS OF JULIE BRILL

“A Common Goal: The U.S. Federal Trade Commission’s Healthcare Enforcement Program and its Implications for ACOs,” text of remarks by Julie Brill, Commissioner, FTC, before the Sixth Annual Accountable Care Organization Summit Preconference (June 17, 2015), **App. E244**

“What’s Past is Prologue: FTC’s Competition and Consumer Protection Priorities,” text of remarks by Julie Brill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E236**

### REMARKS OF LINA M. KHAN

Study on Pharmacy Benefit Managers, **App. E280**

### REMARKS OF MARK BOTTI

“Observations on and From the Antitrust Division’s buyer-side cases: How can ‘lower’ prices violate the antitrust laws” at Antitrust Law Spring Meeting (Apr. 19, 2007), **App. E147**

### REMARKS OF MARTIN GAYNOR

“Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care,” text of remarks before the 2014 American Antitrust Institute Annual Conference, **App. E234**

### REMARKS OF MARY LOU STEPTOE

(Speech), **App. E40**

### REMARKS OF MAUREEN K. OHLHAUSEN

“Brother, May I? The Challenge of Competitor Control over Market Entry” remarks before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E243**

“When Regulation Protects Privilege Instead of People: Government Restraints of Trade-A Competition Enforcer’s Perspective,” text of remarks before The Antitrust Enforcement Symposium 2015 of Journal of Antitrust Enforcement (June 27, 2015), **App. E245**

### REMARKS OF PAMELA JONES HARBOUR

“A ‘Check-Up’ of Selected Health Care Activity at FTC” (Mar. 30, 2005), **App. E132**

“Clinical Integration: The Changing Climate and What It Means for Care Coordination” (Apr. 27, 2009), **App. E170**

### REMARKS OF REBECCA KELLY SLAUGHTER

8220Antitrust and Health Care Providers: Policies to Promote Competition and Protect

**REMARKS OF REBECCA KELLY  
SLAUGHTER—Cont'd**

Patients, 8221 **App. E267**

Keynote, FTC/DOJ Pharmaceutical  
Task Force Workshop, **App.  
E286**

**REMARKS OF TERRELL  
MCSWEENEY**

Federal Trade Commission, Commis-  
sioner, text of remarks (Apr 28,  
2015), **App. E241**

“Reflections on an Active Year in  
Merger Enforcement,” keynote  
remarks (Feb. 5, 2016), **App.  
E250**

**REMARKS OF THOMAS B.  
LEARY**

Generally, **App. E114**

**REMARKS OF TIMOTHY J.  
MURIS**

Generally, **App. E113, App. E115**

**REMARKS OF WILLIAM  
BLUMENTHAL**

“The Rhetoric of Gun Jumping,”  
remarks before Association of  
Corporate Counsel Annual  
Antitrust Seminar of Greater  
New York Chapter (Nov. 10,  
2005), **App. E138**

**REMARKS OF WILLIAM J. BAER**

“Origin of the Species: The 100 Year  
Evolution of the Clayton Act,”  
text of remarks before ABA  
Clayton Act 100th Anniversary  
Symposium (Dec. 4, 2014),  
**App. E237**

**RESALES OF PREFERENTIALLY  
PRICED COMMODITIES**

Generally, § 23:1

Non-Profit Institutions Act

generally, § 23:3

see also entries throughout this  
topic

Practical considerations, § 23:6

Ramifications of preferential pricing  
on nonprofit health care provid-  
ers

Federal Trade Commission advi-  
sory opinions, § 23:5

**RESALES OF PREFERENTIALLY  
PRICED COMMODITIES**

—Cont'd

Ramifications of preferential pricing  
on nonprofit health care provid-  
ers—Cont'd

NPIA court decisions, § 23:4

Robinson-Patman Act

generally, § 23:2

see also entries throughout this  
topic

**RESOURCES**

Antitrust laws, § 1:10

**RESTRAINING ORDER**

Temporary, pursuant to Section 13(b)  
of the Federal Trade Commis-  
sion Act, **App. N2**

**RESTRAINTS**

**Agreements** (this index)

**Ethical Restraints** (this index)

**RETAIL HEALTH CARE  
FACILITIES**

Letter from FTC to Illinois State  
Representative concerning  
proposed regulation of retail  
health care facilities (May 29,  
2008), **App. D124**

**REVERSE PAYMENTS**

“Antitrust Analysis of Reverse Pay-  
ments After Actavis: Three  
Questions and Proposed  
Answers,” text of remarks of  
Joshua D. Wright, Commis-  
sioner, FTC, before the ABA  
Master Course VII (Oct. 10,  
2014), **App. E235**

“FTC v. Actavis and the Future of  
Reverse Payment Cases,”  
remarks of Joshua D. Wright,  
Commissioner, FTC, before the  
Concurrences Journal Annual  
Dinner, New York, New York  
(Sept. 26, 2013), **App. E224**

**REVISED JURISDICTIONAL  
THRESHOLDS**

Section 7A, Hart Scott-Rodino  
premerger notification filings  
Clayton Act, **App. B26**

## INDEX

### **RHODE ISLAND ATTORNEY GENERAL**

FTC staff letter to Patrick C. Lynch,  
Attorney General of Rhode  
Island (Apr. 8, 2004), **App.**  
**D106**

### **RIO GRANDE EYE ASSOCIATES, P.A.**

Business review letter, **App. C91**

### **RISK MINIMIZATION**

Exclusive contracts and, § **14:16**  
In hospital diversification, § **17:13**  
Practitioner credentialing and,  
§ **13:21**

### **RISK SHARING**

Provider-controlled contracting  
networks, antitrust safety zones,  
§ **20:5**

### **ROBINSON-PATMAN ACT**

Generally, § **7:2**  
Exemptions and applicability, § **7:10**  
Injury in private treble-damage litigation, § **7:11**  
Overview of, § **23:2**  
**Resales of Preferentially Priced  
Commodities** (this index)  
Section 2(a)  
competitive effects, § **7:5**  
defenses, § **7:6**  
essential elements, § **7:3**  
jurisdictional requirements, § **7:4**  
Section 2(c), § **7:7**  
Section 2(f), § **7:9**  
Sections 2(d) and 2(e), § **7:8**  
Text of, excerpts, **App. A3**

### **ROSS HOSPITAL (FEB. 11, 1997)**

Business review letters, **App. C77**

### **RULE OF REASON**

Practitioner credentialing, analysis  
under Sherman Antitrust Act  
Section 1  
generally, § **13:14**  
effect on competition, § **13:16**  
intent and purpose, § **13:17**  
relevant market, § **13:15**

### **RULE OF REASON—Cont'd**

Unreasonably anticompetitive effect  
element, Sherman Antitrust Act  
Section 1, § **3:11**

### **RURAL HEALTH CARE COOPERATIVES**

Letter from FTC to Minnesota State  
Representative concerning joint  
negotiations (Mar 18, 2009),  
**App. D125**

### **RWHC NETWORK, INC.**

Business review letters (Nov. 12,  
1996), **App. C76**

### **SANOFI/ MAZE THERAPEUTICS**

Chair Lina M. Khan joined by com-  
missioner Rebecca Kelly  
Slaughter, statement of, **App.**  
**B24**

### **SANTA FE, NEW MEXICO MANAGED CARE ORGANIZATION, INC.**

Business review letters  
(Feb. 12, 1997), **App. C78**  
(Sept. 16, 1998), **App. C87**

### **SCHMIDT, JEFFREY**

Prepared slides of Jeffrey Schmidt,  
Director, Bureau of Competi-  
tion, before ABA Section of  
Antitrust Law 2007 Fall Forum  
concerning “Critical Loss Anal-  
ysis: A Merger Lawyer’s View”  
(Nov. 16, 2007), **App. E157**

### **SECOND CIRCUIT ORDER**

8220Pharma Bro8221 Martin  
Shkreli’s lifetime ban, upholding  
federal trade commission, state-  
ment of, **App. B25**

### **SEESKIN, PAAS, BLACKBURN & CO.**

Business review letter, **App. C43**

### **SELECTIVE CONTRACTING**

Physician-owned facilities, § **18:3**

### **SENATOR WILLIAM J. SEITZ**

FTC staff letter concerning collective  
bargaining by home care provid-

**SENATOR WILLIAM J. SEITZ**

—Cont'd

ers (Feb. 14, 2008), **App. D123**

**SERVICE FOR YOU**

Business review letter, **App. C19**

**SERVICES**

Conditional sale of one service, on purchase of another service, exclusive contracts and, § **14:5**

Joint ventures among competitors to provide new, § **16:9**

**SETTLEMENTS**

**Exclusion Payment Settlements**  
(this index)

**SEWARD, JAMES I.**

FTC letter to New York Senator James I. Seward concerning pharmacy-benefit-manager regulation (Mar 31, 2009), **App. D126**

**SHARED MONOPOLY**

Generally, § **6:17**

**SHERMAN ANTITRUST ACT  
(SHERMAN ACT)**

Generally, § **3:1**

“Effect on commerce” test, § **2:2**

Expectation of effect on commerce, § **2:2**

“In commerce” test, § **2:2**

“Infected activities,” § **2:2**

Relevant geographic market, § **2:1**

Section 2

generally, § **6:1**

conspiracy to monopolize, § **6:16**

exclusive contracts, § **14:13**

mergers and, § **15:3**

practitioner credentialing, § **13:18**

Section 2: attempted monopolization

generally, § **6:13**

dangerous probability of success, § **6:15**

specific intent and predatory conduct, § **6:14**

Section 2: diversification and

generally, § **17:8**

**SHERMAN ANTITRUST ACT  
(SHERMAN ACT)—Cont'd**

Section 2: diversification and

—Cont'd

diversification and essential facilities doctrine, § **17:10**

diversification and leveraging, § **17:11**

diversification and predatory refusals to deal, § **17:9**

steering as predatory conduct, § **17:12**

Section 1: diversification under generally, § **17:3**

diversification and reciprocal dealing, § **17:6**

diversification resulting from an exclusive dealing agreement, § **17:4**

diversification resulting in a tying arrangement, § **17:5**

Section 1: fundamental concepts, relevant market

generally, § **2:3**

relevant geographic market, § **2:5**

relevant product market, § **2:4**

Section 1: fundamental concepts of generally, § **3:1**

elements of Section 1 violation.

**Violations of Section 1 of Sherman Act** (this index)

interstate commerce requirement, § **2:2**

Section 1: horizontal agreements under

generally, § **4:1**

agreements to exchange or disseminate information, § **4:3**

bid-rigging agreements, § **4:5**

concerted refusals to deal, § **4:7**

covenants not to compete, § **4:6**

horizontal market-allocation agreements, § **4:4**

horizontal price-fixing agreements, § **4:2**

mergers and joint ventures, § **4:8**

standard-setting programs, § **4:10**

unfair competition and dirty tricks, § **4:9**

## INDEX

### **SHERMAN ANTITRUST ACT (SHERMAN ACT)—Cont'd**

- Section 1: mergers, § 15:3
- Section 2: monopolization
  - generally, § 6:2
  - monopoly power, § 6:3
- Section 2: monopolization—
  - anticompetitive conduct
    - generally, § 6:4
    - denial of access to essential facility, § 6:8
    - leveraging, § 6:9
    - mergers, § 6:11
    - monopoly pricing, § 6:5
    - other predatory or unreasonably exclusionary conduct, § 6:12
    - predatory pricing, § 6:6
    - refusals to deal, § 6:7
    - text of, excerpts, **App. A1**
    - vertical integration, § 6:10
- Section 1: practitioner credentialing—analysis under rule of reason
  - generally, § 13:14
  - effect on competition, § 13:16
  - intent and purpose, § 13:17
  - relevant market, § 13:15
- Section 1: practitioner credentialing under
  - generally, § 13:10
  - capacity to conspire, § 13:11
  - conspiracy in fact, § 13:12
  - standard of analysis, § 13:13
- Section 1: vertical agreements under
  - generally, § 5:1
  - distributorship terminations, § 5:4
  - dual distribution, § 5:5
  - exclusive dealing agreements, § 5:7
  - price discrimination and commercial bribery, § 5:9
  - reciprocal dealing agreements, § 5:8
  - tying agreements, § 5:6
  - vertical market-allocation agreements, § 5:3
  - vertical price-fixing agreements, § 5:2

### **SHERMAN ANTITRUST ACT (SHERMAN ACT)—Cont'd**

- Subject matter jurisdiction, § 2:2

### **SIERRA COMMCARE, INC.**

- Business review letters (Aug. 15, 1996), **App. C72**

### **SIMONS, JOSEPH J.**

- “A Health Care Check on COPAs; Assessing the Impact of Certificates of Public Advantage in Health Care Markets” (June 18, 2019), **App. E268**
- FDA / FTC Biosimilars Workshop (March 9, 2020), **App. E271**

### **SINGLE-SPECIALTY HOSPITALS (SSHS)**

- Physician-owned facilities, § 18:2 et seq.

### **SLAUGHTER, REBECCA KELLY**

- Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E288**
- “Antitrust and Health Care Providers: Policies to Promote Competition and Protect Patients,” **App. E267**
- Contact Lens Rule (June 22, 2020), **App. E274**
- Keynote remarks, Pharmaceutical Task Force Workshop, **App. E286**

### **SMITH, TERENCE L., M.D.**

- Business review letters (Oct. 17, 1996), **App. C75**

### **SOLICITATION**

- Limitations on, ethical restraints, § 24:6
- Of government action, antitrust exemption, § 9:8

### **SOUTH CAROLINA HOUSE OF REPRESENTATIVES**

- FTC advocacy letter concerning supervision of advanced practice

**SOUTH CAROLINA HOUSE OF REPRESENTATIVES—Cont'd**  
nurses (Nov. 2, 2015), **App. D178**

Joint statement of FTC and Antitrust Division on Certificate-of-Need laws and proposed legislation (Jan. 16, 2016), **App. D179**

**SOUTH CAROLINA STATE HEALTH PLANNING COMMITTEE**

U.S. Department of Justice Antitrust Division letter concerning certificate-of-need regulation (Dec. 8, 2006), **App. C99**

**SOUTHEAST MANAGED CARE, INC.**

Advisory opinion, **App. D46**

**SOUTHERN ARIZONA THERAPY NETWORK, INC.**

Advisory opinions (Dec. 7, 1995), **App. D60**

**SOUTHERN HEALTH CORPORATION (MARCH 5, 1996)**

Business review letters, **App. C63**

**SOUTHWESTERN MICHIGAN HEALTH SYSTEMS AGENCY**

Business review letter, **App. C12**

**SOUTHWEST FLORIDA ORAL SURGERY ASSOCIATES**

Advisory opinions (Dec. 2, 1996), **App. D67**

**SOUTHWEST ONCOLOGY GROUP**

Business review letters (Nov. 2, 1995), **App. C57**

**SOUTHWEST ORTHOPEDIC SPECIALISTS (JUNE 10, 1997)**

Business review letters, **App. C81**

**SPECIAL COMMITTEE ON AGING, U.S. SENATE**

Barriers to Generic Entry, Prepared Statement of FTC Before (July 20, 2006), **App. E142**

**SPECIALIZED SERVICES**

Joint ventures among competitors to provide new, § **16:9**

**SPEECHES**

Generally, **App. E et seq.**

See also topics beginning “Remarks”

Abandonment by Providence Health & Services of plan to acquire Spokane Cardiology and Health Clinics Northwest, **App. E189**

“A ‘Check-Up’ of Selected Health Care Activity at FTC” (Mar. 30, 2005), **App. E132**

“Anticompetitive Aspects of Exclusive Dealing and Related Practices,” **App. E88**

“Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,” **App. E169**

“Antitrust, Accountable Care Organizations, and the Promise of Health Care Reform,” Edith Ramirex, FTC Comm., **App. E187**

“Antitrust Analysis of Hospital Networks and Shared Services Arrangements,” **App. E65**

“Antitrust Evaluation of Pay-for-Delay Settlements: A Persistent Quest for Balance,” **App. E196**

“Antitrust in Healthcare: A Keynote Address,” **App. E124**

“Antitrust Issues in Settlement of Pharmaceutical Patent Disputes” (Part I - Nov. 3, 2000), **App. E102**

“Antitrust Issues in Settlement of Pharmaceutical Patent Disputes” (Part II - Nov. 3, 2000), **App. E103**

“Antitrust Issues Raised by Rural Health Care Networks,” **App. E80**

“A Stepwise Approach to Antitrust Review of Horizontal Agreements,” **App. E69**

## INDEX

### SPEECHES—Cont'd

- Barriers to Generic Entry, Prepared Statement of FTC Before Special Committee on Aging, U.S. Senate Concerning (July 20, 2006), **App. E142**
- “Bending the Cost Curve: The View from the Federal Trade Commission,” Julie Brill, FTC Comm., **App. E206**
- Brill, Julie, prepared remarks before North Carolina Bar Assoc., **App. E198**
- “Buyer Power Concerns and the Aetna/Prudential Merger,” **App. E91**
- “Combination and Collaboration in Health Care Markets: Antitrust as a Constraint in a Time of Change,” **App. E41**
- “Comments on Nuts and Bolts of Civil Antitrust Investigation by DOJ Involving Healthcare Industry,” **App. E66**
- “Competition and Health Care: A Prescription for High-Quality, Affordable Care,” **App. E199**
- “Consummated Merger Challenges—The Past is Never Dead,” **App. E202**
- Credit Suisse 2018 Washington Perspectives Conference, remarks at, (Jan. 10, 2018), **App. E262**
- “Current Issues in Health Care Antitrust: Boycotts, Mergers, and Provider Networks,” **App. E54**
- “Current Issues in Health Care Antitrust Enforcement at FTC,” **App. E67**
- “Diagnosing Physician-Hospital Organizations,” **App. E125**
- “Efficiencies in Defense of Mergers: Eighteen Months After,” **App. E87**
- “Efficient Justifications for Hospital Mergers,” **App. E45**
- “Exclusionary Vertical Agreements,” **App. E85**

### SPEECHES—Cont'd

- “Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-c-k!,” **App. E141**
- “Guideposts in the Analysis: The Federal Trade Commission and U.S. Department of Justice, Antitrust Division Competitor Collaboration Guidelines,” **App. E92**
- “Health Care Guidelines and Associations—How Associations Can Work with the Department of Justice,” **App. E36**
- “Health Care Mergers: Will We Get Efficiencies Claims Right?,” **App. E79**
- “How Pay-for-Delay Settlements Make Consumers and the Federal Government Pay More for Much Needed Drugs,” **App. E168**
- “Importance of Competition and Antitrust Enforcement to Lower-Cost, Higher-Quality Health Care,” **App. E172**
- “Integrated Joint Ventures,” **App. E57**
- “Joint Ventures in Evolving Health Care Markets,” **App. E34**
- Keynote remarks of Commissioner Rebecca Kelly Slaughter, Pharmaceutical Task Force Workshop, **App. E286**
- Leibowitz, Jon, prepared remarks regarding stereotypes before the AMA, **App. E182**
- Medco Health Solutions, FTC statement concerning acquisition by Express Scripts, **App. E203**
- “New Entry Into Hospital Competition” (May 24, 2005), **App. E134**
- “Oversight of the Antitrust Enforcement Agencies,” **App. E195**
- “Overview of Advisory Opinion Process at FTC,” **App. E74**
- “Patent Settlements, Patent Reform, and Mergers: Recent Developments in Pharmaceutical

**SPEECHES—Cont'd**

- Antitrust,” **App. E190**
- “Preserving Our Hometown Independent Pharmacies Act of 2011,” **App. E201**
- Quality Health-Care Coalition Act, **App. E82, App. E89**
- Recent Developments in the FTC’s Antitrust Program for Health Care Markets”, **App. E51**
- Remarks of Mary Lou Steptoe, **App. E40**
- Remarks of Robert Pitofsky, Chairman, FTC, before Committee on Judiciary (Feb. 27, 1996), **App. E63** (Jul. 29, 1998), **App. E82**
- Respecting proposed regulations implementing the Affordable Care Act, **App. E188**
- “State Action Immunity for Health Care Collaboration after FTC v. Ticor,” **App. E39**
- Statement Of Commissioner Christine S. Wilson in the matter of HSR Premerger Notification, **App. E285**
- “Statement to Negotiated Rulemaking Committee on Shared Risk Exception to Anti-Kickback Statute,” **App. E77**
- “The One-Size-Fits-All Approach of the Affordable Care Act,” **App. E197**
- “The Rhetoric of Gun Jumping,” remarks before Association of Corporate Counsel Annual Antitrust Seminar of Greater New York Chapter (Nov. 10, 2005), **App. E138**
- “Thoughts on ‘Leveling the Playing Field’ in Health Care Markets,” **App. E73**
- “Twenty-Five Years of State Antitrust Enforcement Applied to Health Care,” **App. E96**
- “Use Your Time Wisely: Do’s and Don’ts for Effective Advocacy Before the Federal Trade Commission,” **App. E100**

**SPEECHES—Cont'd**

- Varney, Christine A., prepared remarks before ABA/AHLA Antitrust in Healthcare Conference, **App. E181**
- “Vertical Restraints with Horizontal Consequences: Competitive Effects of ‘Most Favored Customer’ Clauses,” **App. E58**
- “Virtual Mergers of Hospitals: When Does the Per Se Rule Apply?,” **App. E83**

**STAFF COMMENT**

- North Carolina Senate Bill 743 give state action defense to UNC healths collaborative activities, **App. D210**

**STANDARD-SETTING PROGRAMS**

- Under Section 1 of Sherman Act, horizontal agreements, § 4:10

**STANDING**

- As element of damage action, § 11:7

**ST. ANTHONY MEDICAL CENTER**

- Business review letter, **App. C35**

**STARK ANTI-REFERRAL LAWS**

- Physician-owned facilities, § 18:2

**STARK COUNTY HEALTH CARE COALITION**

- Business review letter, **App. C16**

**STATE-ACTION DOCTRINE**

- “License to Compete: Occupational Licensing and the State Action Doctrine,” prepared Statement of FTC before the United States Senate Committee on the Judiciary (Feb. 2, 2016), **App. E249**

**STATE-ACTION EXEMPTION**

- From antitrust, § 9:7
- Mergers, economic effects, § 15:6
- Practitioner credentialing, § 13:6

**“STATE ACTION IMMUNITY FOR HEALTH CARE COLLABORATION AFTER FTC V. TICOR”**

- (Speech), **App. E39**

## INDEX

### STATE-ACTION PROTECTION

Collaborative activity, FTC Staff  
Advocacy letter to West Virginia  
House of Delegates concerning  
state-action protection (Mar. 9,  
2016), **App. D183**

### STATE ATTORNEYS GENERAL

Protocol for coordination in merger  
investigations between federal  
enforcement agencies and state  
attorneys general, **App. B3G**

### STATEMENT

Statement of Chair Lina M. Khan  
Joined by Commissioner  
Rebecca Kelly  
Slaughter and Commissioner  
Alvaro M. Bedoya In the  
Matter of Welsh, Carson  
Anderson & Stowe (January 17,  
2025), **App. N23**

### STATEMENT 8

**Provider-Controlled Networks** (this  
index)

### STATEMENT 9

**Provider-Controlled Networks** (this  
index)

### STATEMENT OF COMMISSIONER

Christine S. Wilson, HSR Premerger  
Notification, **App. E285**  
FTC and State of Rhode Island v.  
lifespan Corporation and Care  
New England Health System,  
**App. E279**  
Rebecca Kelly Slaughter, Contact  
Lens Rule, **App. E274**  
Rohit Chopra, Review of the FTCs  
Pharmaceutical Merger Enforce-  
ment Program, **App. E275**

### STATEMENT OF INTEREST

United States of America in the case  
of Duffy v. Yardi Systems, Inc.  
(3-1-24), **App. N27**

### STATEMENT REGARDING PHYSICIAN AGREEMENTS TO CONTROL MEDICAL PREPAYMENT PLANS

Advisory opinion, **App. D1**

### STATE UNIVERSITY OF NEW YORK

Certificate of public advantage  
application, FTC staff submis-  
sion, **App. D206**

### STATUTE OF LIMITATIONS

As damage action defense, § **11:10**

### STATUTES

See also specific entries throughout  
this index  
**Antitrust Laws** (this index)

### STEERING

Diversification and  
by other providers, § **17:14**  
under Section 2 of Sherman Act,  
§ **17:12**

### ST. JOHN'S HEALTH SYSTEM

FTC staff advisory opinion to (Sept.  
13, 2006), **App. D115**

### ST. LOUIS AREA BUSINESS HEALTH COALITION

Business review letter, **App. C25**

### SUBCOMMITTEE ON FEDERAL FINANCIAL MANAGEMENT, GOVERNMENT INFORMATION, AND INTERNATIONAL SECURITY

“New Entry Into Hospital Competi-  
tion” (May 24, 2005), **App.  
E134**

### SUBJECT MATTER JURISDICTION

Interstate commerce, § **2:2**

### SUBURBAN HEALTH ORGANIZATION, INC.

FTC staff advisory opinion to (March  
28, 2006), **App. D113**

### SUMMARY JUDGMENTS

Generally, § **12:1**  
Dismissal, generally, § **12:1 to 12:3**  
Failure to state a claim, motions to  
dismiss, § **12:2**  
Motions, generally, § **12:3**  
Motions to dismiss, § **12:1 to 12:3**

#### **SUMMARY REPORT**

FDA/FTC workshop on a competitive marketplace for biosimilars, **App. D208**

#### **SUPERVISION**

Georgia Board of Dentistry, FTC comments concerning proposed amendments to rules governing supervision of hygienists, **App. D136**

Georgia State Senate, FTC Advocacy letter to Hon. Valencia Seay concerning supervision of dental hygienists (Jan. 29, 2016), **App. D180**

Massachusetts House of Representatives, FTC letter concerning removal of supervision requirement from nurse practitioners and nurse anesthesiologists (Jan. 17, 2014), **App. D162**

South Carolina House of Representatives, FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D178**

#### **SUPREME COURT DECISIONS**

Federal Trade Commission (FTC), pharmaceutical patent settlements and Supreme Court, **App. E209**

“Lessons from the Commission’s Supreme Court Trifecta,” text of remarks of Jonathan Neuchterlein at American University Administrative Law Review Annual Symposium (Mar 20, 2015), **App. E239**

“Reflections on Supreme Court’s North Carolina Dental Decision and the FTC’s Campaign to Rein in State Action Immunity,” Maureen K. Ohlhausen, FTC Commissioner (Mar 31, 2015), **App. E240**

#### **TARRANT COUNTY MEDICAL SOCIETY**

Advisory opinion  
July 11, 1984, **App. D13**

#### **TARRANT COUNTY MEDICAL SOCIETY—Cont’d**

Advisory opinion—Cont’d  
May 25, 1984, **App. D12**

#### **TELECOMMUNICATIONS**

Delaware Board of Speech/Language Pathologists, Audiologists, and Hearing Aid Dispensers, amendment to telecommunication and telehealth regulations, FTC advocacy letter (Nov. 29, 2016), **App. D191**

#### **TELEHEALTH SERVICES**

Advocacy letter to Antitrust Division (Nov. 29, 2016), **App. C105**

Delaware Board of Speech/Language Pathologists, Audiologists, and Hearing Aid Dispensers, amendment to telecommunication and telehealth regulations, FTC advocacy letter (Nov. 29, 2016), **App. D191**

FTC Advocacy letter to Alaska State Legislature concerning bill permitting (Mar. 25, 2016), **App. D184**

#### **TEMPORARY RESTRAINING ORDER**

Pursuant to Section 13(b) of the Federal Trade Commission Act, **App. N2**

#### **TENNESSEE DEPARTMENT OF HEALTH**

FTC Staff advocacy letter to Malaka Watson, Tennessee Department of Health, concerning cooperative agreements and certificates of public advantage (Sept. 24, 2015), **App. D176**

#### **TERMINATIONS**

Distributorship, under Section 1 of Sherman Act, vertical agreements, § 5:4

#### **TESTIMONY**

Division Director, Licensing & Certification at State of Maine  
William Montejo, **App. N3**

## INDEX

### **TESTIMONY—Cont'd**

Supporting LD 97  
Division Director, Licensing &  
Certification at State of  
Maine, **App. N3**

### **TESTIMONY OF MARK BOTTI**

“Competition in healthcare and cer-  
tificate of need” before Georgia  
General Assembly (Feb. 23,  
2007), **App. E145**

### **TEXAS HOUSE OF REPRESENTATIVES**

Advisory opinions, Joint Negotia-  
tions by Physicians (May 13,  
1999), **App. D85**

### **TEXAS STATE BOARD EXAMINERS**

FTC Staff advocacy letter to Simone  
Salloum concerning proposed  
rules (Oct. 14, 2014), **App.  
D166**

### **TRADE REGULATION AND CONSUMER LAW**

“Health Care Technology: Promoting  
Competition and Protecting  
Innovation,” Maureen K.  
Ohlhausen, Commissioner of  
FTC, before Connecticut Bar  
Association Antitrust amp:  
Trade Regulation and Consumer  
Law Sections (Feb. 26, 2014),  
**App. E228**

### **TRANSPLANT ASSOCIATES**

Business review letter, **App. C29**

### **TRISTATE HEALTH PARTNERS**

FTC staff opinion letter not to recom-  
mend challenge of TriState’s  
proposed program (Apr. 13,  
2009), **App. D127**

### **“TWENTY-FIVE YEARS OF STATE ANTITRUST ENFORCEMENT APPLIED TO HEALTH CARE”**

(Speech), **App. E96**

### **2006 MILTON HANDLER ANNUAL ANTITRUST REVIEW**

Monopsony and the meaning of  
consumer welfare, a closer look

### **2006 MILTON HANDLER ANNUAL ANTITRUST REVIEW**

#### **—Cont'd**

at Weyerhaeuser (Dec. 7, 2006),  
**App. E144**

### **2007 ANTITRUST LAW FALL FORUM**

Prepared slides of Jeffrey Schmidt,  
Director, Bureau of Competi-  
tion, before ABA Section  
concerning “Critical Loss Anal-  
ysis: A Merger Lawyer’s View”  
(Nov. 16, 2007), **App. E157**

### **TYING ARRANGEMENTS**

As vertical agreements under Section  
1 of Sherman Act, § **5:6**  
Diversification resulting in, § **17:5**  
Hospital-physician exclusive  
contracts as  
generally, § **14:3**  
conditional sale of one service on  
purchase of another, § **14:5**  
economic interest in sale of tied  
product, § **14:8**  
effect on substantial amount of  
interstate commerce, § **14:7**  
legitimate business justification,  
§ **14:9**  
market power in the market for the  
tying product, § **14:6**  
separate and distinct products,  
§ **14:4**

### **UNC HEALTHS COLLABORATIVE ACTIVITIES**

FTC amicus brief  
re Bystolic Antitrust Litigation,  
**App. D211**  
North Carolina Senate Bill 743  
give state action defense to UNC  
healths collaborative activi-  
ties, **App. D210**

### **UNFAIR COMPETITION**

Generally, § **7:1**  
Adoption of the Statement of  
Enforcement Policy, Unfair  
Methods of Competition Under

**UNFAIR COMPETITION—Cont’d**  
Section 5 of the FTC Act, **App. E288**

Physician-owned facilities, § **18:2**  
Statement of enforcement principles regarding “Unfair Methods of Competition” under Section 5 of FTC Act (Aug. 13, 2015), **App. II**

Under Section 1 of Sherman Act, horizontal agreements, § **4:9**

**UNFAIR TRADE PRACTICES**

Federal Trade Commission, “Section 5: Principles of Navigation,” Maureen K. Ohlhausen, Commissioner, before U.S. Chamber of Commerce, Washington, DC (July 25, 2013), **App. E220**

**UNITED HEALTH GROUP**

Antitrust Division background of closing investigation of acquisition of Oxford Health Plans (Jul. 20, 2004), **App. E129**

**UNITED STATES SENATE COMMITTEE**

Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights Oversight of the Enforcement of the Antitrust Laws, **App. E287**

**UNIVERSITY OF MICHIGAN**

Federal Trade Commission (FTC), staff advisory opinion to the University of Michigan concerning the Non-Profit Institutions Act, **App. D131**

**UNREASONABLY ANTICOMPETITIVE EFFECT ELEMENT**

**Anticompetitive Effect Element** (this index)

**URONET OF LOUISIANA, LLC**

Advisory opinions (Jan. 23, 1996), **App. D61**

**U.S. DEPARTMENT OF JUSTICE ANTITRUST DIVISION**

Justice Department (United States Department of Justice,

**U.S. DEPARTMENT OF JUSTICE ANTITRUST DIVISION**

—**Cont’d**  
**Antitrust Division**) (this index)

**U.S. DRUG DISTRIBUTION SYSTEM**

Statement of FTC Bureau of Competition Deputy Director Rahul Rao on Lawsuit Against PBMs and the Role of Drug Manufacturers in Distorting Competition in the U.S Drug Distribution System (September 20, 2024), **App. N18**

**“USE YOUR TIME WISELY: DO’S AND DON’TS FOR EFFECTIVE ADVOCACY BEFORE THE FEDERAL TRADE COMMISSION,”**

(Speech), **App. E100**

**U.S. V. AZHAA**

“When Does a Group Purchasing Organization Become an Illegal Monopsonist?” prepared remarks before AHLA annual meeting (June 26, 2007), **App. E151**

**UTAH SOCIETY OF ORAL AND MAXILLOFACIAL SURGEONS**

Advisory opinion, **App. D14**

**VALLEY BAPTIST MEDICAL CENTER**

Advisory opinions (Sept. 19, 1996), **App. D70**

**VALLEY GASTROENTEROLOGISTS**

Business review letters (July 7, 1997), **App. C82**

**VERMONT**

U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E139**

**VERMONT PHYSICIANS CLINIC**

Business review letters (July 30, 1997), **App. C83**

## INDEX

### VERTICAL AGREEMENTS

“Exclusionary vertical agreements”  
(speech), **App. E85**

Mergers, § **15:29**

Provider-controlled contracting  
networks, multi-provider  
networks, § **20:13**

Sherman Act. **Vertical Agreements**  
(**Section 1 of Sherman Act**)  
(this index)

**Vertical Price-Fixing Agreements**  
(this index)

### VERTICAL AGREEMENTS (SECTION 1 OF SHERMAN ACT)

Generally, § **5:1**

Distributorship terminations, § **5:4**

Dual distribution, § **5:5**

Exclusive dealing agreements, § **5:7**

Price discrimination and commercial  
bribery, § **5:9**

Provider-controlled contracting  
networks, multi-provider  
networks, § **20:13**

Reciprocal dealing agreements, § **5:8**

Tying agreements, § **5:6**

Vertical market-allocation agree-  
ments, § **5:3**

Vertical price-fixing agreements,  
§ **5:2**

### VERTICAL INTEGRATION

As anticompetitive conduct under  
Section 2 of Sherman Act,  
§ **6:10**

### VERTICALLY INTEGRATED PHARMACY

Specialty Generic Drugs

Growing Profit Center for Verti-  
cally Integrated Pharmacy  
Benefit Managers (January  
14, 2025), **App. N22**

### VERTICAL MERGERS

Generally, § **15:29**

Under Section 7 of Clayton Act,  
§ **8:14**

### VERTICAL PRICE-FIXING AGREEMENTS

Exclusive contracts and, § **14:15**

Under Section 1 of Sherman Act,  
§ **5:2**

### VERTICAL RESTRAINTS

Most favored customer clauses,  
speech entitled “Vertical  
Restraints with Horizontal Con-  
sequences: Competitive Effects  
of ‘Most Favored Customer’  
Clauses,” **App. E58**

### VETERANS ADMINISTRATION

FTC advocacy letter, advanced  
practice registered nurses  
restrictions (July 25, 2016),  
**App. D188**

### VIOLATIONS OF SECTION 1 OF SHERMAN ACT

Generally, § **3:2**

Agreement element

generally, § **3:3**

capacity to conspire, § **3:5**

conspiracy in fact, § **3:6**

nature of agreement, § **3:4**

Anticompetitive purpose or intent  
element

generally, § **3:7**

intent and purpose in civil antitrust  
cases, § **3:8**

intent in criminal antitrust cases,  
§ **3:9**

purpose and intent in civil antitrust  
cases, § **3:8**

Collaborations among competitors,  
§ **3:14**

Unreasonably anticompetitive effect  
element

generally, § **3:10**

hybrid analyses, § **3:13**

per se rule, § **3:12**

rule of reason, § **3:11**

### VIRGINIA DEPARTMENT OF HEALTH

FTC Staff advisory letter to Susan  
Puglisi concerning cooperative

**VIRGINIA DEPARTMENT OF  
HEALTH—Cont’d**

agreements (Sept. 17, 2015),  
**App. D175**

**VIRGINIA HOUSE OF  
DELEGATES**

Federal Trade Commission Office of  
Policy Planning letter concern-  
ing regulation of pharmaceutical  
benefit managers (Oct. 2, 2006),  
**App. D116**

**VIRTUAL MERGERS**

Single entity status and, § 15:4

**“VIRTUAL MERGERS OF  
HOSPITALS: WHEN DOES  
THE PER SE RULE APPLY?”**

(Speech), **App. E83**

**VOLUNTARY**

**SELF-DISCLOSURES**

New Safe Harbor Policy, Deputy  
Attorney General Lisa O.  
Monaco, **App. B23**

**WALES, DAVID P.**

“Community Pharmacy Fairness Act  
of 2007,” Prepared Statement of  
FTC Before U.S. House of  
Representatives Judicial Com-  
mittee Concerning HR 971 (Oct.  
18, 2007), **App. E156**

“Examining Competition in Group  
Health Care,” Prepared State-  
ment Before U.S. Senate Com-  
mittee on Judiciary (Sept. 6,  
2006), **App. E142A**

**WASHINGTON STATE MEDICAL  
ASSOCIATION**

Business review letter, **App. C94**

**WELLPOINT HEALTH  
NETWORKS, INC.**

Anthem, Inc.’s acquisition of  
WellPoint Health Networks,  
Inc., Antitrust Division state-  
ment on closing of investigation  
of (March 9, 2004), **App. E128**

**WESLEY HEALTH CENTER, INC.**

Advisory opinions (Apr. 29, 1999),  
**App. D84**

**WEST, DIANA**

Business review letters (May 25,  
2004), **App. C98**

**WESTLAKE HEALTH CAMPUS  
ASSOCIATION**

Business review letter, **App. C10**

**WEST VIRGINIA HOUSE OF  
DELEGATES**

Collaborative activity, FTC Staff  
Advocacy letter concerning  
state-action protection (Mar. 9,  
2016), **App. D183**

**WEST VIRGINIA SENATE**

FTC Staff Advocacy letter concern-  
ing placing regulation of  
advanced practice registered  
nurse under State Board of  
Medicine and Osteopathy (Feb.  
10, 2016), **App. D181**

**WICHITA, KANSAS, CHAMBER  
OF COMMERCE**

Advisory opinion, **App. D29**

**WILLIAM J. SEITZ**

FTC staff letter to Ohio State Senator  
Seitz concerning collective  
bargaining by home care provid-  
ers (Feb. 14, 2008), **App. D123**

**WILLIAM W. BACKUS HOSPITAL**

Advisory opinions (June 11, 1996),  
**App. D64**

**WILSON, CHRISTINE S.**

“Bigger than Big Tech? The Need to  
Reform Our Health Care  
Markets Using Choice and  
Competition” (September 9,  
2019), **App. E269**

Keynote remarks, Council for Afford-  
able Health Coverage (January  
16, 2020), **App. E370**

Need to establish privacy rules for  
Big Tech (May 18, 2020), **App.  
E372**

Statement, HSR Premerger Notifica-  
tion, **App. E285**

## INDEX

### WORKSHOP SUMMARY

Pharmaceutical mergers, analysis  
examination

FTC-DOJ, **App. N4**

### WRIGHT, JOSHUA D.

“Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers,” text of remarks before the ABA Master Course VII (Oct. 10, 2014), **App. E235**

“FTC v. Actavis and the Future of Reverse Payment Cases,” remarks of Joshua D. Wright, Commissioner, FTC, before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E224**

### WRIGHT, JOSHUA D.—Cont’d

“Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,” Joshua D. Wright before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E222**

“The FTC’s Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets,” Joshua D. Wright before the 2013 Georgetown Global Antitrust Symposium Dinner, Washington, D.C. (Sept. 24, 2013), **App. E223**

### YELLOWSTONE PHYSICIANS, LLC

Advisory opinions (May 14, 1997), **App. D75**